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A. THEORETICAL PART  
 
General Introduction 
 
Since the discovery of the sulfonimidoyl-group in (2S,5S)-methionine-sulfoximine 
(Figure 1) around the 50s of last century1, the sulfoximine group has been proven 
to be a versatile  building block in organic synthesis.2 When Whitehead and 
Bentley discovered that the sulfoximine of methionine is the agent responsible for 
the toxicity of wheat flour treated with nitrogen trichloride,3 such treatment had 
been widely practaised for many years. The sulfoximine has wider applications as 
a chiral auxiliary4 and also as catalysts in asymmetric synthesis.5,6  
 
O
S
NH
CH3
OH
NH2
O  
 
Figure 1: (2S,5S)-Methionine-Sulfoximine. 
 
Their uncommon versatility originates mainly from the endowment of the 
sulfonymodyl group with an almost unique combination of the features, namely 
chirality, carbanion stabilization, nucleofugacity, basisity, nucleophilicity and low 
redox potential7 (Figure 2).  
 
H3C
S N
H
O
nucleophilic und basic
asymmetric sulfur
acidic hydrogens
acidic hydrogens
 
 
Figure 2: The (S)-S-Methyl-S-phenylsulfoximin functional group. 
 
Chiral allyltitanium complexes have emerged as valuable reagents for the 
enantioselective allylation of aldehydes and imines.8,9 Particularly useful are allyl 
titanium complexes that carry a hetero-atom substituent since they allow the 
transfer of both an allyl moiety and a functional group, amenable to further 
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synthetic transformations. The most versatile use of complexes type I9c has been 
shown by Hoppe et al. Other useful examples of type II has been developed by 
Reggelin et al. (Figure 3).8f 
 
R1 O
TiX3
O
NR2
I II
R1 S
O
N
pTol
TiX3
Ph
CH3
*
R1 = R2 = Me, i-Pr, Bu; X = O-i-Pr, NEt2
*
*
 
 
Figure 3: Allyltitanium complexes of Hoppe et el. and Reggelin et al. 
 
Noteworthy examples are the sulfonimidoyl-substituted allyl titanium(IV) 
complexes IV and V10 (Figure 3), which have found application in the asymmetric 
synthesis of a number of compounds including γ,δ-unsaturated α-amino acids,11a 
bicyclic α-amino acids,11b,c γ-hydroxy β-aminoacids,11d,e homopropragylic 
alcohols,11h homoallyl alcohols and unsaturated  prolines. 11i      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Applications of sulfonimidoyl substituted allyltitanium (IV) complexes. 
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CHAPTER 1 
 
Asymmetric Synthesis of Cycloalkenyl and 
Alkenyloxiranes from Allylic Sulfoximines and Aldehydes 
 
 
 
 
 
 
 
 
 
 
. 
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1       Asymmetric Synthesis of Cycloalkenyl and 
Alkenyloxiranes from Allylic Sulfoximines and Aldehydes 
 
1.1 Introduction 
  
1.1.1 Brief introduction about relevant biologically-active 
molecules 
 
During the last decade alkenyloxiranes have been recognized as valuable 
intermediates in organic synthesis.12,13 Alkenyloxiranes undergo a number of 
useful transformations which include reactions with nucleophiles and Lewis acid 
mediated rearrangements. Of central importance is the possibility to individually 
manipulate each of the four carbon centers of an alkenyloxirane (Figure 5) by a 
proper choice of reagents or reagent combinations.14  
 
     
  
 
 
Figure 5: Alkenyloxiranes and Cycloalkenyloxiranes.  
 
Many natural products that embody the vinyloxirane moiety often possess 
remarkably high biological activity. The eicosanoid-derived algal pheromones 
lamoxirene and caudoxirene (Figure 6), for example, trigger mass release of 
spermatozoids from their gametangia down to threshold concentrations ranging 
from 30-50 pM in seawater.15 Other eicosanoid-derived alkenyloxiranes were 
identified as important intermediates in the biosynthesis of leukotrienes and other 
oxylipins.16 The macrocyclic lactones (Figure 6) have attracted considerable 
attention since they appear to be promising chemotherapeutic agents for the 
treatment of various diseases.17 
 
 
 
 
 
O R3
R2
R1
R 1  =  c C6H11, i-Pr, R2 = H, R1+R2 = (CH2)4, (CH2)5
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Figure 6: Chemotherapeutic agents. 
          
Compounds such as (−)-carbovir, tylactone and allo-pumiliotoxin, which show 
antibiotic activity, have been synthesized from alkenyloxiranes (Figure 7).18 
 
 
 
 
 
 
Figure 7: Antibiotics. 
 
1.1.2 Approaches towards the construction of the alkenyloxirane moiety 
 
Asymmetric syntheses of alkenyloxiranes have been accomplished by several 
methods, including (1) epoxidation of allylic alcohols in combination with an 
oxidation and olefination (Sharpless-Swern-Wittig), (2) epoxidation of dienes 
(Jacobsen method), (3) chloroallylation of aldehydes in combination with 1,2-
elimination (Oehlschlager method), and (4) reactions between S-ylides and 
aldehydes (Metzner method). Each of these methods will be briefly discussed 
below. 
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Sharpless-Swern-Wittig approach 
Marshall et al. have reported a method for the synthesis of alkenyloxiranes based 
on an enantioselective Sharpless epoxidation of the allylic alcohol 2, followed by a 
Swern oxidation in combination with a Wittig olefination (Scheme 1).12a Though the 
method is well suited for the preparation of alkenyloxiranes, it is difficult to extend 
the method to the generation of cycloalkenyloxiranes.       
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1: Sharpless-Swern-Wittig route. 
 
 
Jacobsen approach 
An efficient asymmetric synthesis of alkenyloxiranes was reported by Jacobsen et 
al. in 1990. The method is based on the oxidation of conjugated Z, E dienes by 
using a Mn(salen)-complex (Scheme 2).19 The synthesis of cycloalkenyloxiranes 
by this method has not been described. 
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Scheme 2: Epoxidation of conjugated Z, E-dienes. 
 
 
Oehlschlager approach 
Oehlschlager et al. have reported an improved route for the synthesis of 
alkenyloxiranes via the chloroallylboration of aldehydes in combination with an 1,2-
elimination (Scheme 3).20 The synthesis of cycloalkenyloxiranes by this method 
has not been described. 
 
 
 
 
 
 
 
 
Scheme 3: Allylboration of adehydes in combination with 1, 2-elimination. 
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Metzner approach 
In 2002, Metzner et al. have reported a novel method for the synthesis of 
alkenyloxiranes by the reaction of S-ylides with aldehydes. The required S-ylides 
were obtained from allyl halides and chiral sulfides (Scheme 4).21The extension of 
this method to the synthesis of cycloalkenyloxiranes was not successful in terms of 
ee and de values. 
 
 
 
 
 
 
 
 
Scheme 4: Reactions between S-ylides and aldehydes. 
 
1.2  Present work 
 
1.2.1 Aim 
As illustrated in the earlier section, chiral alkenyloxiranes are valuable 
intermediates in organic synthesis. In 2000, Hainz and Bruns, former members of 
our research group disclosed a method for the regio- and stereoselective 
hydroxyalkylation of allylic sulfoximines (6) with aldehydes leading to the formation 
of the syn-configurated β-N-methylsulfonimidoyl-substitued homoallylic alcohols 
8.11f Thus, titanation of the lithiated allylic sulfoximines of type 6 with ClTi(NEt2)3 
afforded the corresponding mono(2-alkenyl)tris(diethylamino) titaninum (IV) 
complexes 7 which reacted with aldehydes, with moderate to high 
regioselectivities and high diastereoselectivities, preferentially at the α-position to 
give the corresponding syn-configured β-N-methylsulfonimidoyl-substituted 
homoallylic alcohols 8 in good yields (Scheme 5). 
 
 
 
 
 
Scheme 5: Hydroxyalkylation of acyclic allylic sulfoximines. 
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Hainz and Bruns also extended this method to the synthesis of cyclic allylic 
sulfoximines. Thus, the cyclic allylic sulfoximine 9 reacted with aldehydes at the α-
position to yield the corresponding allylic sulfoximines 11 (Scheme 6). 
  
 
 
 
 
 
 
Scheme 6: Hydroxyalkylation of cyclic allylic sulfoximines. 
 
A facile Cl-substitution of the sulfoximine group of S-alkylsulfoximines (12) with 
chloroformate has been observed by R. Loo, a former member of our group. 
Furthermore it was observed that substitution of the sulfoximine group of 13 
occurred much more rapidly than to compound 12, generating compound 14.22 
Additionally, it was anticipated that sulfoximine 13 upon treatment with Meerwein 
salt would convert the sulfoximine group into a very good leaving group. Indeed, 
upon exposure of 14, 15 to a base, intramolecular nucleophilic attack by the vicinal 
hydroxyl group should furnish the alkenyloxirane 16 (Scheme 7).  
 
 
 
 
 
 
 
 
 
Scheme 7: Synthesis of cycloalkenyl and alkenyloxiranes. 
 
A further stimulus for the perusal of this route is its potential for an application to 
solid-phase synthesis which was described by M.Günter, a former member of our 
group whose synthetic strategy is shown in Scheme 8.23 
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Scheme 8: Solid-phase synthesis of alkenyloxiranes. 
 
Due to their immense synthetic and biological importance, alkenyloxiranes have 
become the topic of intensive research activity by various research groups.19-21 
Owing to the prominence of the latter compounds, we undertook a project towards 
the development of a method for the synthesis of alkenyloxiranes (Scheme 9). 
 
1.2.2 Results and Discussion 
 
1.2.2.1  Retrosynthetic analysis 
As illustrated in the foregoing section, alkenyloxiranes are interesting targets and 
their asymmetric synthesis has been accomplished by several methods. Although 
some of these methods are very efficient for the synthesis of alkenyloxiranes, they 
are not so well suited for the attainment of cycloalkenyloxiranes 16. We therefore 
focused our interest in the asymmetric synthesis of both alkenyl and 
cycloalkenyloxiranes from aldehydes and allylic sulfoximines (Scheme 9).24  
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Scheme 9: Retrosynthetic analysis. 
 
The alkenyloxiranes (16) were realised from the corresponding chlorohydrins (14) 
which in turn can be derived from 13 by substitution with chlorine atom.  The 
sulfoximine (13) can be derived from the allylic sulfoximine (12) whose synthesis 
has been reported by our group recently.11f 
 
1.2.2.2     Asymmetric synthesis of cycloalkenyloxiranes. 
The synthesis commenced with the preparation of cyclic allylic sulfoximines. The 
known cyclic allylic sulfoximines 9a and 9b were prepared in a one-pot synthetic 
operation without the isolation of intermediates from chiral N-methyl sulfoximine 
and the corresponding cycloalkanones by the inverse Peterson-olefination and 
isomerization sequence described previously.25 
 
          
 
 
 
 
Scheme 10: Synthesis of cyclic allylic sulfoximine. 
 
Treatment of  the six-membered cyclic allylic sulfoximine 9a in diethyl ether at −78 
°C with 1.1 eq. of n-BuLi resulted in the lithiated sulfoximine which was 
subsequently transmetalated to the corresponding titanium complex with 1.2 eq. of 
ClTi(NEt2)3.  The allyl titanium complex was intercepted with various aldehydes 
including  benzaldehyde and isobutyraldehyde at −78 °C, forming the 
diastereomerically-pure syn-configured, sulfoximine-substituted, homoallylic 
alcohols 11a and 11b with a good yields.11f     Similarly, the new diastereomerically  
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pure seven-membered homoallylic alcohol 11c was obtained in 70% yield and 
≥98% de from the allylic sulfoximine 9b and benzaldehyde. A 1H NMR 
spectroscopic analysis of the crude reaction product showed the hydroxyalkylation 
to be highly diastereoselective (≥95% de) and regioselective (Scheme 11). 
 
 
 
 
 
 
 
Scheme 11: Hydroxyalkylation of cyclic allylic sulfoximine.  
 
 1.2.2.3 Substitution of sulfoximine-substituted homoallylic alcohols 
As described previously,23we envisaged that the sulfoximine group of the 
homoallylic alcohols could be replaced and activated by two methods, as shown in 
Scheme 12. 
 
 
 
 
 
 
 
 
 
Scheme 12: Proposed synthesis of cycloalkenyloxiranes. 
 
It is described in the literature that the activation of 11 can be achieved through 
the methylation of the N-methyl sulfoximine group with Me3OBF4 to afford the 
corresponding (dimethylamino)sulfoxonium salts23. Hence based on the earlier 
literature for the activation, our initial attempt towards the generation of 
cycloalkenyloxiranes is proposed in Scheme 13. Sulfoximine 11a was treated with 
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Me3OBF4 to obtain the (dimethylamino)sulfoxonium salt.  To our surprise aldehyde 
20 was isolated instead of obtaining the sulfoximine salt. 
 
 
 
 
 
 
 
 
Scheme 13: Synthesis of aldehyde. 
 
Formation of 20 could be explained as follows: methylation of 11a with Meerwein 
salt results in the formation of the aminosulfoxonium salt 17, which suffers a 
solvolysis to form the allyl cation 18. Attack by the phenyl group results in the 
phenonium ion 19 which undergoes a rearrangement and a proton-loss to give 
aldehyde 20 (Scheme 14). 
 
 
 
 
Scheme 14: Mechanism for aldehyde formation. 
 
Since the synthesis of 22a via the sulfoxonium salt could not be accomplished, we 
tried to do the chlorine substitution of 11a-c by using 1.2 to 1.3 eq. of 
ClCO2CH(Cl)Me at room temperature in DCM. Accordingly, the corresponding 
chlorohydrins 21a-c, respectively, were afforded each in ≥98% de and in 85-88% 
yields. In addition, sulfinamide 29a was also isolated in 94% yield (Scheme 15).  
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Scheme 15: Substitution with ClCO2CH(Cl)Me. 
 
The next step in the synthesis of alkenyloxirane was the cyclisation of the 
chlorhydrins to the corresponding oxiranes. In general, the formation of oxiranes 
from chlorohydrins is expected to proceed with an inversion of the configuration 
thus producing trans-configured oxiranes. Treatment of the chlorohydrins 21a-c 
with DBU in DCM afforded the alkenyloxiranes in 90-94% yield with high selectivity 
(Scheme 16).  The alkenyloxiranes formed were assigned the cis-configuration by 
measuring the magnitudes of the vicinal coupling constants (4.2-4.4 Hz). These 
values are comparable with a literature26 report that suggests that the coupling 
constants will be larger for the cis-isomer (4.0-5.0 Hz) compared to the trans-
isomer (1.5-2.0 Hz). Furthermore, the cis-configuration shows that the substitution 
proceeded with retention of configuration. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 16: Asymmetric synthesis of cycloalkenyloxiranes. 
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1.2.2.4     Asymmetric Synthesis of Alkenyloxiranes 
Since high selectivities were recorded in the synthesis of the cycloalkenyloxiranes 
22a-c, the possibilites of an analogous synthesis of alkenyloxiranes from acyclic 
allylic sulfoximines was investigated. Successive treatment of the (E)-configured 
allylic sulfoximines 6a and 6b with n-BuLi and ClTi(NEt2)3 gave the corresponding 
allylic titanium complexes which, upon treatment with benzaldehyde, afforded, as 
described previously, the enantio- and diastereomerically pure syn-configured 
sulfoximine-substituted homoallylic alcohols 8a and 8b, respectivly in good yields 
(Scheme17).11f 
       
   
 
 
 
 
 
Scheme 17: Hydroxyalkylation of acyclic allylic sulfoximine. 
 
Substitution of the sulfoximine groups of 8a and 8b by a chlorine atom using 
ClCO2CH(Cl)Me, proceeded readily to give beside 29a, the chlorohydrins 23a and 
23b, respectively in 92-94% yields. 1H NMR analyses of the products showed that 
there existed a mixture of anti- and syn-diastereomers in ratios of 78:22 and 74:26. 
Treatment of each mixture of chlorohydrins with DBU furnished the oxiranes 24a 
and 24b in high yields as a mixture of trans- and cis-isomers in ratios of 78:22 and 
74:26 respectively, thus illustrating complete chirality transfer. The structures of 
the trans- and cis-configured oxiranes 24a and 24b were assigned on the basis of 
the magnitudes of the vicinal coupling constants from their 1H NMR spectra, which 
amounted to 3J = 1.9 Hz for the trans and 3J = 4.3 Hz for the cis isomers (Scheme 
18). 
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Scheme 18: Asymmetric synthesis of alkenyloxiranes. 
 
An attempt was made to probe the configurational stability of the double bond in 
the substituion of the sulfoximine group. Studies on the (Z)-configured double 
bonds containing sulfoximine formed the corresponding syn-configured 
sulfoximine-substituted homoallylic alcohols 26a and 26b. The enantio- and 
diastereomerically pure homoallylic alcohols 26a and 26b were synthesized in 
good yields, as described previously, from the (Z)-configured allylic sulfoximines 
25a and 25b, respectively, as mentioned in Scheme 19. The treatment of 
homoallylic alcohols 26a and 26b with ClCO2CH(Cl)Me and DBU afforded the 
alkenyloxiranes 24a (89%) and 24b (88%), while the (E)-configured double bonds 
resulted each as a mixture of trans and cis isomers in ratios of 75:25 and 80:20, 
respectively. 1H NMR spectroscopy of the mixtures of trans 24a, cis 24a and trans 
24b, cis 24b showed the presence of an additional 11% and 7% of the 
corresponding isomers (27) with (Z)-configured double bonds. The substituion of 
the sulfoximines groups of 26a and 26b had thus to a large extent been 
accompanied by isomerization of the double bonds (Scheme 19). 
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Scheme 19:  Asymmetric synthesis of alkenyloxiranes from (Z)-configured allylic          
sulfoximines. 
 
1.2.2.5     Mechanistic Consideration of the Cl substitution of Sulfoximines 
The reactions between the cyclic allylic sulfoximines 11a-c and ClCO2CH(Cl)Me 
proceeded with almost complete retention of configuration, while those between 
the acyclic allylic sulfoximines 9a and 9b and the chloroformate resulted in the 
respective chlorohydrins with predominant inversion of configuration. We had 
previously observed that S-alkyl-N-methyl sulfoximines are also amenable to this 
latter type of Cl substitution, the mechanism of which is not yet known but the 
speculative mechanism is as follows (Scheme 20).22 
 
 
 
 
 
 
 
 
 
Scheme 20: Mechanism for chlorine substitution. 
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corresponding alkyl chlorides and urethanes.27 Based on this literature precedent, 
the first step of the mechanism is speculated to involve acylation of the sulfoximine 
groups of 11a-c, 8a and 8b at the N-atom to form the aminosulfoxonium salts   
28a-c, 31a and 31b (Scheme 21). The allylic aminosulfoxonium groups of 28a-c, 
31a and 31b would be expected to be excellent leaving groups.22 SN1 substitution 
of the allylic aminosulfoxonium salts is proposed resulting in generation of the 
allylic carbenium ions 30a-c, 32a and 32b, and accompanying formation of the 
sulfinamide 29a. The allylic carbenium ions 30a-c, 32a and 32b would be 
expected to undergo facile Cl  addition to form the products.  In the case of the 
acyclic systems, the major products formed (anti-23a,b) are those with S-
stereochemistry, along with minor amounts of the R-isomers.  Obviously, chlorine 
substitution must occur preferentially at the Si face, (vs. attack at the Re face), but 
why such selectivity should be observed is unclear.  On the other hand, for the 
cyclic systems, the only products observed are those with R-stereochemistry.  This 
may be explained by the fact that the cyclic allylic carbenium ions 30a-c 
preferentially adopt the C(OH)-C(sp2)-conformation A, in which the hydroxy group 
is gauche to the H-atom at the C(sp2)-atom (to minimize the destabilizing 
interactions between the hydroxy group and the ring containing the double bond) 
(Scheme 21) and the chloride ion is forced to attack from the Re face due to steric 
crowding.   
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Scheme 21:  Mechanism for Cl substitution of sulfoximines. 
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Such a mechanism could also be used to explain the (Z)/(E) isomerization that 
occurred in the case of the reactions of the (Z)-configured, sulfoximine-substituted, 
homoallylic alcohols described earlier. 
 
1.2.2.6     Recycling of the Chiral Auxiliary 
The purpose of this work was to demonstrate that the sulfoxime moiety in the 
allylic sulfoximes acts as an auxillary. Our group had previously shown that the  
treatment of (S)-configured S-alkyl-N-methyl sulfoximines with ClCO2Me resulted 
in the formation of the sulfinamide 29b with 98% ee (Scheme 22).11d Sulfinamide 
29b was converted upon treatment with MeMgCl to sulfoxide 33 of 98% ee, the 
conversion of which to the (S)-configured sulfoximine 34 of 98% ee had already 
been described in the literature.28 The sulfoximine in turn is the starting material for 
the synthesis of allylic sulfoximines 9a, 9b, 6a, 6b, 25a, and 25b. In order to 
examine whether 29a could also be used as starting material for the synthesis of 
34, the sulfonamide 29a was treated with MeMgCl which gave sulfoxide 33 with 
96% ee24  (Scheme 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 22: Recycling of the chiral auxiliary. 
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1.3 Conclusion 
 
A highly selective asymmetric synthesis of cis-configured cycloalkenyloxiranes, 
otherwise not easily accessible by existing methods, has been developed. The 
three-step sequence consists of an allylation of an aldehyde with a cyclic allylic 
sulfoximine bearing a tris(diethylamino)titanium group, a Cl substitution of the 
sulfoximine group of the resulting homoallylic alcohol, and a cyclization of the 
resulting chlorohydrin (Scheme 23). 
 
 
 
 
Scheme 23: Synthesis of alkenyloxiranes. 
 
The synthesis of the cyclic allylic sulfoximines is accomplished from commercially 
avialable enantiomerically pure S-methyl-S-phenyl sulfoximine and the 
cycloalkanone by a six-step sequence of transformations requiring the isolation 
and purification of only one intermediate, N,S-dimethyl-S-phenyl sulfoximine 
(Scheme 24). 
 
 
 
 
 
 
Scheme 24: Synthesis of cyclic allylic sulfoximine.  
A solid-phase asymmetric synthesis of cycloalkenyloxiranes by this route with the 
use of the sulfoximine group as a traceless chiral linker is also feasible (Scheme 
25).23 The asymmetric synthesis of alkenyloxiranes by this route is also possible, 
but yields mixtures of cis and trans isomers, in which the latter dominate. The 
facile Cl substitution of the sulfoximine group with retention of configuration at the 
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S atom and the recycling of the sulfinamide provide the basis for a full utilization of 
the sulfoximine group as a chiral auxiliary. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 25: Solid-phase synthesis.  
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    CHAPTER 2 
 
 
Asymmetric Synthesis of 2,3-Dihydrofurans and of   
Unsaturated Bicyclic Tetrahydrofurans 
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2 Asymmetric Synthesis of 2,3-Dihydrofurans and of   
Unsaturated Bicyclic Tetrahydrofurans  
 
 
2.1  Introduction 
 
2.1.1   Brief introduction about relevant biologically-active molecules 
 
Five-membered oxygen-containing heterocycles have been valuable targets for 
the synthetic chemists during past five decades, since they are present in a variety 
of naturalproducrs, many of which possess biological activity. For example, (+)-
allomuscarine exhibits antibiotic biological activity, where its epimer (−)-
allomuscarine exihibits cholinomimetic activity. Similarly, (−)-dihydrosesamin is a 
potent anticanser activity (Figure 8).29 
 
               
   
 
 
 
 
 
 
Figure 8: Bioactive tetrahydrofurans. 
 
Synthesis of 2,5-dihydrofurans with chiral centers and their importance for the 
synthesis of natural products has been reviewed several times.27n,o The synthesis 
of 2,3-dihydrofurans bearing chiral centers which are enantiomerically and 
diastereomerically pure has received much less attention.27 Substituted 2,3-
dihydrofurans of type A, B (Figure 9)  would make particularly interesting starting 
materials for the asymmetric synthesis of tetrahydrofurans, structural motifs which 
can be found in many important natural products including polyether antibiotics, 
lignans and nucleosides (Figure 10). 
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Figure 9: Applications of tetrahydrofurans. 
 
2,3-Dihydrofurans contain a vinyl ether moiety that can undergo various chemical 
transformations.28    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Importance of the tetrahydrofuran moiety. 
 
O
R2
R1
Me
SiEt3
O
R
SiEt3
n
O
R
SiEt3
n
O
R2
R1
Me
SiEt3
Polyether antibiotics
Nucleosides
Lignans
A
B
*
*
*
*
O
OMe
MeO
HO
O
OMe
OMe
O
OMe
HO
O
OMe
OMe
OMeMeO
O O O O
Me
OH
CH2OH
H
Me
H
Me
H
Et
H
Me
O
CO2H
OH
Me
Me
MeO
Me
O OHOHOH
CO2H
O
H
OH
Magnone A
Magnone B
Monensin
Lonomycin
                                                 THEORETICAL PART                                                                     26 
 
 
 
 
 
2.1.2 Approaches towards the construction of dihydrofuran moiety 
 
 
 
Pierre Bruns approach 
In the year 2003, Brun et al. disclosed a synthesis of (+)-phyltetralin 38, a 2,3-
dihydrofuran derivative, by using a diastereoselective, Mn-promoted, radical 
addition reaction. Thus, addition of β-oxo ester 35 to the chiral N-
cinnamoyloxazolidine 36 yielded the diastereomeric 2,3-dihydrofurans 37a and 
37b in 72% with 80% de.  (Scheme 26).29 Though this method is novel, high 
selectivity have yet to be achieved. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 26: Asymmetric synthesis of dihydrofurans. 
 
David Evans contribution 
Evans et al. devised a method for the asymmetric synthesis of 2,3-dihydrofurans 
via [3+2] cycloaddition (or anulation) of allenylsilanes (with bulkier substituents on 
silicon) and an aldehyde or glyoxalate, catalyzed by 8-Sc[(S,S)-Ph-pybox](OTf)3. 
The tert-butyldiphenylsilyl group was found to be critical to achieve optimla enantio 
selectivity (92% ee) (Scheme 27).30  
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Scheme 27: Sc-catalyzed asymmetric synthesis of 2,3-dihydrofurans.  
 
 
Davies contribution 
Davies et al. disclosed an asymmetric synthesis of 2,3-dihydrofurans by a rhodium 
(II) octanoate catalyzed decomposition of 2-diazo-3-siloxybutenoates containing 
pentalactone as a chiral auxiliary, in the presence of vinyl ethers.  Thus, the 2,3-
dihydrofurans were afforded in good yields, via the two-step reaction sequence 
shown in the Scheme 28. 31 
 
 
 
 
 
 
 
 
Scheme 28:   Rh Catalyzed asymmetric synthesis of 2,3-dihydrofurans.  
 
 
2.2   Present Work 
 
2.2.1 Aim  
 
As illustrated in the earlier section, chiral tetrahydrofurans can be found in many 
important natural products including polyether antibiotics, lignans and nucleosides. 
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A novel asymmetric approach to such natural products could involve using 
substituted 2,3-dihydrofurans as synthetic precursors to this structural motif.27 
In 2000, R. Hainz, a former member of our research group, found a method for the 
region- and stereoselective hydroxyalkylation of allyl sulfoximines leading to the 
synthesis of enantiopure, acyclic, homoallylic alcohols. 11f 
Titanation of the lithiated (E)-configured allylic sulfoximines 39 with ClTi(OiPr)3 
afforded the corresponding bis(allylsulfoximine)titanium complexes 40 which 
reacted with aldehydes with high regio- and stereoselectivities at the γ-position to 
give the corresponding (Z)-anti-configured, δ-N-methylsulfonimidoyl-substituted, 
homoallylic alcohols 41(Scheme 29). 
 
 
 
 
 
 
 
 
Scheme 29: Hydroxyalkylation of acyclic allylic sulfoximines. 
 
Hainz also extended the method to cyclic allylic sulfoximines.11f Thus, cyclic allyl 
sulfoximines reacted with aldehydes with high regio- and stereoselectivily at the γ-
position to yield the corresponding vinylic sulfoximines (Scheme 30). 
 
            
 
 
 
 
 
 
Scheme 30: Hydroxyalkylation of cyclic allylic sulfoximines. 
 
 
The above mentioned method was successfully applied to the asymmetric 
synthesis of anti-homopropargylic alcohols by L. R. Reddy (Scheme 31). 32 
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Scheme 31: Asymmetric synthesis of homopropargylic alcohols. 
 
During the course of these investigations, it was observed that the β-Me-
substituted alkenyl sulfoxonium ylides 42 (R1 = Ph, R2 = i-Pr, R3 = Me) afforded the 
2,3-dihydrofurans 45 rather than the expected methyl-substituted alkynes 44 
(Scheme 32). The racemic acyclic siloxy alkylidene carbenes41,42of type 43 were 
also reported in literature. 
                          
 
 
 
 
 
 
 
 
Scheme 32: Generation and reactivity of silyloxy-substituted alkylidene carbenes. 
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S. Koep has recently observed that upon treatment with DBU  the 
(sulfonylamino)alkyl-substituted 1-alkenyl aminosulfoxonium salt 46 suffers a novel 
migratory cyclization, leading to the formation of the unsaturated fused bicyclic 
proline derivative 48 via the allylic aminosulfoxonium salt 47 (scheme 33).11b  
 
 
 
 
 
 
 
Scheme 33: Migratory cyclization of sulfonylamino substituted 1-alkenyl amino- ..   
sulfoxonium salts. 
 
 
2.2.2      Results and Discussions 
 
2.2.2.1   Retrosynthetic analysis 
Not only the activated double bond but also the vinylic silyl group of 45 should 
allow useful synthetic transformations, including the replacement of the silyl moiety 
by a metal atom.33-35 Up to now, the application of chiral 2,3-dihydrofurans in 
natural product synthesis has been hampered by the lack of general methods for 
their asymmetric synthesis.36,37 Thus, it would be a great interest to develop a 
general and highly efficient asymmetric approach to access  these compounds.             
Thus, the dihydrofurans 45 were realized from the corresponding sulfoxonium 
ylides 49. The ylide 49 can be derived from the allylic sulfoximine 50 whose 
synthesis was recently reported by our group.11f As also shown in the retro 
synthetic approach, the bicyclic dihydrofuranes 51 and bicyclic tetrahydrofurans 56 
were realised from the ylides 53 via an analogous route (Scheme 34). 
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Scheme 34: Retrosynthetic analysis. 
 
Although the primary goal of our investigations was the development of an 
asymmetric synthesis of 2,3-dihydrofurans of types 45 and 51, the prospect of 1-
alkenyl aminosulfoxonium salts 49 and 53 serving as a new source for chiral 
alkylidene carbenes was also of particular interest. Since carbenes of type 52 
were unknown at the begining of our investigation, it was particularly interesting to 
see whether 1,5-O,Si-bond insertion, with formation of the corresponding alkynes, 
would occur.38-40 
 
2.2.2.2     Hydroxyalkylation of acyclic allyl sulfoximines  
As depicted in the retrosynthetic approach, the initial targets in the synthesis of 
acyclic sulfoximines, the vinyl sulfoximines were prepared by following the 
addition-elimination-isomerization route depicted in Scheme 35.11f Thus, treatment 
of the chiral sulfoximine 34 with n-BuLi at -78 °C, followed by addition of 
corresponding methyl ketones and methylchloroformate, and then by DBU  gave 
vinylsulfoximines  57a and 57b.  These were treated with DBU in acetonitrile at 
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elevated temperatures to afford allyl sulfoximines as a mixture of (E) and (Z) 
isomers.  The (E/Z) ratio for compound 58a was 70:30 and 79:21 for compound 
58b. These isomers were separated by preparative HPLC.  Isomerization of the 
unwanted (Z) isomers with DBU in acetonitrile, again gave mixtures of the (E) and 
(Z) isomers.       
 
 
 
 
 
Scheme 35: synthesis of acyclic allylic sulfoximines. 
 
The succesive treatment of 58a and 58b with n-BuLi, ClTi(Oi-Pr)3 and 0.5 equiv of 
aldehydes 59a-d, followed by subsequent silylation of the thus-formed homoallylic 
alcohols with chlorotriethylsilane in the presence of imidazole, afforded the 
diastereomerically pure (anti,Z)-configured silyl ethers 50a-d in good yields (Table 
1).  Hydroxyalkylation of the methyl substituted titanium complexes derived from 
58a and 58b with the aromatic and aliphatic aldehydes 59a-d proceeded with high 
regio- and stereoselectivities, similar to those of the corresponding titanium 
complexes having only a disubstituted C=C double bond. 11f  
 
                
 
 
 
 
 
Scheme 36: asymmetric synthesis of sulfoximine substituted acyclic homoallylic      
alcohols. 
 
Formation of the vinyl sulfoximines proceded in approximately 50% yields, with 
recovery of unreacted allylic sulfoximines in 38-44% yield.  The reason attributed 
to the incomplete conversion of allyl sulfoximines is due to the formation of 
bis(allyl)titanium complexes, which are capable of only transferring one allylic 
sulfoximine unit with high selectivities to the aldehyde11f (Scheme 37). 
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Scheme 37: Formation of bis(allylitanium) complexes. 
 
2.2.2.3     Hydroxy alkylation of the cyclic allyl sulfoximines 
The cyclic allylic sulfoximines 9a and 9b were prepared in a one-pot operation 
without isolating the intermediates from sulfoximine 34 and the corresponding 
cycloalkanones by the inverse Peterson-olefination and isomerization sequence.25  
Thus, compound 34 was treated with n-BuLi at -78 °C and then with a 
cycloalkanone to afford the corresponding β-hydroxy sulfoximine. This was without 
isolation treated with chlorotrimethylsilane and then n-BuLi.  Finally, treatment with 
NaOMe afforded the cyclic allylic sulfoximines 9a and 9b in good yields (74-78%). 
Similarly, the eight-membered cyclic allylic sulfoximine ent-9c was synthesized 
from sulfoximine ent-34 and cyclooctanone in 79% yield. 
 
 
 
 
 
 
 
Scheme 38: Asymmetric synthesis of sulfoximine-substituted cyclic homoallylic 
alcohols. 
 
The succesive treatment of the cyclic allylic sulfoximines 9a, 9b and ent-9c with n-
BuLi, ClTi(Oi-Pr)3 and 0.5 equiv of aldehyde 59b, and the subsequent silylation of 
the intermediate homoallylic alcohols afforded the silyl ethers 54a, 54b and ent-
54c, respectively, each as a single diastereomer in good yields (Table 2). Similar 
to the acyclic allylic sulfoximines, the conversion of 9a, 9b and ent-9c was found to 
be approximately 50% with 38-40% recovery of unreacted allylic sulfoximines.11f  
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2.2.2.4     Synthesis of 2,3-dihydrofurans 
It has been found in our group that the activation of 50 can be achieved through 
the methylation of the N-methyl sulfoximine group with Me3OBF4 to afford the 
corresponding (dimethylamino)sulfoxonium salt 49.23,32 Hence, based on the 
earlier literature for the activation, our initial attempt towards the generation of 2,3-
dihydrofurans is proposed in scheme 35. Thus, the methylation of the alkenyl 
sulfoximines 50a-h with Me3OBF4 in dichloromethane afforded the 
(dimethylamino)sulfoxonium salts 49a-h in almost quantitative yields. Treatment of 
the salts 49a-h with 1.1 eq. of Li(NH)t-Bu in THF, first at −78 °C and then at room 
temperature, afforded the silyl-substituted 2,3-dihydrofurans 45a-h in high overall 
yields, based on 50a-h. The structure of the substituted 2,3-dihydrofurans were 
established by spectral analysis. These results show that this 2,3-dihydrofuran 
synthesis works equally well for derivatives carrying aliphatic and aromatic 
substituents, including sterically demanding groups. The sulfonamide 29c was 
isolated with > 98% ee in all cases in high yields (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 39: Asymmetric synthesis of monocyclic 2,3-dihydrofurans. 
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Table 1: Asymmetric synthesis of 2,3-dihydrofurans 45a−h 
compd R1 R2 R3 50 
yield (%)a,b
50 
dr 
45 
yield (%) 
29c 
yield (%)
a IPr CH3 Ph 77(96) ≥ 98:2 95 86 
b IPr CH3 p-MeOC6H4 76(95) ≥ 98:2 90 85 
c IPr CH3 p-BrC6H4 76(92) ≥ 98:2 92 85 
d IPr CH3 c-C6H11 80(95) ≥ 98:2 86 87 
e Ph CH3 Ph 71(94) ≥ 98:2 96 89 
f Ph CH3 p-MeOC6H4 81(97) ≥ 98:2 92 85 
g Ph CH3 p-BrC6H4 77(95) ≥ 98:2 94 86 
h Ph CH3 c-C6H11 79(94) ≥ 98:2 92 90 
a Yields are based on recovered allylic sulfoximine. b Values in parentheses are yields 
based on aldehyde. 
 
2.2.2.5     Synthesis of Bicyclic 2,3-Dihydrofurans 
Having developed a high yield synthesis of the enantio- and diastereomerically 
pure monocyclic 2,3-dihydrofurans 45a-h from the acyclic, δ-silyloxy-substituted, 
alkenyl sulfoximines 50a-h, the synthesis of bicyclic 2,3-dihydrofurans of type 51 
was investigated. Thus, the methylation of sulfoximines 54a, 54b, and ent-54c with 
Me3OBF4 proceeded readily and gave the cyclic (dimethylaminosulfoxonium) salts 
53a, 53b and ent-53c, respectively, in practically quantitative yields (Scheme 40). 
Upon treatment with LiN(H)tBu, first at -78 °C and then at room temperature, salts 
53a, 53b, and ent-53c cleanly delivered the enantio-and diastereomerically pure 
bicyclic 2,3-dihydrofurans 51a, 51b, and ent-51c, respectively, having a six, seven, 
and eight membered carbocyclic ring, in overall yields, based on 54a, 54b, and 
ent-54c, respectively. 
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Scheme 40: Asymmetric synthesis of bicyclic 2,3-dihydrofurans. 
 
Table 2: Asymmetric synthesis of bicyclic 2,3-dihydrofurans 
compd n 54/ent-54 51/ent-51 
yield (%) 
29c/ent29c 
Yield (%) yield (%)a,b dr 
A 1 78(96) ≥ 98:2 89 86 
B 2 79(95) ≥ 98:2 91 90 
C 3 77(96) ≥ 98:2 90 88 
a Yields are based on recovered allylic sulfoximine. b Values in parentheses are yields 
based on aldehyde. 
 
 
 
 
2.2.2.6     Mechanistic Considerations of the 2,3-Dihydrofuran formation 
 
The formation of 2,3-dihydrofurans 45a-h, 51a, 51b and ent-51c from the 
aminosulfoxonium salts 49a-h, 53a, 53b and ent-53c, respectively may be 
described mechanistically as follows (Scheme 41). On the basis of the results 
obtained previously with the synthesis of ylides 42 (R3 = H),32 it is proposed that 
the reaction of the aminosulfoxonium salts 49a-h, 53a, 53b and ent-53c with the 
lithum amide at low temperatures affords the alkylidene carbene sulfoxonium 
ylides 60a-h, 63a, 63b and ent-63c, respectively (Scheme 41).  
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Scheme 41: Mechanistic scheme for mono and bicyclic 2,3-dihydrofurans. 
 
At higher temperatures, these alkylidene carbenoids eliminate sulfinamides 29c 
and ent-29c, resulting in the formation of the δ-silyloxy alkylidene carbenes 43a-h, 
52a, 52b, and ent-52c, respectively. Because of the different conformations the 
alkylidene carbenes 43a-h can adopt with regard to the Csp2-Csp3 bond and the 
high propensity that alkylidene carbenes normally show for C,H-bond insertion, not 
only a 1,5-O,Si-bond but also a 1,5-C,H-bond insertion38 could, in principle, occur 
with formation of the cyclopentene derivatives 62a-c. This was, however, not 
observed within the limits of the yields obtained and the δ-silyloxy alkylidene 
carbenes 43a-h, 52a, 52b and ent-52c instead delivered the 2,3-dihydrofurans 
45a-h, 51a, 51b, and ent-51c, respectively, via a nonconcerted 1,5-O,Si-bond 
insertion reaction followed by [1,2]–silyl migration. These postulations are in 
accordance with the results of previous studies.38,41-43  
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2.2.2.7     Synthesis of Unsaturated Bicyclic Tetrahydrofurans 
Tetrahydrofurans 56 having the various ring size should be of particular synthetic 
interest because of the many natural products containing a bicyclic 
tetrahydrofuranoid skeleton or structural element (Figure 11).44-47 
 
 
 
 
 
 
 
Figure 11: Importance of of bicyclic tetrahydrofurans. 
 
It was rercently observed that (sulfonylamino) alkyl-substituted 1-alkenyl 
aminosulfoxonium salts of type 46 suffer upon treatment with DBU a novel 
migratory cyclization leading, via allylic aminosulfoxonium salts of type 47, to the 
formation of unsaturated fused bicyclic proline derivatives of type 48 (Scheme 
42).23 
 
 
 
 
 
 
Scheme 42:  Asymmetric synthesis of bicyclic proline derivatives. 
This observation initiated us to study the reaction of the cyclic aminosulfoxonium 
salts 53a, 53b and ent-53c with DBU in order to see whether an access to 
unsaturated fused bicyclic tetrahydrofurans 56a, 56b and ent-56c respectively 
(Scheme 46) could also be affected. Tetrahydrofurans 56 fused to a variety of ring 
sizes should be of particular synthetic interest because of the many natural 
products containing a bicyclic tetrahydrofuranoid skeleton or structural element. 
The double bond present in this 56 should allow for further synthetic 
transformations. An asymmetric synthesis of 56 has, to the best of knowledge not 
yet been described.48 While the chances for a regioselective isomerization of 54 to 
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the allylic aminosulfoxonium salts 55 seemed to be good, the prospects for  
cyclization of the latter and formation of 56 were considered to be less promising, 
because of the poor nucleophilicity of the silyloxy group. The DBU-assisted 
conversion of 47 to 48 is, perhaps, not representative because the strongly- 
nucleophilic, deprotonated, sulfonylamino group attacks the C-atom in the alpha 
position to the aminosulfoxonium group. 
 
 
 
 
 
 
 
Scheme 43: Asymmetric synthesis of unsaturated fused bicyclic tetrahydrofurans. 
 
Table 3: Asymmetric synthesis of bicyclic tetrahydrofurans. 
Compd n 56/ent-56 
yield (%) 
29c/ent-29c 
yield (%) 
a 1 69 84 
b 2 72 87 
c 3 74 88 
 
Treatment of 53a, 53b and ent-53c with DBU in DCM at RT lead to a highly- 
regioselective migratory cyclization and gave the enantio- and diastereomerically -
pure bicyclic tetrahydrofurans 56a, 56b and ent-56c respectively, in yields of 69-
72% after aqueous workup and chromatography. Formation of 51a, 51b and ent-
51c under these conditions was not observed. The structures of the 
tetrahydrofurans 56b and ent-56c, containing a seven-and eight-membered 
carbocyclic ring respectively, were determined by X-ray crystal structure analysis 
(Figure 8) and also establiblished by spectral analysis. Besides 56a, 56b and ent-
56c, the sulfinamides 29c and ent-29c, respectively, were isolated in good yields 
(Table 3). 
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Figure 12: Structure of the bicyclic tetrahydrofurans 56b and ent-56c derived from                   
single crystal X-ray analysis. 
 
2.2.2.8     Mechanistic Considerations 
 
The formation of unsaturated fused bicyclic tetrahydrofurans 56a, 56b and ent-56c 
from the aminosulfoxonium salts 53a, 53b and ent-53c, respectively may be 
described mechanistically as follows (Scheme 44). Although the mechanism of the 
isomerization of 53a, 53b and ent-53c is, like that of 46, not known,23 the formation 
of the allylic aminosulfoxonium ylide intermediates 63a, 63b and ent-63c may play 
an important role. Deprotonation of 53a, 53b and ent-53c at the γ-position is 
expected to be a facile process because of the stabilization of the negative charge 
of 63a, 63b and ent-63c by the aminosulfoxonium group and the double bond. For 
example N,N-dimethyl-S-methylphenylsulfoxonium tetrafloroborate already has a 
Pka value of 15.5, and the double bond is expected to raise the acidity of 53a, 53b 
and ent-53c even further.49,50 Cyclization of the allylic aminosulfoxonium salts 55a, 
55b, and ent-55c should primarily lead to the silyl tetrahydrofuranium salts 65a, 
65b and ent-65c, respectively.  
These salts are desilylated either by DBU, the sulfonimide, or water upon aqueous 
workup51 with formation of 56a, 56b and ent-56c. In considering the low reactivity 
of for example silyl ethers of 3-bromomethyl-but-3-en-1-ol derivatives towards 
cyclization with formation of the corresponding 3-methylene tetrahydrofurans.52 
The facil cyclization of 55a, 55b and ent-55c is noteworthy. This points to a high 
nucleofugacity of the allylic (dimethylamino)sulfoxonium group. 
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Scheme 44: Asymmetric synthesis of unsaturated fused bicyclic 2,3-dihydrofurans. 
 
 
2.2.2.9     Recycling of the Chiral Auxiliary 
Besides the 2,3-dihydrofurans 45a-h, 51a and 51b and the tetrahydrofurans 56a 
and 56b sulfinamide 29c was isolated in high yields with 98% ee. Thus, a 
conversion of 29c to the sulfoximine 34, the starting material for the synthesis of 
allylic sulfoximines, was desirable. To this end, sulfinamide 29c was treated with 
MeMgCl, which gave, under inversion of configuration, the sulfoxide 33 which was 
isolated in 93% yield with 98% ee (Scheme 45). Since the conversion of 33 to 
sulfoximine 34 has already been described,53 the synthesis of 34 from 29c 
represents a recycling of the chiral auxiliary. 
 
 
 
 
 
 
Scheme 45: Recycling of the chiral auxiliary. 
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2.2 Conclusion 
 
We have devised an asymmetric synthesis of highly substituted mono- and bicyclic 
2-silyl-2,3-dihydrofurans from enantio- and diastereomerically pure silyloxy 
alkylidene carbene (dimethylamino)sulfoxonium ylides carrying two stereogenic 
centers. Key steps are the elimination of the ylides with formation of silyloxy 
alkylidene carbenes and the O,Si-bond insertion of the latter. 
 
 
 
 
 
 
 
Scheme 46: Asymmetric synthesis of 2,3-dihydrofurans. 
 
The advantage of this synthesis is that it provides access to enantio- and 
diastereomerically pure 2,3-dihydrofurans carrying various aryl and alkyl 
substituents including sterically-demanding ones. The results show that 1-alkenyl 
(dimethylamino)sulfoxonium salts can, with the intermediacy of alkylidene carbene 
(dimethylamino) sulfoxonium ylides, serve as versatile starting materials for the 
generation of chiral alkylidene carbenes. 
 
 
 
 
 
 
 
 
Scheme 47: Asymmetric synthesis of bicyclic 2,3-dihydrofurans. 
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Interestingly 1-alkenyl (dimethylamino) sulfoxonium salts show a synthetically 
highly-useful dichotomy in their reactivity toward bases. While with strong bases 
an α-elimination of the aminosulfoxonium salts occurs, weak bases induce an 
isomerization to the allylic aminosulfoxonium salts whose (dimethylamino) 
sulfoxonium group shows a high nucleofugacity in intramolecular substitution by a 
silyloxy group leading to tetrahydrofurans. 
 
 
 
 
 
 
 
 
 
Scheme 48:  Asymmetric synthesis of bicyclic tetrahydrofurans. 
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CHAPTER 3 
 
A  Method for the Asymmetric Synthesis of Acyclic, 
Mono- and Bicyclic  γ,δ– Unsaturated α-Amino Acids by 
employing ClTi(NEt2)3. 
 
. 
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3       A Method for the Asymmetric Synthesis of 
          Acyclic, Mono- and Bicyclic γ,δ – Unsaturated  
          α-Amino Acids by employing ClTi(NEt2)3 
 
3.1    Introduction 
 
3.1.1 Brief introduction about relevant biologically-active molecules 
 
The synthesis of α-amino acids (AAAs) has been of immense interest to organic 
chemistry for over 150 years. It is well known that AAAs are vital to life itself as the 
“building blocks” for peptides, proteins and many other natural products.56 Beyond 
this fundamental role, AAAs are extensively used as food additives and as 
agrochemical, pharmaceutical and crop protection agents. The most important 
applications of AAAs are shown in Figure 13. Amino acids have also been used as 
a source of the chiral pool57 and as catalysts for asymmetric synthesis.58,59 The 
importance of AAAs has prompted the development of a multitude of synthetic 
methods for their preparation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Applications of amino acids.  
 
CLASSIFICATION OF α-AMINO ACIDS 
AAAs are one of the five major classes of natural products and can be grouped 
broadly into proteinogenic and non-proteinogenic AAAs. The proteinogenic AAAs 
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(derived by protein hydrolysis) are twenty in number, and a large number of 
naturally occurring amino acids are reported in the literature. Non-proteinogenic 
AAAs are simple derivatives of proteinogenic amino acids, are mainly produced by 
various micro organisms and interfere with the biochemical pathways of other 
organisms. According to a survey in 1985, there are about 700 natural AAAs and 
the list continues to grow.60 In addition to proteinogenic and non-proteinogenic 
AAAs, there is a larg number of synthetic AAAs have been reported. These AAAs 
are often termed as unusal (unnatural/non-natural/non-standard) amino acids. 
Unusual AAAs can be further classified depending on the degree of substitution at 
the α-position. 
 
Cα-SUBSTITUTED α-AMINO ACIDS 
α-Alkylated α-amino acids play an important role in the design of therapeutically 
useful products (Figure 14). Representative examples of this class are 
phenylglycine and p-hydroxy phenylglycine. D-phenylglycine is used as a building 
block in the synthesis of best selling drugs such as ampicillin and ceflexin.61 
Similarly, D-p-hydroxy phenylglycine is used in the preparation of several 
antibiotics such as amoxicillin and cefadroxil (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Therapeutically useful amino acids. 
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Cα  N -SUBSTITUTED α-AMINO ACIDS (Constrained Imino Acids) 
In this class of amino acids the nitogen atom of the amino acid group is part of a 
ring. These amino acids (68-76) play an important role in inducing the 
conformation of the peptide into which the amino acid is incorporated. Since the 
nitogen in these amino acids is unable to act as hydrogen bond donor unless it is 
located in a terminal position of a langer molecule. A few examples of this class 
are shown in Figure 13. L-Azetodinecarboxylic acid 68 and its derivatives are 
important amino acids both chemically and biologically.62,63 Naturally occurring 
proteinogenic AAA proline (69) plays an important role in many biologically active 
peptides. Recently, phenylproline 70 was used as a synthon in the synthesis of 
angiotensin-converting enzyme (ACE) inhibitors.64 Several examples of peptides 
which are based on the proline residue are also described in the literature. 
Captopril 75 is the first orally active sulfhydryl Ala-pro derivative approved for use 
in the treatment of hypertension and congestive heart failure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Applications of cyclic α-amino acids. 
 
Another interesting imino acid 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
(Tic)-(71) is a critical component in quinaprilat (H) (77). Tic is commonly used as 
structural replacement for phenylalanine in many biologically active peptides. 
Incorporation of Tic-(71) into a peptides not only restrics the conformational 
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freedom of the aromatic ring but also impose constraints in the peptide 
backbone.65 These modifications provide valuble insight into the bioactive 
conformations of the peptide ligands and have led to potent and selective drugs. 
For example, when the phenylalanine component of the naturally-occuring farnesyl 
transferase inhibitor 78, shown in Figure 14 is replaced with Tic, the peptidomimitic 
structure 79 was obtained and found to be 50-fold more active than the natural 
product 78.66 
 
 
 
 
 
 
Figure 16: Importance of bicyclic α-amino acids.      
 
3.1.2 Approaches towards the construction of proline derivatives 
 
The literature on the synthesis of optically-pure AAAs is large and it is beyond the 
scope of this thesis. In the following section we have opted to discuss methods for 
the synthesis of 3-substituted unsaturated prolines, in order to place our work in 
the proper perspective.  
Helmchen approach 
Helmchen et al. disclosed a synthesis of proline derivatives involving ring closing 
metathesis (RCM), directed alkoxycarbonylation and enzymatic kinetic resolution 
of the racemate (Scheme 49).67  
 
 
 
 
 
 
 
 
Scheme 49:  Asymmetric synthesis of prolines via RCM. 
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Schmitt contribution 
Schmitt et al. disclosed an asymmetric synthesis of 3-substituted prolines by a 
palladium-mediated coupling reaction of the O-triflate of 2-cyano-3-oxopyrrolidine 
(Scheme 50).68 This method could generate proline derivatives but with lower de 
and ee.  
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Scheme 50: Asymmetric synthesis of prolines via a palladium-mediated coupling        
                    reaction. 
Gais approach 
Gais et al. disclosed the asymmetric synthesis of 3-substituted prolines by using 
allyltitaniumsulfoximine chemistry.69 
  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 51: Asymmetric synthesis of prolines using sulfoximine chemistry. 
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3.2   Present work 
 
3.2.1  Aim 
  
As illustarted in the earlier section, proline derivatives are valuable compounds in 
organic synthesis. In 2000, Hainz and Bruns, former members of our research 
group, found a method for the region- and diastereoselective hydroxyalkylation of 
the allylic sulfoximines (Scheme 52). 
 
  
 
 
 
 
 
 
 
Scheme 52: Asymmetric synthesis of sulfoximine substituted homoallylic alcohols. 
 
Schleusner extended the method to aldehyde analogues such as the α-iminoester, 
as dipected in Scheme 53.70 
 
 
 
 
 
 
 
 
 
Scheme 53:   Reactivity of bis(allylsulfoximine)titanium complexes with aldehyde        
                       and α-imino ester. 
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The above mentioned method was succesfully applied to the asymmetric 
synthesis of 3-substituted unsaturated proline derivatives by Tiwari and Schneider 
(Scheme 54).69  
 
 
 
 
 
 
 
 
Scheme 54: Asymmetric synthesis of proline derivatives by Tiwari and Schneider. 
 
Based on these interesting observations, the following objectives were set forth for 
the present investigation. 
  
1) Development of  γ-aminoalkylation using ClTi(NEt2)3 and α-iminoester. 
2) To develop an efficient method for the synthesis of both cyclic and acyclic 
allylic sulfoximines. 
3) To develop a method for the asymmetric synthesis of proline derivatives  
using chlorine substitution. 
 
3.2.2    Results and Discussion . 
 
3.2.2.1     Reterosynthetic Aproach 
 
The reactions of allylmetal reagents with carbonyl compounds and imines have 
been extensively studied during the last twenty years.71,72We have previously 
reported mono-allylsulfoximinetitanium complex formation with ClTi(NEt2)3 and bis-
allyltitanium complex formation with ClTi(O-iPr)3. Though the mono-allyltitanium 
complex formation with ClTi(NEt2)3 was previously known, we have explored the 
use of bis-allyltitanium complexes for the synthesis of optically pure acyclic and 
cyclic α-amino acids. Now, in the following section, we describe the application of 
mono-allyl titanium complexes to the synthesis of monocyclic and bicyclic α-amino 
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acids (Scheme 55). As depicted in the retrosynthetic Scheme 55, the intial target 
was the synthesis of the starting allylic sulfoximines and iminoester which has 
been described by our group previously. 70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 55:  Retrosynthetic scheme.. 
 
3.2.2.2     Synthesis of acyclic allylic sulfoximines 
As depicted in the retrosynthetic approach, the initial targets in the synthesis of the 
acyclic sulfoximines, the vinyl sulfoximines, were prepared by following the 
addition-elimination-isomerization route11a,39 shown in Scheme 59.  Thus, 
treatment of the chiral sulfoximine 3440 with n-BuLi at -78 °C, followed by the 
addition of aldehydes and methylchloroformate, and subsequently by DBU gave 
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acetonitrile at elevated temperatures to afford allyl sulfoximines 84a, b as mixtures 
of (E) and (Z) isomers which were separated by preparative HPLC (Scheme 56).       
 
 
 
 
 
 
Scheme 56: Synthesis of acyclic allylic sulfoximines.. 
 
3.2.2.3     Synthesis of cyclic allylic sulfoximines 
The known cyclic allylic sulfoximines 9a and 9b were prepared in a one pot 
synthetic operation, without the isolation of intermediates, from the chiral N-methyl 
sulfoximine 34 and the corresponding cycloalkanones by the inverse Peterson-
olefination and isomerization sequence previously described.16 
          
 
 
 
 
 
Scheme 57: Synthesis of cyclic allylic sulfoximine. 
 
3.2.2.4  Synthesis of the N-Bus-protected α-iminoester 
Synthesis of tert-butylsulfonamide 
The intermediate tert-butylsulfinyl chloride can be prepared from commercially- 
available bis-tert-butyl disulfide as shown in scheme 58.73 
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Scheme 58: Synthesis of tert-butylsulfonamide.. 
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Synthesis of α-iminoester from tert-butylsulfonamide 
The sulfonamide was treated with SOCl2 in refluxing toluene and followed by the 
addition of ethyl glyoxylate to give the N-Bus α-Imino ester (Scheme 59).73 
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Scheme 59: Synthesis of the α-imino ester... 
 
3.2.2.5 Addition to α-Imino Ester 
Having now synthesized the starting materials by using literature procedures we 
now set out to reach the goals presented earlier in this chapter. For the study of 
the addition of mono-allyl titanium complexes to the α-imno ester, we selected 
both cyclic and acyclic allylic sulfoximines. Titanation of lithiated-9a-d with 1.4-1.5 
eq. of ClTi(NEt2)3 at -78 °C for one hour, was followed by the dropwise addition of 
the α–imino ester. After stirring the reaction mixture for 15 h at room temperature, 
a diastereomeric mixture of (E)-82a-d and (E)-83a-d was formed. The dr was 
determined by 1H NMR spectroscopy of the crude reaction mixture. The crude 
reaction mixture was recrystallised to afford (E)-82a-d and (E)-83a-d (69-87%, 2-
14% depending upon the ring size). The 1H NMR spectrum of (E)-82c showed a 
multiplet at 4.22 for 11-H, and the signal of the 2-H protons as a doublet of 
doublets at 4.04. For (E)-83c we observed signals for the corresponding protons at 
3.90 and 3.71, respectively. This indicates the formation of (E)-82c, as the major 
diastereomer, the structure of which was further established by X-ray crystal 
analysis (Figure16).  
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Scheme 60: Asymmetric synthesis of sulfoximine substituted α-amino acid                                 
                     derivatives. 
Table 4: Asymmetric synthesis of γ,δ-unsaturated α-amino acids 
n Allylic 
sulfoximine 
Aminoalkylation
Product 
E82ad/Ea-   
83a-d 
E-82a-d 
Yield      de 
E-83a-d 
Yield        de
1 9a E-82a / E-83a 5.7-6 : 1 70           ≥98 14          ≥98
2 9b E-82b / E-83b 9.7-10 : 1 69           ≥98 8            ≥98
3 9c E-82c / E-83c 23-24 : 1 82           ≥98 4            ≥98
4 9d E-82d / E-83d 45-46 :1 87           ≥98 2            ≥98
aDetermined by 1H NMR spectroscopy of the crude reaction mixture 
 
We have observed the exclusive formation of the (E)-isomer in case of entries 3 
and 4 (Table 4). The configuration of the double bond of each set of isomers was 
determined by NOE experiments that revealed strong NOE effects between the 
olefinic proton and the allylic proton at the stereogenic center for the (E)-isomer, 
and also a strong NOE between the phenyl and the methylene protons of the 
alaiphatic ring (Figure 15). 
 
 
 
 
 
Figure 15:   NOEs of compound E-82c and E- 83c (500 MHz, CDCl3).. 
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The spectroscopic data of the minor diastereomer E-83c showed complete 
agreement with the data previously reported by our group.23 We have observed 
high diastereoselectivity in the case of 7- and 8-membered rings. Having 
confirmed, the formation of (E)-82c as the major diastereomer, we wished to 
examine the effect of ring size on diastereoselectivity. Following the same 
experimental procedure, we performed futher reactions using substrates with  
various ring sizes. High diastereoselectivity and yield were observed in the case of 
the 7- and 8-membered systems (Table 4, entries 3, 4). This shows that ring size 
affects the distereoselectivity of the amino alkylation reaction. The configuration of 
(E)-82c was determined by X-ray crystal analysis which was carried out by Prof. 
Dr. G. Raabe (Figure 16). 
 
 
 
 
 
 
 
Figure 16: Structure of Compound E-82c as determined by single crystal X-ray                            
                  analysis. 
Having successfully completed the study of cyclic systems we turned our attention 
towards the acyclic systems in order to demonstrate the efficiency of our 
approach. As examples, 84a and 84b were chosen to prove the feasibility of regio- 
and stereoselective addition of acyclic mono-allyl titanium complexes 85a and 85b 
to α-imino ester. Thus, the treatment of 85a and 85b, which were prepared from 
allylic sulfoximine 84a and 84b in the usual manner with 1.2 equiv of N-Bus α-
imino ester 81 in the presence of ClTi(NEt2)3 resulted in a 95-96% conversion of 
84a and 84b. Diastereomeric mixtures of the acyclic amino acid derivatives (E)-
86a-b and (E)-87a-b were obtained in a ratio of 6:1 and 1.9:1, respectively (Table 
5). Spectroscopic data for the minor diastereomer matched that previously 
reported by our group.70 
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Scheme 61:  Asymmetric synthesis of sulfoximine substituted α-amino  
                      acid.derivatives.. 
 
Table 5: Asymmetric synthesis of γ,δ-unsaturated α-amino acids 
n Allylic 
sulfoximine 
Aminoalkylation 
Product 
E-86a-b/Ea-   
87a-b 
E-86a-b 
Yield        de 
E-87a-b  
Yield        de 
1 84a E-86a / E-87a 1.8-1.9 : 1 56            ≥98 10           ≥98
2 84b E-86b / E-87b 5.8-6 : 1 58            ≥98 32           ≥98
aDetermined by 1H NMR spectroscopy of the crude reaction mixture. 
 
3.2.2.6     Stereochemical consideration of the amino alkylation 
The stereochemical outcome of reactions involving mono(alkenyl)aminotitanium 
complexes was already rationalised in the case of reactions with aldehydes.11 A 
stereochemical rationalisation of the aminoalkylation of cyclic allylic sulfoximines 
using ClTi(OiPr)3 was proposed by Schleusner and Koep.70 In this case 
compounds 83 and 94 were obtained.23,70 
For the rationalization of the regio- and stereoselectivities of the reactions of the 
mono (alkenyl) aminotitanium complexes 9a-d with imines, we make the following 
assumptions. 
(1) Complex 88 is an equilibrium mixture of C-Ti complexes 88A and epi-
88A and the N-Ti comlexe 88B (Figure 17). 
(2) The reactions of 88A, epi-88A, and 88B with the iminoester are 
governed by the Curtin-Hammett principle.70 As a conseqvence, the 
product composition is not in direct proportion to the relative 
concentration of 88A and epi-88A of the substrate, but is controlled 
mainly by the difference in standard free energies of the respective 
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transition states. Thus, 88A leads to TS-89 and TS-90, whereas epi-
88A leads to TS-91 and TS-92 (Figure 17). 
(3) The reactions of the titanium complexes with the iminoester proceed 
through cyclic six-membered transition states. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Stereochemical consideration of the aminoalkylation of cyclic    
                 allyl(titanium) complexes. 
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On the basis of the above-mentioned assumptions the following proposals are 
made to explain the regio- and diastereo-selectivities. 
(1) In TS-89 and TS-91, the iminoester and the sulfoximine group are co-
ordinated through their N-atoms to the Ti-atom, and the tert-Bus and the 
ester group both occupy pseudoaxial positions.  
(2) The major and decisive differences between the Si and Re chairlike 
transition state models TS-91 and TS-92 and the analogous Re and Si 
transition state models TS-89 and TS-90, which would lead to the formation 
of the distereomers of (E/Z)-82 having the opposite configurations at both 
stereogenic C-atoms are the positions of the sulfoximine group being 
pseudo-equatorial in the case of the former and pseudo-axial in the case of 
the latter.  
(3) In comparing TS-89 and TS-91, the difference between both is the position 
of the phenyl group of the sulfoximine moiety. In TS-89 the phenyl group is 
in the sterically-non-hindering exo position, where as in TS-91, it is in the  
sterically hindering endo-position. Thus making TS-89 lower in energy. In 
TS-91 the sulfoximine group is expected to cause 1,2 interaction with the 
methylene groups of the unsaturated ring, whereas it is not possible in TS-
89.  
It is proposed that for larger rings (n = 3 and 4) the 1,2 interactions are expected to 
be very high which could give very high diastereoselectivity leading to the 
formation of compound 82. The complex 88B should react with imino ester via 
transition state TS-A to give the diastereomer CA. Formation of this isomer has, 
however, not been observed. This can be ascribed to an unfavorable steric 
interaction of the phenyl group with the Bus group of the imino ester.           
Similar transition state models (not depicted in Figure 18) and arguments can be 
applied to the reactions of the acyclic, mono(allylisulfoximine)titanium complexes 
with the imino ester. 
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Figure 18: Stereochemical consideration of the aminoalkylation of (allyl)titanium  
                 complexes. 
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3.2.2.7 Substitution of the sulfoximine group by a chlorine atom  
Chlorine substitution of vinylic sulfoximines 95a-d has been observed by Tiwari 
and Schindier.69 This substitution was performed by first activating the 
sulfoximines 87a-d through methylation at the N-atom by treatment with Me3OBF4 
(1.1eq.) in CH2Cl2 at room temperature for 2 h.  
The aminosulfoxonium salts 95a-d (95%) thus obtained from this reaction were 
than treated with saturated brine solution (in excess) in ethyl acetate at room 
temperature for 3 h-3 d (Table 6) to afford the corresponding chlorine substituted 
α-amino acid derivatives 97a-d. The chlorides were obtained in high yields as a 
mixture of (E/Z) isomers which were separable by column chromatography. 
 
 
 
 
 
 
 
 
 
Scheme 61: Synthesis of substituted α-amino acid derivatives. 
 
It is noteworthy that the (E/Z) ratios are depended on bulkiness of the R group. 
The tert-butyl substituted sulfoximine salt 95c gave exclusively (Z)-isomer in 82%, 
besides sulfinamide was isolated in medium to high yield (Table 6, entry 3). In 
contrast, the methyl-substituted sulfoximines (Table, entry 4) gave a mixture of the 
(E/Z)-isomers, the (E)-isomer predominanting. Conversion of sulfonamide 29c to 
(S)-N,S-dimethyl-S-phenyl sulfoximine of 98% ee has already been described. 
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Table6: Synthesis of  substituted α -amino acid derivatives 
Entry R Time Yield  (29c)  
(%) 
0BE/Z Yield  ( 97)  
(%) 
1 iPr 3 h 93 4/1 94 
2 cC6H11 2.5 d 89 6/4 80 
3 tBu 3 d 82 Only Z 76 
4 2BMe 2.5 d 82 88/12 81 
 
It is assumed that the vinyl aminosulfoxonium salts 95a-d suffer a Cl  catalyzed 
isomerisation with the formation of the corresponding allyl aminosulfoxonium salts 
96a-d. Due to the high nucleofugacity of the allylic amino sulfoxinium group, salts 
96a-d undergo a facile nucleophilic substitution with the Cl ion which is present in 
the organic phase and leads to the formation of chlorine substituted α-amino acids 
(Scheme 62). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 62: Postulated reaction pathway of the Cl substitution 
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afford the chlorine substituted cyclic amino acid derivative 99 in 70 % yield and 
sulfonamide 29c in 72% yield (Scheme 62). The structure of chloride 99 was 
confirmed by comparison of its spectral data with that reported for similar 
compounds in the literature. 
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Scheme 63: Synthesis of bicyclic proline derivatives. 
 
3.2.2.8     Synthesis of proline analogoues 
As described in the introduction section, proline derivatives have gained much 
attention in recent years. Particularly interesting are prolines that carry 
substituents at the 3- and 4-positions. This substitution pattern offers not only new 
possibilities for the attainment of conformationally-restricted peptide mimetics, but 
can also be found as the core structure of the kainod amino acids.74,75 
 
 
 
 
Figure 16: Natural products containing 3-substituted prolines. 
 
Treatment of (Z)-97a-c with 1.2 eq. of DBU for 30 min in CH2Cl2 afforded the 3-
substituted, unsaturated proline analogues 101a-c in quantitative yields (Scheme 
64). The spectroscopic data of the unsaturated proline analogues thus obtained 
show complete agreement with the data reported in the literature.70 
Subsequently, our attention turned towards the synthesis of bicyclic proline 
derivative of type 100. Thus, the chlorine-substituted cyclic amino acid 99 also 
cyclised in similar fashion to that described above, and afforded in quantitative 
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yield 100. It is assumed that the reaction pathway follows the base- catalysed, 
intramolecular, nucleophilic substitution reaction to lead to the proline derivatives. 
 
 
 
 
 
 
 
 
 
Scheme 64: Synthesis of proline derivatives. 
 
It should be noted that the proline derivative 101c was deprotected by treatment 
with CF3SO3H in DCM (0.05-0.1 M)76 to afford the proline ester 107 in good yield 
(Scheme 65). 
 
 
 
 
Scheme 65: Deprotection of the unsaturated proline 101c.   
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3.2.2.9     Cyclization of the Aminosulfoxonium Salts with LDA 
 
In 1980, Johnson et al. reported the formation of sulfur ylides starting from S-
aminosulfoxonium salts.77,78 According to the results of Günter and Köhler, the 
compounds 102 and 103, upon treatment with LiNHt-Bu, gave the corresponding 
keto alkylsulfoxonium ylides 104 and 105, respectively (Scheme 66).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 66: Günter route for the synthesis of keto aminosulfoxonium ylide.                             
                      
 
Similarly, we observed the formation of amino sulfoxonium ylides by deprotonation 
of the salt by using more than two equivalents of LDA. Thus, treatment of the salt 
of (E)-83b with 3.1 eq. of LDA at -78 °C in 30 min gave the keto aminosulfoxonium 
ylide 106. Unfortunately, this compound could not be isolated in pure form due to 
its unstability. The 13C NMR spectrum of the crude product shows the appearance 
of a new signal at δ = 185 ppm attributed to carbonyl carbon of the ester group.  
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We have also observed in 1H NMR of the crude product a new signal at 5.5 ppm, 
which is indicative of the allylic proton. These results suggest that the reaction 
occurred via the mechanism proposed in Scheme 67. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 67: Possible mechanism for the formation of the keto aminosulfoxonium  
                    ylide. 
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3.2 Conclusion 
In summary, we have achieved a highly-efficient asymmetric aminoalkylation of 
cyclic and acyclic allyl sulfoximines with the α-imino ester using ClTi(NEt2)3, which 
led to the unexpected formation of diastereomers ( Scheme 68). 
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Scheme 68: Asymmetric synthesis of sulfoximine substituted cyclic and acyclic  
                   α-amino acid derivatives. 
 
Further to our study, we have observed the substitution of the sulfoxonium group 
by Cl ion during the normal work up with saturated brine solution (Scheme 69). 
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Scheme 69: Synthesis of substituted α-amino acid derivatives. 
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The base-catalyzed cyclization of acyclic and cyclic α-amino acids has 
demonstrated the capacity of the newly developed strategy to allow formation of 
unsaturated acyclic cyclic and bicyclic α-amino acids ( Scheme 70). 
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Scheme 70:  Synthesis of proline derivatives. 
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CHAPTER 4 
 
 
 
Cu-catalyzed stereoselective synthesis of Allylic    
Alcohols 
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4.     Cu-catalyzed stereoselective synthesis of Allylic    
Alcohols 
 
4.1    Introduction 
 
4.1.1 Brief introduction about relevant biologically-active molecules 
 
During the last decade, allylic alcohols have been recognized as valuable 
intermediates in organic synthesis. The allylic alcohols of type 108a-c would be of 
particular interest due to the presence of additional chiral center at the δ-position 
(Figure 19).78-80    
 
 
  
 
 
 
Figure 19: Allylic alcohols. 
 
Allylic alcohols of this type are found as structural elements of many natural 
products, which often possess remarkably high biological activity.81,82 In addition 
these are synthetically useful chiral building blocks. Amphidinium R (Figure 20)) 
belongs to the family of amphidinolides, which were isolated from dinoflagellate 
Amphidinium sp. found off the coast of Okinawa/japan in 1986.83, They exihibited 
significant toxicity against murine lymphoma L1210 and human epidermoid 
carcinoma KB cells.84An example of a antifungal macrolide is the antibiotic 
roxaticin.85 Besides being interesting synthetic targets per se, allylic alcohols with 
additional chiral center at the δ-position of defined conifiguration also represent 
exceedingly valuable key intermediates for the preparation of more complex 
compounds like fluviricin B1.86  
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Figure 20: Importance of allylic alcohols. 
 
Siphonarienolone is a member of the siphonarienes, a class of polypropionates 
produced by mollusks of the genus Siphonaria. It was isolated and tentatively 
identified in 1988 by Norte et al.87 Compounds bearing a chiral quaternary carbon 
center are ubiquitous in nature. Their construction poses a difficult challenge to the 
synthetic chemists.88 
In the following section we discuss various approaches reported in the literature 
for the synthesis of allylic alcohol derivatives.  
 
4.1.2   Approaches  towards the construction of allylic alcohols 
 
Marshall approach 
Marshall et al. have reported a method for the synthesis of 1,4-bifunctional 
compounds based on the Cu-catalyzed SN2′ reaction of alkenyloxiranes (Scheme 
71). 89 
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Scheme 71: Asymmetric synthesis of allylic alcohols by Marshal. 
 
Trost approach 
In 1997, Trost et al. have reported a novel method involving a palladium catalyzed 
reaction of alkenyloxiranes with prenucleophiles.90 The required alkenyloxirane 
was obtained by Sharpless-Swern-Wittig route. 
 
 
 
 
 
 
Scheme 72: Asymmetric Synthesis allylic alcohols by Trost. 
 
Tanaka approach 
An efficient asymmetric synthesis of 1,4-bifunctional compounds has been 
reported by Tanaka et al. in 2004.91 This method involves alkenylation of a α-
hydroxyaldehyde followed by regio- and diastereoselective Pd-catalyzed allylic 
substitution as shown in Scheme 73. The substitution however, usually proceeds 
not with high enantioselectivity. 
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Scheme 73: Asymmetric synthesis of allylic alcohols by Tanaka. 
 
 
4.2 Present Work 
 
4.2.1  Aim 
 
From the above discussion it is clear that only very few methods are available for 
the asymmetric synthesis of allyl alcohols. Most of the known methods start with 
alkenyloxirane, which are not easy to access (Scheme 74). The documented 
difficulties with the known routes for the synthesis of allyl alcohols encouraged us 
to search for alternative methods. 
 
 
 
 
 
 
 
Scheme 74:   Sharpless-Swern-Wittig route. 
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 N. Giesen, a former member of our group, had studied the asymmetric synthesis 
of allylic alcohols of type 108d,f from sulfoximine substituted homoallylic alcohols 
of type 892 (Scheme 75). It was thus of interest to see whether this method could 
be extended to the synthesis of various cyclic alcohols of type 108a,b. 
 
 
 
  
 
 
 
 
 
 
 
Scheme 75:   Substitution of sulfoximine-substituted homoallylic alcohols 
 
4.2.2        Results and Discussion 
 
4.2.2.1     Retero synthetic analysis 
As illustrated in the foregoing section, allylic alcohols are interesting targets and 
their asymmetric synthesis has been accomplished by several methods. Although 
some of these methods are very efficient, they all lack of generality and are not 
well suited for the synthesis of allylic alcohols of type 108b,c. We were therefore 
interested in the asymmetric synthesis of both acyclic and cyclic allylic alcohols of 
type 108a-c from aldehydes and allylic sulfoximines (Scheme 76).93  
 
     
 
   
 
 
Scheme 76: Retrosynthetic analysis. 
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The synthesis of the allylic alcohols 108a-c were envisioned from the 
corresponding sulfoximine substituted homoallylic alcohols 13 which in turn can be 
derived from 12 via the α-hydroxyalkylation whose synthesis is reported by our 
group recently.93  The  allylic sulfoximine 12 can be  derived from the sulfoximine 
34 by addition, elimination and isomerisation route (AEI).11 
 
4.2.2.2     Hydroxyalkylation of allylic sulfoximines 
The acyclic allylic sulfoximines 110a-c were selected for the synthesis of the 1,4-
bifunctional compounds of type 108a-c. Sulfoximines 110a and 110b were 
prepared from sulfoximine 34 and the corresponding aldehydes following the 
addition-elimination-isomerization route depicted in Scheme 77. Similarly the new 
allylic sulfoximine 110c was synthesized from sulfoximine 34 and 2-methyl-
butyraldehyde. The intermediate 1-alkenyl sulfoximine 109c was not isolated but 
treated with DBU in MeCN at elevated temparature to give mixtures of the (E) and 
(Z)- configured allylic sulfoximines (E)-110c and (Z)-110c in ratio of 70:30. The 
(E/Z)–isomers were readily separated by preparative HPLC. Isomerization of the 
unwanted (Z)-isomer with DBU in MeCN again gave a mixture of the (E)- and (Z)- 
isomers which were separated.  The N-methyl-S-phenyl sulfoximines 110a-c were 
selected because of the ease of the preparation of 34 in enantiomerically pure 
form.11 
 
 
 
 
 
 
 
 
 
 
 
Scheme 77: Asymmetric synthesis of allylic sulfoximines. 
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Successive lithiation and titanation of the 110a with 1.1 equiv. of nBuLi and 1.2 eq. 
of ClTi(NEt2)3 at –78 °C in THF afforded the corresponding allylic titanium 
complex, which upon treatment with benzaldehyde at –78 °C gave, as described 
previously,11  the diastereomerically pure syn-configured sulfoximine-substituted 
homoallylic alcohol 111a in good yield (Table 7). Similarly, the new 
diastereomerically pure homoallylic alcohols 111b and 111c were obtained in 
good yields from the allylic sulfoximines 110b and 110c, respectively and 
isobutyraldehyde. (Table7) NMR spectroscopic analysis of the crude reaction 
products showed the hydroxyalkylation to be, as in all previously described cases, 
highly diastereoselective (≥ 98% de) and regioselective (≥ 98:2). 
 
 
 
 
 
 
 
Scheme 78: Asymmetric synthesis of sulfoximine substituted homoallylic alcohols. 
 
 
Table7: Synthesis of sulfonimidoyl-substituted homoallylic alcohols 
Entry Starting 
material 
Aldehyde Product dr (%)a Yield (%) 
1 E-110a PhCHO E-111a ≥98 : 2 70 
2 E-110b i-PrCHO E-111b ≥98 : 2 -b- 
3 E-110c i-PrCHO E-111c ≥98 : 2 75 
aFrom 1H NMR spectroscopic analysis. b not isolated.. 
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4.2.2.3 Substitution of sulfoximine substituted homoallylic alcohols 
The substitution recently developed in our group by N. Giesen90 for the synthesis 
of allylic alcohols is depicted in Scheme 79.  
 
 
 
 
 
 
 
 
Scheme 79: Asymmetric synthesis of allylic alcohols compounds.  
 
To a solution of CuI (3.2 mmol) in THF (5 mL) and Me2S (3 mL) was added nBuLi 
(3.2 mmol) at -78 °C. After stirring the mixture for 45 min at this temperature, the 
allylic sulfoximine 111a (1 mmol) in THF (2 mL) was added. The solution was 
stirred for 18 h at -78 °C. Aqueous workup of the reaction mixture and purification 
of crude product by chromatography gave the allylic alcohol 112 in 75% yield and 
≥98% de.  Similarly, the diastereomercally pure allylic alcohol 113 was obtained in 
67% yield from allylic sulfoximine 111c. In this reaction, 10% of unreacted 111c 
was recovered. 
The structure of 112 and 113 were established based on their spectral data. The 
de-values were determined by NMR spectroscopy of crude reaction products. 
 
 
 
 
 
 
 
 
 
Scheme 80: Asymmetric synthesis of allylic alcohols. 
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After having a successful demonstration of Cu assisted substitution of sulfoximine 
substituted homoallylic alcohols in various acyclic systems, we studied the 
feasibility of this novel substitution also in cyclic systems. Therefore as a last 
example sulfoximine 11a was treated with n-BuCu (3.2 eq.) to afford allylic alcohol 
derivative 114. Thus, to a solution of CuI (3.2 mmol) in THF (5 mL) and Me2S (3 
mL) was added n-BuLi (3.2 mmol) at -78 °C. After stirring for 45 min at this 
temperature, the allylic sulfoximine 11a (1 mmol) in THF (2 mL) was added. The 
solution was stirred for 18 h at -78 °C. Aqueous workup of the reaction mixture and 
purification of crude product by chromatography gave the allylic alcohol 114 in 
70% yield and ≥98% de. In addtion 10% of unreacted 11a was recovered. 
The structure of 114 was established based on their spectral data. The de-value 
was determined by NMR spectroscopy of the crude reaction product. 
 
 
 
 
 
 
Scheme 81: Asymmetric synthesis of allylic alcohols. 
 
 
4.2.2.4 Absolute Configuration of the Allylic alcohol derivative 
The absolute configuration of the alcohol 118 had been determined by convertion 
to the corresponding urethane derivative and X-ray crystal structure analysis by N. 
Giesen (Scheme 82).92 
 
 
 
 
 
Scheme 82: Synthesis of urethane derivative by N. Giesen. 
 
Ph
OH
S
NMe
OPh Ph
OH
BuCuI(3.2 eq.)/n-BuLi (3.2 eq.)
THF, -78 °C 5 °C
18 h
70% yield
11a 114
Bu
OH NCO
Bu
O
O
NH
Petrolether
118
                                                         THEORETICAL PART                                                      79  
Attempts to convert alcohol 114 to urethane 115 were unsuccessful. Treatment of 
114 with phenylisocyanate in n-hexane led to a decomposition of the starting 
material.92 
 
 
 
 
 
Scheme 83: Urethane derivative synthesis. 
After having these unsuccesesful results we turned our attention towards a 
chemical correlation method which was described by our group previously.93,94 
Thus the ozonolysis of (+)-114 gave the decomposition of the starting material.  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 84:   Ozonolysis of compounds 116 and 114 
 
 
 
4.2.2.5      Mechanistic Considerations 
The creation of central chirality by the γ-substitution of an allylic substrate with an 
organocopper or an organocuprate reagent constitutes an important process in 
organic synthesis. 95-100 The mechanistic scheme put forward by Rudler et al.,101 
Goering et al.,102 and Bäckvall et al.103 for the reaction of primary biased allylic 
substrates with cupper organyls is based on homoleptic cuprates B (Y = R) and 
heteroleptic cuprates B (Y = Hal) and features the following steps (Scheme 84):  
(1) reaction of substrate A with  cuprate B with formation of the π-complex  C, (2) 
convertion of C through an oxidative addition-substitution to σ-allycomplex D, and 
(3) reductive elimination of D to give the substitution product F. In the case of γ-D 
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(Y = R2), reductive elimination is though to be relatively slow because of the two C-
bonded organic ligands, thus allowing for an equilibration via π-allyl complex E (Y 
= R2), to isomeric α-D (Y = R2), followed by the reductive elimination of the latter to 
α-F. Reductive elimination of α-D is anticipated to be faster than that of γ-D 
perhaps because of steric reasons. In the case of γ-D (Y = Hal), reductive 
elimination is assumed to be faster than its isomerization to α-D (Y = Hal) because 
of the electronegative halide and thus γ-F would be formed preferentially.    
 
 
 
                
 
 
 
 
 
 
 
 
 
Scheme 85:   Mechanistic scheme for the allylic substitution. 
 
The selectivity of the reactions of the acyclic and cyclic allylic sulfoximines 
(Scheme 86 and 87) with n-BuCu can be summarized as follows. 
High regioselectivity was observed in case of 111a,c and 11a resulting in the 
formation of the corresponding γ-subsitution product. The formation of the α-
substitution product was not observed. According to the absolute configuration of 
the newly formed stereogenic center it was clear that the substitution involved a   
Re-face addition to the double bond. 
According to the crystal structure the hydroxy allylic sulfoximine (E)-8 has a rigid 
cyclic six membered ring through H-bonding as shown in Scheme 86. The α-H and 
β-H are anti-periplanar to each other. The butenyl and R2 groups occupy pseudo 
equatorial positions and β-H and γ-H are antpriplanar to each other. 
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It is clear from our results that at least 2 equivalents of the Cu-reagent are 
necessary to achieve the substitution. The first equivalent could deprotonate the 
OH group. The proposed structure for the deprotonated intermediate (E)-8 is 
shown in Scheme 86.  Here the Cu atom is co-ordinated with the oxygen atom of 
the sulfoximine group. The high regioselectivity (γ-position) observed in the 
substitution reaction supports a favorable chair like transition state which was 
depicted in Scheme 87.  
  
 
 
 
 
 
 
Scheme 86:   Deprotonation of E-8 with 1 eq. of  n-BuCu. 
  
The high selectivity of the reaction with the second equivalent of the n-BuCu may 
be attributed to the intramolecular syn-nucliophilic attack of n-BuCu at the γ-carbon 
atom (Scheme 87). It is proposed that the second equivalent of the n-BuCu is co-
ordinated to the lone pair of the sulfoximine N-atom before the nucleophile attack. 
This co-ordination might be responsible for the attack on the Re-face of the double 
bond which leads to the product. 
  
 
 
 
 
 
 
Scheme 87:  Mechanistic scheme for the formation of allylic alcohols..ifor the 
forma 
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4.3 Conclusion 
 
In summary, we have achieved a highly efficient asymmetric synthesis of allyl 
alcohols based on Cu-mediated SN2′ reaction of sulfoximine substituted 
homoallylic alcohols (Scheme 88). We have also demonstrated that this method 
allows the construction of a quaternary carbon center. 
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Scheme 88:  Asymmetric synthesis of allylic alcohols. 
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we have also successfully  demonstrated that the Cu assisted substitution also 
works in the case of  cyclic sulfoximie substituted homoallylic alcohol of type 11a.  
 
 
 
 
 
 
 
Scheme 89:  Asymmetric synthesis of allylic alcohols. 
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B. 1BExperimental Part 
 
5 Experimental Section 
  
5.1 General Remarks 
All reactions were carried out in absolute solvents under argon with syringe 
Schlenk techniques in oven-dried glassware. THF and ether were distilled under 
argon from potassium/benzophenone and sodium/benzophenone, respectively. 
Reagents and solvents were transferred under argon via syringe or cannula. Thin-
layer chromatography was performed on silica gel 60 (Merck F254), coated on 
aluminium plates and visualized by UV or permanganate treatment. Flash 
chromatography was performed on silica gel 60 particle size 0.040-0.063 mm 
(Merck). Solutions of crude reactions mixture were filtered through Celite (Fluka 
535). ClTi(Oi-Pr)3, ClTi(NEt2)3 of ≥96% purity (1H NMR) were prepared according 
to the literature.104 Enantiomerically pure (S)- and (R)-S-methyl-S-
phenylsulfoximine, which are also commercially available, were synthesized as 
described previously. CuI was purchased by Aldrich. All other chemicals were 
obtained from commercial sources used without further purification. 
 
 5.2 Analytic 
U
1H NMR Spectroscopy 
 Varian Mercury 300 (300 MHz) 
 Varian Inova 400 (400 MHz) 
 Varian Unity 500 (500 MHz) 
                  Internal Standard: Tetramethysilan 
The following abbreviations are used to designate the multiplicity of the peaks in 
the 1H NMR spectra: 
s = Singlet 
d = Doublet 
t = Triplet 
q = Quartet 
quin = Quintet 
sext = Sextet 
sept = Septet 
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oct = Octett 
m = Multiplet 
br = broad 
%100
/
/
..
.. •=
nI
nI
gesges
beobbeobNOE  
Ibeob. = Signalintensität (Integral) des beobachteten Kerns 
Iges. = Betrag der Signalintensität (negatives Integral) des gesättigten 
Kerns 
nbeob., nges. = Anzahl der jeweils chemisch äquivalenten Kerne 
 
U
13C NMR Spectroscopy: 
 Varian Mercury 300 (75 MHz) 
 Varian Inova 400 (100 MHz) 
 Varian Unity 500 (125 MHz) 
                 Internal Standard: Tetramethysilan 
 
Peaks in the 13C NMR spectra are donated as „u“ for carbons with zero or two 
attached protons or d for carbons with one or three attached protons, as 
determined from APT pulse sequence. 
 
UInfrared Spectroiscopy  
IR spectra were taken with a Perkin-Elmer PE 1759 FT, Perkin Elmer FTIR 1760 
S, and only peaks of > 600 cm are listed. 
 
w = weak (Absorption 20 – 40 %) 
m = medium (Absorption 40 – 70 %) 
s = strong (Absorption > 70 %) 
 
UMass Spectrometry 
Varian Mat 212 S und Finnigan MAT 312 
 EI. 70 eV; chemical Ionisation (CI) 100 eV; Directe chemical Ionisation (DCI) 70 
eV. 
HRMS: Varian MAT 95 (EI, 70 eV). 
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UElemental Analysis 
Heraeus CHN-O-RAPID and Elemental Vario El. 
 
UOptical Rotatoary Power 
Optical rotations were measured on a Perkin Elmer Model 241 Polarimeter at 25 
°C. 
 
UMelting Point 
Melting points were determined using a Büchi apparatus SMP-20 and are 
uncorrected. 
 
5.3   General procedures 
 
5.3.1 General Procedure for the Substitution of Sulfoximine-Substituted 
Homoallylic Alcohols (GP1)  
 
ClCO2CH(Cl)Me (1.3 mmol) was added at room temperature to a solution of the 
sulfoximine-substituted homoallylic alcohol (1 mmol) in CH2Cl2 (10 mL). The 
progress of the reaction was monitored by TLC ( EtOAc/n-hexane, 1:9). After the 
mixture had been stirred at room temperature for 1.5 h, it was concentrated in 
vacuo. Purification by flash chromatography (EtOAc/n-hexane, 1:9) gave the 
alkenyl/cycloalkenyl chlorohydrine and sulfinamide as colorless oils. 
 
5.3.2 General Procedure for the Elimination of Alkenyl/Cycloalkenyl  
Chlorohydrins (Gp2)     
 
DBU (1 mmol) was added at room temperature to a solution of chlorohydrine (1 
mmol) in CH2Cl2 (10 mL). The progress of the reaction was monitored by TLC 
(EtOAc/hexane, 1:9). After the mixture had been stirred at room temperature for 
1.5 h, CH2Cl2 was carefully evaporated under reduced pressure (highly volatile 
compound!). Conventional workup followed by purification by flash 
chromatography (EtOAc/n-hexane, 1:9) gave the alkenyl/cycloalkenyloxirane as a 
colorless oil. 
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 5.3.3 General Procedure for the Synthesis of Silylated Homoallylic 
Alcohols (GP3)  
 
To a solution of the allylic sulfoximine (2 mmol) in THF (20 mL) was added at −78 
oC n-BuLi (2.1 mmol, 0.69 mL of 1.6 M in hexane) and the reaction mixture was 
stirred at −78 oC for 1 h. Then neat ClTi(Oi-Pr)3 (2.1 mmol) was added and the 
resulting mixture was stirred first at −78 oC for 30 min and then at 0 oC for 2 h. 
Subsequently the mixture was cooled to –100 oC and the aldehyde (1.0 mmol) 
was added. After stirring the mixture at –78 oC for 2 h, saturated aqueous 
(NH4)2CO3 (10 mL) was added and the mixture was stirred at room temperature 
for 30 min. Then the mixture was extracted with ethyl acetate and the combined 
organic phases were dried (MgSO4) and concentrated in vacuo. The residue was 
dissolved in DMF (10 mL) and imidazole (273 mg, 4 mmol) and ClSiEt3 (4 mmol) 
dropwise were added successively. After stirring the reaction mixture for 20 h at 
room temperature, half-saturated aqueous NaHCO3 was added and the resulting 
mixture was extracted with ether. The combined organic phases were dried 
(MgSO4) and concentrated in vacuo. The crude product was purified by column 
chromatography (silica gel, ethyl acetate/hexane, 1:3 then 1:1) to give the silyl 
ether and allylic sulfoximine.  
 
 5.3.4 General Procedure for the Synthesis of Dihydrofurans (GP4) 
 
Sulfoximin (1 mmol) and Me3OBF4 (1.3 mmol) were placed under argon in a 
Schlenk flask. The flask was consecutively evacuated and refilled with dry argon 
(3 times). Then CH2Cl2 (30 mL) was added and the reaction mixture was stirred at 
room temperature for 1 h. Subsequently water (25 mL) was added and the 
reaction mixture was stirred at room temperature for 15 min. Then the mixture was 
extracted with CH2Cl2 and the combined organic phases were dried (MgSO4) and 
concentrated in vacuo and the residue was dried in high vacuum (10-3 mbar) for 3 
h. The thus obtained salt was dissolved in THF (50 mL) and freshly prepared 
LiN(H)tBu (1.1 mmol, 1.1 ml of 1 M in THF) was added at −78 °C. After stirring the 
mixture at room temperature for 15 h, saturated aqueous NaHCO3 (25 mL) was 
added and stirring was continued for 10 min. Then the mixture was extracted with 
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ether and the combined organic phase were dried (MgSO4) and concentrated in 
vacuo. Purification of the residue by column chromatography (silica gel, ethyl 
acetate/hexane, 1:20) gave the dihydrofuran as a colorless oil and sulfinamide 
(ethyl acetate/hexane, 1:1) 
 
 5.3.5 General Procedure for the Synthesis of Bicyclic Tetrahydrofurans 
(GP5)  
 
Sulfoximine (1 mmol) and Me3OBF4 (1.3 mmol) were placed under argon in a 
Schlenk flask. The flask was consecutively evacuated and refilled with dry argon 
(3 times). Then CH2Cl2 (30 mL) was added and the reaction mixture was stirred at 
room temperature for 1 h. Subsequently water (25 mL) was added and the 
reaction mixture was stirred at room temperature for 15 min. Then the mixture was 
extracted with CH2Cl2 and the combined organic phases were dried (MgSO4) and 
concentrated in vacuo and the residue was dried in high vacuum (10-3 mbar) for 3 
h. The thus obtained salt was dissolved in CH2Cl2 (50 mL) and DBU (1.5 mmol) 
was added at room temparature. After stirring the mixture at room temperature for 
8-10 h, water (15 mL) was added and stirring was continued for 10 min. Then the 
mixture was extracted with DCM and the combined organic phases were dried 
(MgSO4) and concentrated in vacuo. Purification of the residue by column 
chromatography (flashsilica gel, ethyl acetate/hexane, 1:20) gave the 
tetrahydrofuran as colorless crystals and sulfinamide (ethyl acetate/hexane, 1:1). 
 
5.3.6 General Procedure for the Synthesis of Sulfoximine Substituted 
Amino Acids (GP6) 
 
n-BuLi (1.37 mL of 1.6 M solution in n-hexane, 2.2 mmol) was added dropwise at –
78 °C to a solution of the allylic sulfoximine (2.0 mmol) in THF (20 mL). After the 
mixture was stirred at –78 °C for 40 min, neat ClTi(NEt2)3 (2.8 mmol) was added, 
and stirring at this temperature was continued for 45 min. The cooling bath was 
removed and the mixture was allowed to stir for 60 min, then recooled to –78 °C, 
and allowed to stir at this temparature for 60 min. Then the  α-imino ester (2.4 
mmol) was added dropwise and the mixture was stirred at –78 °C for 5 h. Then it 
was allowed to warm to ambient temperature within 15 h. Saturated aqueous 
(NH4)CO3 (150 ml) was added, and the mixture was stirred at ambient temperature 
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for 30 min. Then the mixture was extracted with ethyl acetate (150 ml) and the 
combined organic phases were dried (MgSO4) and concentrated in vacuo. The 
residual yellow oil was dissolved in CH2Cl2 and n-pentane was added until the 
solution became slightly turbid. The solution was kept overnight at 2 °C to give the 
major diastereomer of the amino acid derivative of ≥98% de (1H NMR) as fine 
white crystals. Preparative HPLC (EtOAc/n-hexane, 4:1) of the mother liquor 
afforded the minor diastereomer as a colorless solid of ≥98% de (1H NMR). 
 
5.3.7 General Procedure for the Synthesis of Allylic Alcohols  (GP7)  
 
To a solution of CuI (3.2 mmol) in THF (5 mL) and Me2S (3 mL) was added nBuLi 
(3.2 mmol) at -78 °C. After stirring for 45 min at this temperature, and the allylic 
sulfoximine (1 mmol) in THF (2 mL) was added. The solution was stirred for 18 h 
at -78 °C, and then a 10:1 mixture of saturated aqueous NH4Cl and concentrated 
NH3 was added. The resulting mixture was stirred for 30 min. at room temperature, 
and extracted with Et2O (4 x 20 mL). The combined organic extracts were dried 
(MgSO4) and concentrated in vacuo. Purification of the residue by chromatography 
(9% EtOAc/n-hexane) gave the allylic alcohol. In addition 10% of allylic sulfoximine 
was   isolated. 
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5.4      Synthesis of Allylic Sulfoximine 
 
5.4.1 Synthesis of (S,E)-N-methyl-S-(4,2-dimethyl-2-pentenyl)-S- 
phenylsulfoximine and (S,Z)-N-methyl-S-(4,2-dimethyl-2-pentenyl)-S-
phenylsulfoximine (E-58a and Z-58a). 
  
To a solution of 34 (12.0 g, 0.07mol) in THF (200 ml) at –780C was added n-BuLi 
(48.5 mL, 1.60 M solution in hexane, 0.08 mol). After stirring the mixture for 30min, 
4-methyl-2-pentanone (10 mL, 0.08 mol) was added. The mixture was stirred for 2 
h and then CICOOMe (6 mL, 0.08 mmol) was added. After warming the resulting 
mixture to room temperature, it was stirred for 1h. It was then cooled to –78 °C and 
DBU (13.5 mL, 0.09 mol) was added, which led to the deposition of a colorless 
precipitate. After allowing the mixture to warm to room temperature over a period 
of 12 h, it was treated with half-saturated aqueous NH4Cl solution and extracted 
with EtOAc. The combined organic phases were dried  (MgSO4) and the solvent 
was removed in vacuo. The residue was dissolved in acetonitrile (200 mL) and 
DBU (13.5 mL, 0.09 mol) was added. After heating the mixture to 80-90 °C for 8 d, 
it was allowed to cool to room temperature, treated with half-saturated aqueous 
NH4Cl, and extracted with EtOAc. The combined organic phases were dried  
(MgSO4) and the solvent was removed in vacuo. Purification of the residue by 
chromatography (EtOAc/hexane, 1:1) gave a mixture of E-58a and Z-58b (15.3 g, 
86%) in a ratio of 60:40 as a colorless oil. The (E) and (Z) isomers were separated 
by HPLC (EtOAc/n-hexane, 4:1). 
 
S
Ph
O NMe
H
NOE
NOE
E-58a  
E-58a: 
 
1H NMR (400 MHz, CDCl3): δ 0.68 (dd, 3 H, J =6.6, J =2.2 Hz, CH3), 0.80 (dd, 3 H, 
J =6.6, J =2.2 Hz, CH3), 1.76 (s, 3 H, CH3), 2.24 (m, 1 H, CH(CH3)3), 2.72 (s, 3 H, 
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NCH3), 3.79 (d, 2 H, CH2), 4.68 (d,  J =9.3  Hz, 1 H, CH=C),  7.55 (m, 3 H, Ph), 
7.80 (m, 2 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 16.66 (CH3, d), 22.15, 22.18 (CH3, d), 27.33 
(CH(CH3)3, d), 29.75 (NCH3, d), 66.11 (CH2, u), 121.34 (C=CH, u),  128.74, 
129.51, 129.75, 132. 40 (o-, m-, p-C, d), 136.38 (i-C, u), 143.50 (C=CH).  
 
 
 
1H{1H}-NOE-Experiment (400 MHz, CDCl3) of E-58a 
[%] H-2 H-3 H-5 H-6
H-2 0.7 5.2
H-3 0.8 7.5 0.01
H-4 5.0
H-5 2.2 1.2
H-6 1.5 0.1 1.2
H-7 1.1
 -
Emitted Frequency
O
bs
er
ve
d 
Fr
eq
ue
nc
y
 
 
IR (capillary): ν 3061 (s), 2959 (vs), 2926 (s), 2870 (s), 2802 (s), 1463 (m), 1446 
(m), 1404 (m), 1388 (m), 1246 (vs), 1157 (vs), 1106 (s), 1081 (s), 896 (s), 858 (s) 
cm−1.  
 
CI-MS m/z (relative intensity, %): 252 [M++1] (100), 251 [M+]  (2), 212 (2), 208 (6), 
194 (2), 158 (2), 157 (3), 156 (28), 154 (4), 140 (3), 126 (3), 99 (2), 98 (6), 97 (3), 
85 (2).  
Elemental Analysis:  
Anal. Calcd for C14H21NOS (251.39): C, 66.89; H, 8.42; N, 5.57 
Found                                                : C, 66.74; H, 8.63; N, 5.55. 
 
Optical rotation: [α]D = +80.5 (c 1.01, MeOH) 
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S
Ph
O NMeMe
H
NOE
Z-58a  
Z-58a: 
 
1H NMR (400 MHz, CDCl3): δ 0.60 (d, 3 H, J =6.6 Hz, CH3), 0.72 (d, 3 H, J =6.6 
Hz, CH3), 1.78 (d, J =1.4 Hz, 3 H, CH3), 2.10 (m, 1 H, CH(CH3)3), 2.69 (s, 3 H, 
NCH3), 3.97 (quart, J =11.00 Hz,  2 H, CH2), 5.23 (dd,  J =9.8, J =0.8 Hz, 1 H, 
CH=C),  7.60 (m, 3 H, Ph), 7.87 (m, 2 H, Ph). 
13C NMR (100 MHz, CDCl3): δ 22.31 (CH3, d), 22.52 (CH3, d), 23.90 (CH3, d), 
29.60 (CH(CH3)3, d), 27.69 (NCH3, d), 59.31 (CH2, u), 120.52 (C=CH, u),  128.95, 
129.48, 132.56 (o-, m-, p-C, d), 137.34 (i-C, u), 142.12 (C=CH, d).  
 
1H{1H}-NOE-Experiment (500 MHz, CDCl3) of Z-58a 
 
[%] H-3 H-5 H-10 NCH3
H-1 2.0 0.4
H-2 0.8
H-3 5.0
H-4 0.4 3.0
H-5 3.7
H-11
NCH3  -
Emitted Frequency
O
bs
er
ve
d 
Fr
eq
ue
nc
y
 
 
IR (capillary): ν 3061 (s), 2957 (vs), 2869 (s), 2803 (s), 1465 (m), 1445 (m), 1410 
(m), 1382 (m), 1249 (vs), 1156 (vs), 1140 (vs), 1105 (s), 1181 (s), 906 (s), 863 (s) 
cm−1.  
 
CI-MS m/z (relative intensity, %): 252 [M++1] (100), 250 [M+]  (2), 212 (3), 208 (4), 
194 (3), 167 (2), 157 (3), 156 (33), 154 (14), 140 (3), 126 (3), 99 (4), 98 (10), 97 
(5), 85 (7), 85 (6), 83 (4), 81 (4), 71 (4).  
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Elemental Analysis:  
Anal. Calcd for C14H21NOS (251.39): C, 66.89; H, 8.42; N, 5.57 
 Found                                               : C, 66.61; H, 8.30; N, 5.60. 
 
Optical rotation: [α]D = +82.4 (c 1.01, MeOH) 
 
 
 
 
5.4.2 Synthesis of (S,E)-N-methyl-S-(3-methyl-2-pentenyl)-S- 
phenylsulfoximine and (S,Z)-N-methyl-S-(3-methyl-2-pentenyl)-S-
phenylsulfoximine (E-109c and Z-109c). 
  
To a solution of 34 (12.0 g, 0.07mol) in THF (200 ml) at –78 °C was added nBuLi 
(48.5 mL, 1.60 M solution in hexane, 0.08 mol). After stirring the mixture for 30 
min, 2-methylbutyraldehyde (8.6 mL, 0.08 mol) was added. The mixture was 
stirred for 2 h and then CICOOMe (6 mL, 0.08 mmol) was added. After warming 
the resulting mixture to room temperature, it was stirred for 1h. It was then cooled 
to –78 °C and DBU (13.5 mL, 0.09 mol) was added, which led to the deposition of 
a colorless precipitate. After allowing the mixture to warm to room temperature 
over a period of 12 h, it was treated with half-saturated aqueous NH4Cl solution 
and extracted with EtOAc. The combined organic phases were dried (MgSO4) and 
the solvent was removed in vacuo. The residue was dissolved in acetonitrile (200 
mL) and DBU (13.5 mL, 0.09 mol) was added. After heating the mixture to 70-80 
°C for 5 d, it was allowed to cool to room temperature, treated with half-saturated 
aqueous NH4Cl, and extracted with EtOAc. The combined organic phases were 
dried  (MgSO4) and the solvent was removed in vacuo. Purification of the residue 
by chromatography (EtOAc/hexane, 1:1) gave a mixture of E-110c and Z-110c 
(14.3 g, 85%) in a ratio of 70:30 as colorless oil. The E and Z isomers were was 
separated by HPLC (EtOAc/n-hexane, 4:1). 
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S
Ph
O NMeH
NOE
NOE
E-110c  
 
 E-110c: 
 
1H NMR (400 MHz, CDCl3): δ 0.90 (t, J =6.6, 3 H, CH3), 1.20 (br s, 3 H, CH3), 1.98 
(q, J = 7.4 Hz 2 H, CH2CH3), 2.72 (s, 3 H, NCH3), 3.88 (m, 2 H, SCH2), 5.20 (m, 1 
H, CH=C),  7.55 (m, 3 H, Ph), 7.80 (m, 2 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 12.25 (CH3, d), 15.83 (CH3, d), 29.65 (NCH3, d), 
32.38 (CH2, u), 55.80 (SCH2),109.34 (C=CH, u), 128.82, 129.69,132.53 (o-, m-, p-
C, d), 136.57 (C=CH, u), 147.23 (i-C, u).  
 
IR (capillary): ν 3060 (s), 2929 (w), 2876 (w), 2802 (m), 1446 (w), 1467 (s), 1246 
(w), 1151 (w), 1106 (s), 1081 (w), 942 (s), 856 (s), 737 (w) cm−1. 
  
CI-MS m/z (relative intensity, %): 238 [M++1] (63), 237 [M+]  (2), 184 (3), 156 
(100), 125 (11), 83 (9), 81 (4).  
 
Elemental Analysis:  
Anal. Calcd for C13H19NOS (237.39): C, 65.78; H, 8.07; N, 5.90 
Found             : C, 65.78; H, 8.29; N, 5.93 
 
Optical rotation       : [α]D = +70.5 (c 1.01, CH2Cl2) 
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S
Ph
O NMeH
Me
NOE
Z-110c  
          
 Z-110c:         
                                          
1H NMR (400 MHz, C6D6): δ 0.56 (t, J =7.4, 3 H, CH3), 1.45 (br s, 3 H, CH3), 1.55 
(q, J = 7.4 Hz 2 H, CH2CH3), 2.85 (s, 3 H, NCH3), 3.78 (d, J = 7.9 2 H, SCH2), 5.25 
(m, 1 H, CH=C),  7.15 (m, 3 H, Ph), 7.80 (m, 2 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 12.07 (CH3, d), 22.89 (CH3, d), 29.63 (NCH3, d), 
24.67 (CH2, u), 55.65 (SCH2),110.48 (C=CH, u), 129.08,129.78,132.78 (o-, m-, p-
C, d), 136.94 (C=CH, u), 147.26 (i-C, u).  
 
IR (capillary): ν 3058 (s), 2935 (m), 2802 (m), 2729 (s), 1446 (w), 1403 (s), 1410 
(m), 1248 (w), 1152 (w), 1140 (vs), 1105 (s), 997 (s), 969 (s), 894 (m), 856 (m), 
772 (w) cm−1. 
 
EI-MS m/z (relative intensity, %): 238 [M++1] (63), 237 [M+]  (2), 184 (3), 156 
(100), 125 (11), 83 (9), 81 (4), 71 (4).  
 
Elemental Analysis:  
Anal Calcd for C13H19NOS (237.39): C, 65.78; H, 8.07; N, 5.90 
Found                                              : C, 65.24 ; H,8.03 ; N, 6.24. 
 
Optical rotation: [α]D = +76.4 (c 1.01, CH2Cl2) 
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5.5    Synthesis of Syn-configurated Homoallylic Alcohols 
 
5.5.1 (1R,2R)-2-(Cyclohept-1-enyl)-2-[ (S)-N-methyl-S-
phenylsulfonimidoyl]-1-phenylethanol (11c).. 
 
S
NMe
Ph
O
OH
Ph
11c  
 
n-BuLi (3.12 mL, 5.0 mmol, 1.6 M solution in hexane) was added at -78 °C to a 
solution of the cyclic allylic sulfoximine 1b (1.20 g, 4.56 mmol) in Et2O (50 mL). 
After the mixture was stirred for 10 min at -78 °C, neat ClTi(NEt2)3  (1.76 mL, 5.7 
mmol) was added. The resulting mixture was stirred for 10 min at -78 °C, warmed 
to room temperature, and stirred for 2 h. After the mixture was cooled to -78 °C, 
benzaldehyde (689 mg, 8.2 mmol) was added dropwise. After the mixture was 
stirred for 2 h at -78 °C, it was poured into aqueous (NH4)2CO3 solution and 
extracted with EtOAc. The combined organic phases were dried (MgSO4) and 
concentrated in vacuo. Recrystallization from diethyl ether afforded 11c (1.17 g, 
70%, 98% de) as colorless crystals. 
  
1H NMR (400 MHz, CDCl3): δ 0.90-1.06 (m, 4H, cC7H11), 1.30-1.74 (m, 6 H, 
cC7H11), 2.70 (s, 3 H, NCH3), 3.75 (m, 1 H, CHS), 5.46 (br. d, J = 9.7 Hz, 1 H, 
CHOH), 7.48-7.72 (m, 5 H, Ph), 7.78-7.84 (m, 3H, Ph). 
 
13C NMR (100 MHz, CDCl3): δ 21.1 (cC7H11, u), 24.3 (cC7H11, u), 28.2 (cC7H11, u), 
28.5 (cC7H11, u), 28.6 (d), 28.7 (cC7H11, u), 71.9 (CHS, d), 72.4 (CHOH, d), 125.9 
(d), 126.0 (d), 126.4 (d), 126.6 (d), 126.7 (d), 127.5 (d), 127.8 (d), 131.9 (d), 135.3 
(u), 139.2 (u).  
 
CI-MS m/z (relative intensity, %): 370 (M+ +1) (10), 264 (44), 231 (10), 215 (43), 
156 (100), 140 (13), 107 (19). 
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 IR (capillary): ν  3631 (s), 3460 (s, br), 3183 (w), 3056 (m), 3025 (s), 2962 (m), 
2802 (w), 2802 (w), 2696 (S), 2475 (s), 2373 (s), 2344 (s), 2282 (s), 2160 (s), 
2064 (s), 1985 (s), 1964 (s), 1918 (s), 1890 (s), 1809 (s), 1737 (s), 1702 (s), 1687 
(s), 1605 (s), 1582 (s), 1545 (s), 1496 (s), 1170 (m), 896 (s), 856 (w), 822 (s), 777 
(w), 764 (m) cm−1.  
 
Elemental Analysis:  
Anal. Calcd for C22H27 NO2: C, 71.51;  H, 7.36; N, 3.79 
Found                                : C, 71.64;  H, 7.77; N, 3.65. 
 
Optical rotation: [α]D –21.4 (c 1, CH2Cl2).  
 
M.p: 115-116 °C 
 
 
 
5.5.2    Synthesis of (+)-(E)-(3R,4R,Ss)-4-(N-methyl-S- phenylsulfonimidoy)-
2,6-dimethyl-oct-5-en-3-ol (2c) . 
 
S
OH
O
NMePh
2c                                         
n-BuLi (3.12 mL, 5.0 mmol, 1.6 M solution in hexane) was added at -78 °C to a 
solution of the allylic sulfoximine 110c (1.20 g, 3.88 mmol) in THF (50 mL). After 
the mixture was stirred for 10 min at -78 °C, neat ClTi(NEt2)3  (1.76 mL, 5.7 mmol) 
was added. The resulting mixture was stirred for 10 min at -78 °C, warmed to room 
temperature, and stirred for 2 h. After the mixture had again been cooled to -78 °C, 
isobutyraldehyde (689 mg, 8.2 mmol) was added dropwise. After the mixture was 
stirred for 2 h at -78 °C, it was poured into aqueous (NH4)2CO3 solution and 
extracted with EtOAc. The combined organic phases were dried  (MgSO4) and 
concentrated in vacuo. Recrystallization from diethyl ether afforded 2c (1.11 g, 
71%, 98% de) as colorless oil. 
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1H NMR (400 MHz, CDCl3): δ 0.75 (d, J = 6.9 Hz, 6 H, CH(CH3)2), 0.85 (t, J = 7.5 
Hz, 3 H CH2CH3), 1.05 (d, J = 6.4 Hz, 3 H CH3), 1.70 (m, 1 H, CH(CH3)2, 1.90 (m, 
2 H, CH2CH3),   2.66 (s, 3 H, NCH3), 3.90 (dd, J = 9.4 Hz, J = 1.7 Hz, 1 H, CHS), 
4.36 (dd, J = 9.1, J = 1.9 Hz, 1 H, CHOH), 5.0 (m, 1 H, =CH), 6.9 (br s, OH) 7.48-
7.72 (m, 5 H, Ph). 
 
 13C NMR (100 MHz, CDCl3): δ 12.3, 13.8 (CH(CH3)2, d), 15.5 (CH2CH3, d), 20.0 
(CH3, d), 29.6 (NMe, d), 30.9 (CH(CH3)2, d), 32.4 (CH2CH3, u), 68.0 (CHS, d), 72.4 
( CHOH, d), 112.1 (CH=C, d), 128.7 (d), 128.8 (d), 129.0 (d), 147.0 (i-C, u), 136.4 ( 
C=CH, u).  
 
CI-MS m/z (relative intensity, %): 311 (M+ +2) (9), 310 (M+ +2) (6), 157 (9), 156 
(100), 155 (35), 137 (53). 
  
IR (capillary): ν  3661 (s), 3260 (m), 3061 (s), 3025 (s), 2931 (w), 2805 (m), 2725 
(s),  2381 (s), 2344 (s), 1817 (s),1809 (s), 1724 (s), 1664 (s), 1605 (s), 1582 (s), 
1545 (s), 1447 (w), 1308 (s), 1282 (s), 1108 (m), 938 (s), 861 (w), 856 (w), 754 (w) 
cm-1.  
 
HRMS (EI, 70 eV):  
calcd for C17H27NO2S-C4H8O: 237.118000 
Found                  : 237.118737.  
 
Optical rotation: [α]D = +241.4 (c 1.22, CH2Cl2).  
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5.6  Synthesis of Alkenyl/Cycloalkenyl Chlorohydrines. 
 
5.6.1   Synthesis of (-)-(1R,2R)-2-Chloro-2-(cyclohex-1-enyl)-1-phenylethanol 
(21a). 
 
Cl
OH
Ph
21a  
  
Following GP3, reaction of 11a (550 mg, 1.55 mmol) with ClCO2CH(Cl)Me (0.2 
mL, 1.86 mmol) afforded chlorohydrine 21a (322 mg, 88%, ≥98% de) and 
sulfinamide 29a (380 mg, 94%):  
 
1H NMR (400 MHz, CDCl3): δ 1.34-1.54 (m, 4H, cC6H9), 1.75-2.00 ( m, 2H, cC6H9), 
2.05-2.15 (m, 2H, cC6H9 ), 2.66 (br. s, 1H, OH), 4.51 (d, J  = 8.5 Hz, 1H, 2-H), 4.79 
(d, J  = 8.5 Hz, 1H, 1-H), 5.52 (m, 1H, =CH), 7.27-7.35 (m, 5H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 21.8 (cC6H9, u), 22.2 (cC6H9, u), 24.5 (cC6H9, u), 
25.0 (cC6H9, u), 75.3 (C-2, d), 76.2 (C-1, d), 126.6 (o-Ph, d), 128.0 (m-Ph, d), 
128.1 (p-Ph, d), 129.0 (=CH, d), 133.7 (i-Ph, u), 139.3 (=C, u).  
 
CI-MS m/z (relative intensity, %): 236( M+) (11), 218(66), 201(9), 183(43), 159(17), 
141(100), 128(18), 115(31), 91(35).  
 
IR (capillary): ν  3450 (m, br), 3062 (m), 3031 (m), 2709 (s), 2667 (s), 1951 (s), 
1884 (s),1767 (s), 1632 (s), 1600 (s), 1496 (m), 1372 (s), 1349 (m), 1324 (m), 
1249 (m), 1190 (m), 1142 (m), 1085 (m), 1028 (m), 969 (w), 912 (s), 891 (s), 845 
(s) cm-1.    
 
Elemental Analysis:  
Anal. Calcd for C14H17ClO (236.74): C, 71.03; H, 7.24  
Found       : C, 71.16; H, 6.86.  
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Optical rotation: [ α]D = -10.8 (c 0.45, CH2Cl2)  
                                                                       
5.6.2 Synthesis of (-)-(1R,2R)-1-Chloro-1-(cyclohex-1-enyl)-3-methylbutan-
2-ol (21b) . 
 
Cl
OH
21b  
 
Following GP3, reaction of 11b (520 mg, 1.62 mmol) with ClCO2CH(Cl)Me (0.21 
mL, 1.94 mmol) afforded chlorohydrine 21b (294 mg, 85%, ≥98% de) and 
sulfinamide 29a (393 mg, 93%). 
  
1H NMR (400 MHz, CDCl3): δ 0.85 (d, J = 6.8 Hz, 3 H, CH3), 0.95 ( d, J = 6.8, 3 H, 
CH3), 1.40-1.70 (m, 4 H, cC6H9),1.75-1.90(m, 4 H, cC6H9),  1.95-2.05 (m, 1 H, 
CH(CH3)2), 2.10-2.20 (br. s, 1 H, OH), 3.55 (dd, J  = 8.2 , J = 3.3 Hz, 1 H, 2-H), 
4.35 (d, J  = 8.2 Hz, 1 H, 1-H), 5.75 (m, 1 H, =CH).  
 
13C NMR (100 MHz, CDCl3): δ 15.2 (CH3, d), 20.9 (CH3, d), 24.4 (cC6H9, u), 22.7 ( 
cC6H9, u), 24.1 (cC6H9, u) 25.5 (cC6H9, u) 30.3 (CH(CH3)3, d),74.3 (C-2, d), 76.9 ( 
C-1, d), 128.5 (=CH, d), 135.3 (=C, u).  
 
CI-MS m/z (relative intensity, %): 201 [M+ -1] (2), 180(4), 185(9), 167(35), 150(33), 
149(100), 135(14), 123(22), 107(14), 95(19), 79 (11), 69 (19).   
 
IR (capillary): ν 3470 (m, br), 3043 (m), 2660 (s), 1730 (s), 1659 (s), 1465 (m), 
1368 (m), 1302 (s), 1270 (s), 1235 (m), 1173 (m), 1138 (m), 1061 (m), 971 (s), 920 
(m), 891 (s), 848 (s), 817 (s) cm-1.  
 
HRMS (EI, 70 eV):  
calcd for C11H19ClO: 202.112505  
Found            : 202.112443.  
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Optical rotation: [ α]D = -14.2 (c 0.30, CH2Cl2) 
  
5.6.3 Synthesis of (-)-(1R,2R)-2-Chloro-2-(cyclohept-1-enyl)-1-
phenylethanol (21c) . 
Cl
OH
Ph
21c  
 
Following GP3, reaction of 11c (525 mg, 1.42 mmol) with ClCO2CH(Cl)Me (0.18 
mL, 1.70 mmol) afforded chlorohydrine 21c (306 mg, 86%, ≥98% de) as a 
colorless oil and sulfinamide 29a (341 mg, 92%)  
 
1H NMR (400 MHz, CDCl3): δ  1.30-1.45 (m, 3 H, cC7H11), 1.50-1.60 ( m, 2 H, 
cC7H11), 1.8-2.0 (m, 3 H, cC7H11 ), 2.1-2.2 (m, 1 H, cC7H11), 2.30 (m, 1 H, cC7H11), 
2.81 (br. s, 1 H, OH), 4.58 (d, J  = 8.9 Hz, 1 H, 2-H), 4.79 (d, J  = 8.9 Hz, 1 H, 1-H), 
5.65 (m, 1 H, 4-H), 7.22-7.40 (m, 5 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ  26.2 (cC7H11, u), 26.8 (cC7H11, u), 28.2 (cC7H11, u), 
29.1 (cC7H11, u), 32.2 (cC7H11, u), 76.4 (C-2, d), 77.2 (C-1, d), 127.0 (o-Ph, d), 
128.30 (m-Ph, d), 128.4 (p-Ph, d), 134.4 (=CH, d), 139.5 (i-Ph, u), 139.26 (=C, u).  
 
CI-MS m/z (relative intensity, %): 250 (M+) (1.5), 232 (11), 155 (8), 144 (9), 
141(30), 129(11), 108(33), 107(100), 105(29), 91 (17), 79 (33), 77 (22).  
 
IR (capillary): ν 3444 (s, br), 3020 (m), 2927 (w), 2853 (m), 1954 (s), 1882 (s), 
1703 (w), 1601 (s), 1493 (s), 1383 (s), 1318 (s), 1275 (s), 1147 (s), 1053 (m), 965 
(s), 915 (s), 852 (s) cm−1.  
 
HRMS (EI, 70 eV):  
calcd for C15H19ClO: 250.112421 
Found            : 250.112443.  
 
Optical rotation: [ α]D = -18.8 (c 1, CH2Cl2)  
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5.6.4 (1R, 2S)- and (1R,2R)-2-Chloro-5-methyl-1-phenylhex-3-en-1-ol (anti-
23a and syn-23a) . 
 
Ph
OH
Cl
Ph
OH
Cl
+
anti-23a                       syn-23a  
 
Treatment of 8a (650 mg, 1.89 mmol) with ClCO2CH(Cl)Me (0.26 mL, 2.46 mmol) 
as described in GP1 afforded a mixture of chlorohydrins anti-23a and syn-23a 
(377 mg, 89%) in a ratio of 78:22 together with sulfinamide 29a (465 mg, 94%).  
 
Compound syn-23a: 1H NMR (400 MHz, CDCl3): δ  0.80 (d, J = 6.7 Hz, 3 H, 6-H), 
0.86 ( d, 2 J = 6.7 Hz, 3 H, 7-H), 2.22-2.30 (m, 1 H, 5-H ), 2.32-2.40 (br. s, 1 H, 
OH), 4.52 (dd, J  = 7.3, J = 8.2 Hz, 1 H, 2-H), 4.69 (d, J  = 7.3 Hz, 1 H, 1-H), 5.36-
5.46 (m, 2 H, 3-H, 4-H), 7.28-7.36 (m, 5 H, Ph).  
 
Compound syn-23a:  13C NMR (100 MHz, CDCl3): δ  21.6 (C-6 or C-7, d), 21.7 (C-
6 or C-7, d), 30.6 (C-5, d), 70.0 (C-2, d), 77.6 (C-1, d), 123.6 (C-4, d), 139.2 (i-Ph, 
u), 142.9 (C-3, d).  
 
Compound syn-23a + anti-23a : CI-MS m/z (relative intensity, %): 207 (23), 190 
(14), 189(100), 173(10), 107(13).  
 
IR (capillary) ν 3425 (m, br), 3085 (s), 3062 (m), 3031 (m), 2929 (w), 2870 (w), 
2386 (s), 2286 (s), 1951 (s), 1882 (s), 1807 (s), 1663 (m), 1601 (s), 1546 (s), 1494 
(m), 1454 (w), 1385 (m), 1366 (m), 1328 (m), 1232 (s), 1189 (m), 1054 (w), 1028 
(w), 917 (s), 854 (m), 763 (w) cm-1. 
 
Compound anti-23a: 1H NMR (400 MHz, CDCl3): δ  0.90 (d, J = 6.7 Hz, 3H, 6-H), 
0.93 ( d, J = 6.7 Hz, 3H, 7-H), 2.22-2.30 (m, 1H, 5-H ), 2.32-2.40 (br. s, 1H, OH), 
4.50 (m, 1H, 2-H), 4.90 (d, J  = 4.7 Hz, 1H, 1-H), 5.46-5.54 (m, 2H, 3-H, 4-H), 7.25-
7.35 (m, 5H, Ph).  
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Compound anti-23a: 13C NMR (100 MHz, CDCl3): δ  21.8 (C-6, C-7, d), 31.1 (C-5, 
d), 68.1 (C-2, d), 77.1 (C-1, d), 122.4 (C-4, d), 139.3 (i-Ph, u), 143.6 (C-3, d).  
 
 
 
5.6.5 Synthesis of (1R,2S)-and  (1R,2R)-2-Chloro-4-cyclohexyl-1-
phenylbut-3-en-1-ol (anti-23b and syn-23b)  
 
Ph
OH
Cl
Ph
OH
Cl
+
anti-23b                               syn-23b  
Following GP3, reaction of 8b (400 mg, 1.04 mmol) with ClCO2CH(Cl)Me (0.26 
mL, 2.46 mmol) afforded a mixture of chlorohydrins anti-23b and syn-23b  (249 
mg, 90%) in ratio of 74:26 together with sulfinamide 29a (255 mg, 93%):  
 
 Compound syn-23b:1H NMR (400 MHz, CDCl3): δ  0.85-1.35 (m, 5 H, cC6H11), 
1.48-1.72 (m, 5 H, cC6H11), 1.80-1.86 (m, 1 H, 5-H), 2.55-2.59 (br. s, 1 H, OH), 
4.50-4.55 (m, 1 H, 2-H), 4.68 (d, J  = 7.6 Hz, 1 H, 1-H), 5.38-5.54 (m, 2 H, 3-H, 4-
H), 7.28-7.36 (m, 5 H, Ph).  
 
Compound syn-23b: 13C NMR (100 MHz, CDCl3): δ  25.6 (cC6H11, u), 25.7 
(cC6H11, u), 25.9 (cC6H11, u), 32.1 (cC6H11, u), 32.2 (cC6H11, u), 40.1 (C-5, d), 68.1 
(C-2, d), 70.3 (C-1, d), 123.9 (C-4, d), 139.1 (i-Ph, u), 141.9 (C-3, d). 
  
Compound syn-23b + anti-23b : CI-MS m/z (relative intensity, %): 264 (M+) (38), 
263 (14), 262 (100), 183(8), 126(14).  
 
IR (capillary): ν  3188 (m, br), 3028 (m), 2924 (w), 2853 (w), 2800 (m), 1656 (m), 
1448 (w), 1384 (m), 1330 (m), 1235 (w), 1203 (m), 1177 (m), 1146 (w), 1107 (m), 
1081 (w), 1049 (w), 997 (m), 913 (m), 865 (w), 851 (w), 784 (w), 742 (w), 702 (w) 
cm−1.  
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Elemental Analysis:  
Anal. Calcd for C13H17ClO: C, 72.58;  H, 7.99 
 Found:     C, 72.59; H, 8.21. 
 
Compound anti-23b: 1H NMR (400 MHz, CDCl3): δ 0.85-1.35 (m, 5H, cC6H11), 
1.48-1.72 (m, 5H, cC6H11), 1.90-1.98 (m, 1H, 5-H ), 2.84 (br. s, 1 H, OH), 4.50-
4.55 (m, 1 H, 2-H), 4.90 (d, J  = 4.6 Hz, 1 H, 1-H), 5.38-5.54 (m, 2H, 3-H, 4-H), 
7.28-7.36 (m, 5H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 25.7 (cC6H11, u), 25.7 (cC6H11, u), 25.9 (cC6H11, u), 
32.1 (cC6H11, u), 32.2 (cC6H11, u), 39.9 (C-5, d), 68.1 (C-2, d), 70.3 (C-1, d), 122.7 
( C-4, d), 139.1 (i-Ph, u), 142.6 (C-3, d).  
 
 
 
 
 
5.7       Synthesis of Cyclo/Alkenyloxiranes 
 
5.7.1 (2S,3R)-2-(Cyclohex-1-enyl)-3-phenyloxirane (22a).  
 
O Ph
22a  
 
Following GP4, reaction of 21a (430 mg, 1.82 mmol) with DBU (0.29 mL, 2.00 
mmol) afforded oxirane 22a (342 mg, 94%, ≥98% de) as a colorless oil. 
 
1H NMR (400 MHz, CDCl3): δ 1.20-1.34 (m, 4 H, cC6H9), 1.40-1.50 (m, 2 H, 
cC6H9), 1.65-2.00 (m, 2 H, cC6H9), 3.62 (m, 1 H, 2-H), 4.12 (d, J = 4.4 Hz, 1 H, 1-
H), 5.71 (m, 1 H, cC6H9), 7.20-7.25 (m, 5 H, Ph).  
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13C NMR (100 MHz, CDCl3): δ 22.1 (cC6H9, u), 22.3 (cC6H9, u), 22.5 (cC6H9, u), 
25.4 (cC6H9, u), 58.3 (C-2, d), 61.1 (C-1, d), 126.7 (o-Ph, d), 127.3(m-Ph, d), 
127.5(p-Ph, d), 125.4 (=CH, d), 130.2 (=C, u), 135.4 (i-Ph, u).  
 
CI-MS m/z (relative intensity, %): 201 [M+ + 1] (9), 200 (M+) (63) 199 (100), 171 
(72), 157(36), 143 (19), 129 (91), 105 (78), 91 (71).  
 
IR (capillary): ν  3087 (m), 3061 (m), 3031 (m), 2859 (w), 2835 (w), 2673 (s), 1951 
(s), 1885 (s), 1723 (m), 1671 (m), 1605 (m), 1585 (s), 1451 (w), 1410 (m), 1337 
(m), 1315 (m), 1270 (m), 1251 (m), 1195 (m), 1137 (m), 1001 (m), 967 (m), 921 
(w), 830 (m), 801 (m), 751 (w) cm−1.  
 
HRMS (EI, 70 eV):  
calcd for C14H16O: 200.120047  
Found:                   200.120115 
 
Optical rotation: [ α]D = -14.6 (c 0.30, CH2Cl2)  
  
 
5.7.2 (2S,3R)-2-(Cyclohex-1-enyl)-3-isopropyloxirane (22b).  
 
O
22b  
Following GP4, reaction of 21b (420 mg, 2.08 mmol) with DBU (0.34 mL, 2.29 
mmol) afforded oxirane 22b (318 mg, 92%, ≥98% de) as a colorless oil. 
 
1H NMR (400 MHz, CDCl3): δ 0.85 (d, J = 6.6 Hz, 3 H, CH3), 1.05 (d, J = 6.6 Hz, 3 
H, CH3), 1.38-1.47 (m, 1 H, CH(CH3)2), 1.50-1.70 (m, 4 H, cC6H9), 1.90-2.08 ( m, 
4 H, cC6H9), 2.68 (dd, J = 4.1, J = 9.0 Hz, 1 H, 1-H), 3.29 (m, 1 H, 2-H), 5.61 (m, 1 
H, =CH).  
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13C NMR (100 MHz, CDCl3): δ 18.8 (CH3, d), 20.1 (CH3, d) 22.5 (cC6H9, u), 22.6 ( 
cC6H9, u), 24.5 (cC6H9, u), 25.7 (CH(CH3)3, d), 26.4 (cC6H9, u), 58.8 (C-1, d), 64.6 
( C-2, d), 122.7 (=CH, d), 131.0 (=C, u).  
 
CI-MS m/z (relative intensity, %): 166 (M+) (45) 150 (11), 149 (100), 113(11), 71 
(18), 70 (14), 57 (26), 55 (11).  
 
IR (capillary): ν  2932 (w), 2669 (s), 1729 (s), 1673 (s), 1462 (m), 1387 (s), 1364 
(s), 1340 (s), 1252 (s), 1162 (s), 1136 (s), 1075 (s), 958 (m), 922 (m), 828 (s), 801 
(s), 752 (s) cm-1.  
 
HRMS (EI, 70 eV):  
calcd for C11H18O: 166.135698  
Found:                   166.135765. 
 
Optical rotation: [ α]D = -43.4 (c 0.35, CH2Cl2)  
 
 
 
 
 
 
 
5.7.3   (2S,3R)-2-(Cyclohept-1-enyl)-3-phenyloxirane (22c)  
  
O Ph
22c  
Following GP4, reaction of 21c (450 mg, 1.80 mmol) with DBU (0.29 mL, 1.98 
mmol) afforded oxirane 22c (347 mg, 90%, ≥98% de) as a colorless oil. 
 
1H NMR (400 MHz, CDCl3): δ 1.22-1.34 (m, 4 H, cC6H9), 1.42-1.55 ( m, 4 H, 
cC6H9), 1.60-2.00 (m, 2 H, cC6H9), 3.67 (m, 1 H, 2-H), 4.13 (d,  J = 4.2 Hz, 1 H, 1-
H),  5.88-5.93 (m, 1 H, cC7H11), 7.22-7.28 (m, 5 H, Ph).  
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13C NMR (100 MHz, CDCl3): δ 25.7 (cC7H11, u), 26.7 (cC7H11, u), 28.0 (cC7H11, u), 
29.7 (cC7H11, u), 32.1 (cC7H11, u), 58.6 (C-2, d), 62.2 (C-1, d), 126.9 (o-Ph, d), 
127.4 (m-Ph, d), 127.5 (p-Ph, d), 129.8 (=CH, d), 135.2 (=C, u), 135.6 (i-Ph, u).  
 
CI-MS m/z (relative intensity, %): 215 [M+ + 1] (100), 214 (M+) (27) 197 (34), 105 
(27).  
 
IR (capillary): ν  3030 (m), 2696 (s), 1946 (s), 1880 (m), 1730 (s), 1671 (s), 1605 
(s), 1540 (s), 1495 (s), 1450 (w), 1407 (s), 1377 (s), 1274 (s), 1221 (s), 1193 (s), 
1075 (s), 1027 (s), 966 (s), 899 (m), 860 (m), 770 (s), 748 (w) cm−1.  
 
Elemental Analysis:  
Anal. Calcd for C15H18O (214.): C, 84.07; H, 8.47 
Found                                      : C, 84.28; H, 8.27. 
 
Optical rotation: [ α]D = -7.1 (c 1.80, CH2Cl2)  
 
 
 
 
5.7.4   Synthesis of (3R,2R) and (3R,2S)-2-(3-Methylbut-1-enyl)-3-
phenyl.oxirane (trans-24a and cis-24a)   
 
O Ph O Ph+
trans-24a cis-24a  
  
Treatment of mixture of  anti-23a and syn-23a (640 mg, 2.85 mmol) with DBU 
(0.43 mL, 2.85 mmol) as described in GP2 afforded a mixture of the oxirane trans-
24a and cis-24a (504 mg, 94%) in a ratio of 78:22.  
 
Compound cis-24a: 1H NMR (400 MHz, CDCl3): δ  0.88 (d, J = 7.4 Hz, 3 H, 6-H), 
0.91 (d, J = 6.9 Hz, 3 H, 7-H), 2.21 (octd, J = 6.6 Hz, J = 1.1 Hz, 1 H, 5-H), 3.64 
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(dd, J = 4.1 Hz, J = 8.5 Hz, 1 H, 2-H), 4.20 (d, J = 4.4 Hz, 1 H, 1-H), 4.97 (ddd, J = 
8.5, J = 15.4, J = 1.1 Hz, 1 H, 3-H), 5.94 (dd, J  = 6.9, J = 15.4 Hz, 1 H, 4-H), 7.25-
7.37 (m, 5 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 21.9 (C-6, C-7, d), 30.9 (C-5, d), 58.9, 59.8 (C-1, C-
2, d), 120.2 (C-4, d), 126.3,127.1, 127.9 (o-, m-, p-Ph, d), 135.29 (i-Ph, u), 146.5 
(C-3, d).  
 
Compounds cis-24a + trans-24a : CI-MS m/z (relative intensity, %): 188 [M+] (6), 
171 (16), 106 (10), 105 (100), 77 (34), 51 (12).  
 
IR (capillary): ν  3063 (s), 3031 (m), 2963 (w), 2872 (m), 1963 (s), 1884 (s), 1692 
(m), 1623 (s), 1598 (s), 1580 (s), 1495 (m), 1465 (m), 1386 (m), 1315 (s), 1179 (s), 
1136 (s), 1106 (w), 1068 (w), 1009 (m), 969 (m), 894 (m), 842 (s), 760 (w) cm−1.  
 
Elemental Analysis:  
Anal. Calcd for C13H16O: C, 82.93; H, 8.51 
 Found:                            C, 82.94; H, 8.69. 
   
Compound trans-24a: 1H NMR (400 MHz, CDCl3): δ 1.01 (d, J = 6.6 Hz, 3H, 6-H), 
1.03 ( d, J = 6.6 Hz, 3H, 7-H), 2.32-2.41 (octd, J = 6.9 Hz, J = 1.4 Hz, 1H, 5-H), 
3.33 (dd, J = 1.9, J = 8.0 Hz, 1H, 2-H), 3.76 (d, J = 2.2 Hz, 1H, 1-H), 5.26-5.30 
(ddd, J = 8.0, J = 15.7, J = 1.4 Hz, 1H, 3-H), 5.94-5.98 (dd, J  = 6.6, J = 15.4 Hz, 
1H, 4-H), 7.25-7.37 (m, 5H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 22.1 (C-6, C-7, d), 30.9 (C-5, d), 60.2, 63.3 (C-1, C-
2, d), 124.0 (C-4, d), 125.5, 127.1, 127.9 (o-, m-, p-Ph, d), 137.40 (i-Ph, u), 144.2 
(C-3, d).  
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 5.7.5   Synthesis of (3R,2R)- and (3R,2S)-2-(2-Cyclohexylvinyl)- 3 -  ..      
.phenyloxirane (trans-24b and cis-24b)   
O Ph
O Ph
+
trans-24b cis-24b  
Treatment of a mixture of anti-23b and syn-23b (450 mg, 1.7 mmol) with DBU 
(0.28 mL, 1.87 mmol) as described in GP2 afforded a mixture of oxiranes trans-
24b and cis-24b (361 mg, 93%) in a ratio of 74:26.   
 
Compound cis-24b: 1H NMR (400 MHz, CDCl3): δ  0.90-1.30 (m, 5 H, cC6H11), 
1.60-1.80 (m, 5 H, cC6H11), 3.64 (dd, J = 4.4 Hz, J = 8.8 Hz, 1 H, 2-H), 4.20 (d, J = 
4.4 Hz, 1 H, 1-H), 1.95-2.05 (m, 1 H, 5-H), 4.97 (ddd, J = 8.5, J = 15.4, J = 1.1 Hz, 
1 H, 3-H), 5.89 (dd, J  = 6.6, J = 15.3 Hz, 1 H, 4-H), 7.25-7.37 (m, 5 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 26.2 (cC6H11, u), 26.5 (cC6H11, u), 29.7 (cC6H11, u), 
32.7 (cC6H11, u), 32.8 (cC6H11, u), 41.1 (C-5, d), 60.6, 63.7 (C-1, C-2, d), 120.9 (C-
4, d), 145.5 (C-3, d), 125.8, 128.7, 128.3 (o-, m-, p-C, d), 135.7 (i-Ph, u).  
 
Compounds cis-24b + trans-24b : CI-MS m/z (relative intensity, %): 228 [M+] (5), 
145 (100), 144 (12), 146 (26), 127 (8), 117 (36), 105 (10), 91 (29), 77 (13), 55 (18).  
 
IR (capillary) ν 3087 (s), 3063 (s), 2666 (s), 1948 (s), 1881 (s), 1807 (s), 1762 (s), 
1691 (s), 1663 (s), 1604 (m), 1542 (s), 1497 (m), 1449 (w), 1421 (s), 1374 (m), 
1349 (s), 1255 (s), 1197 (s), 1152 (s), 1072 (s), 1027 (s), 966 (w), 916 (s), 878 (w), 
849 (m), 753 (w), 740 (m) cm-1.  
 
HRMS (EI, 70 eV)  
Calcd for C16H20O:  228.151504 
 Found:                   228.151415.  
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Compound trans-5e: 1H NMR (400 MHz, CDCl3): δ 0.90-1.30 (m, 5 H, cC6H11), 
1.55-1.80 (m, 5 H, cC6H11), 3.32 (dd, J = 1.9, J = 8.0 Hz, 1 H, 2-H), 3.76 (d, J = 1.9 
Hz, 1 H, 1-H), 1.95-2.05 (m, 1 H, 5-H), 5.28 (ddd, J = 8.0, J = 15.6, J = 1.4 Hz, 1 
H, 3-H), 5.90 (dd, J  = 6.6, J = 15.3 Hz, 1 H, 4-H), 7.25-7.37 (m, 5 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 26.3 (cC6H11, u), 26.4 (cC6H11, u), 30.1 (cC6H11, u), 
32.8 (cC6H11, u), 32.9 (cC6H11, u), 40.8 (C-5, d), 59.4, 60.3 (C-1, C-2, d), 120.9 (C-
4, d), 143.3 (C-3, d), 126.7, 127.8, 127.7 (o-, m-, p-Ph, d), 137.6 (i-Ph, u).  
 
5.7.6   Synthesis of the Alkenyloxirane trans-24b and cis-24b from Z-25b  
 
Reaction of Z-25b (400 mg, 1.04 mmol) with ClCO2CH(Cl)Me (1.32 mL, 1.25 ml) 
according to GP3 procedure afforded a mixture of chlorohydrines anti-23b and 
syn-23b together with sulfinamide (253 mg, 93%). Treatment of the mixture of 
chlorohydrines with DBU (0.15 mL, 1 mmol) according to GP2 afforded a mixture 
of trans-24b and cis-24b (203 mg, 89 %) in ratio of 75:25, also containing 11% of 
the correspondig Z isomers. 
trans- 24b: 1H NMR (400 MHz, CDCl3): δ  1.05-1.30 (m, 5 H, cC6H11), 1.60-1.80 
(m, 5 H, cC6H11), 3.33 (dd, J = 1.9 Hz, J = 8.0 Hz, 1 H, 2-H), 3.76 (d, J = 1.9 Hz, 1 
H, 1-H), 1.95-2.05 (m, 1 H, 5-H), 5.28 (ddd, J = 8.0, J = 15.7, J = 1.4 Hz, 1 H, 3-H), 
5.89 (dd, J  = 6.6, J = 15.3 Hz, 1 H, 4-H), 7.25-7.37 (m, 5 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 26.2 (u, cC6H11), 26.3 (u, cC6H11), 26.5 (u, cC6H11), 
32.8 (u, cC6H11), 32.9 (u, cC6H11), 40.7 (d, C-5), 59.3, 60.5 (d, C-1, C-2), 120.9 (d, 
C-4), 143.2 (d, C-3), 126.7, 127.8, 127.7 (d, o-, m-, p-Ph), 137.6 (u, i-Ph).  
 
CI-MS m/z (relative intensity, %): 228 [M+] (5), 146 (26), 145 (100), 144 (12),  127 
(8), 117 (36), 105 (10), 91 (29), 81 (10), 77 (13), 67 (10), 55 (18).  
 
IR (capillary): ν  3061 (s), 3030 (m), 2666 (s), 1949 (s), 1881 (s), 1807 (s), 1726 
(s), 1663 (s), 1495 (m), 1449 (m), 1371 (s), 1348 (s), 1260 (s), 1196 (s), 1071 (s), 
1027 (s), 967 (w), 916 (s), 879 (m), 843 (s), 753 (m) cm−1.  
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HRMS (EI, 70 eV)  
Calcd for C16H20O:  228.151504 
Found:                     228.151415.  
 
cis-24b: 1H NMR (400 MHz, CDCl3): δ  1.05-1.30 (m, 5 H, cC6H11), 1.60-1.80 (m, 5 
H, cC6H11), 3.65 (dd, J = 4.4, J = 8.8 Hz, 1 H, 2-H), 4.21 (d, J = 1.4 Hz, 1 H, 1-H), 
1.95-2.05 (m, 1 H, 5-H), 4.97 (ddd, J = 8.5, J = 15.4 Hz, J = 1.1 Hz, 1 H, 3-H), 5.89 
(dd, J  = 6.6 Hz, J = 15.3 Hz, 1 H, 4-H), 7.25-7.37 (m, 5 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 26.1 (u, cC6H11), 26.2 (u, cC6H11), 26.4 (u, cC6H11), 
32.8 (u, cC6H11), 33.6 (u, cC6H11), 41.1 (d, C-5), 60.3, 63.7 (d, C-1, C-2), 120.9 (d, 
C-4), 145.5 (d, C-3), 125.6, 128.65, 128.2 (d, o-, m-, p-Ph), 135.7 (u, i-Ph).  
 
CI-MS m/z (relative intensity, %): 228 [M+] (5), 146 (26), 145 (100), 144 (12),  127 
(8), 117 (36), 105 (10), 91 (29), 81 (10), 77 (13), 67 (10), 55 (18).  
 
IR (capillary): ν  3061 (s), 3030 (m), 2666 (s), 1949 (s), 1881 (s), 1807 (s), 1726 
(s), 1663 (s), 1495 (m), 1449 (m), 1371 (s), 1348 (s), 1260 (s), 1196 (s), 1071 (s), 
1027 (s), 967 (w), 916 (s), 879 (m), 843 (s), 753 (m) cm−1.  
 
HRMS (EI, 70 eV)  
Calcd for C16H20O:  228.151504 
Found:                    : 228.151415.  
 
 
 
 
 
 
5.7.7   Synthesis of the Alkenyloxiranes trans-24a and cis-24a from Z-25a   
 
Reaction of Z-25a (344 mg, 1.00 mmol) with ClCO2CH(Cl)Me (0.13 mL, 1.2 mmol) 
according to  GP3 procedure afforded a mixture chlorohydrines syn-23a and anti-
23a together with sulfinamid (243 mg, 93%). Treatment of the mixture of 
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chlorohydrins with DBU (0.15 mL, 1 mmol) according to GP2 afforded a mixture of 
the oxiranes trans-5e and cis-5e (166 mg, 88%) in ratio of 80:20, also containing 
7% of the corresponding (Z) isomers. 
    
trans-24a:1H NMR (400 MHz, CDCl3): δ 1.01 (d, J = 6.6 Hz, 3 H, 6-H), 1.05 ( d, J = 
6.6 Hz, 3 H, 7-H), 2.30-2.45 (octd, J = 8.1 , J = 1.5 Hz, 1 H, 5-H), 3.34 (dd, J = 2.0, 
J = 7.9 Hz, 1 H, 2-H), 3.77 (d, J = 2.0 Hz, 1 H, 1-H), 5.23-5.30 (ddd, J = 7.9, J = 
15.6, J = 1.2 Hz, 1 H, 3-H), 5.94-5.99 (dd, J  = 6.7, J = 15.6 Hz, 1 H, 4-H), 7.25-
7.39 (m, 5 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 21.9 (d, C-6, C-7), 30.9 (d, C-5), 60.2, 63.2 (d, C-1, 
C-2), 124.0 (d, C-4), 125.5, 126.5, 127.5 (d, o-, m-, p-Ph), 137.40 (u. i-Ph), 146.5 
(d, C-3).  
 
CI-MS m/z (relative intensity, %): 188 [M+] (6), 171 (16), 106 (10), 105 (100), 77 
(34), 51 (12).  
 
IR (capillary): ν  3063 (s), 3031 (m), 2963 (w), 2872 (m), 1963 (s), 1884 (s), 1692 
(m), 1623 (s), 1598 (s), 1580 (s), 1495 (m), 1465 (m), 1386 (m), 1315 (s), 1179 (s), 
1136 (s), 1106 (w), 1068 (w), 1009 (m), 969 (m), 894 (m), 842 (s), 760 (w) cm−1. 
 
cis-24a: 1H NMR (400 MHz, CDCl3): δ  0.88 (d, J = 2.2 Hz, 3H, 6-H), 0.90 (d, J = 
1.0 Hz, 3H, 7-H), 2.20-2.27 (octd, J = 1.50 Hz, J = 6.7 Hz, 1H, 5-H), 3.63-3.66 (dd, 
J = 4.7 Hz, J = 8.6 Hz, 1H, 2-H), 4.23 (d, J = 4.2 Hz, 1 H, 1-H), 4.95-5.0 (ddd, J = 
8.8, J = 15.7, J = 1.2 Hz, 1H, 3-H), 5.94-5.98 (dd, J  = 6.7, J = 15.6 Hz, 1H, 4-H), 
7.25-7.37 (m, 5H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 20.0 (d, C-6, C-7), 31.2 (d, C-5), 59.0, 59.9 (d, C-1, 
C-2), 120.4 (d, C-4), 128.0,128.4, 129.0 (d, o-, m-, p-Ph), 135.20 (u, i-Ph), 145.8 
(d, C-3).  
 
CI-MS m/z (relative intensity, %): 188 [M+] (6), 171 (16), 106 (10), 105 (100), 77 
(34), 51 (12). 
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IR (capillary): ν  3063 (s), 3031 (m), 2963 (w), 2872 (m), 1963 (s), 1884 (s), 1692 
(m), 1623 (s), 1598 (s), 1580 (s), 1495 (m), 1465 (m), 1386 (m), 1315 (s), 1179 (s), 
1136 (s), 1106 (w), 1068 (w), 1009 (m), 969 (m), 894 (m), 842 (s), 760 (w) cm−1.  
 
 
 
5.7.8 (−)-(S)-N-Phenylsulfinyl-N-methyl-chlrocarboxylicacidethylester (29a) 
 
N
Me
CO2CH(Cl)MeS
O
Ph
29a  
 
 
1H NMR (400 MHz, CDCl3): δ 1.90 (d, J = 6.0 Hz, 3 H), 2.70 (d, J = 5.5 Hz, 3 H, N-
CH3), 6.55-6.60 (m, 1H), 7.25-7.37 (m, 5H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 25.2 (NCH3, d), 25.3 (d), 83.5 (d) 124.9 (d), 129.2 
(d), 131.95 (d), 141.71 (u).  
 
CI-MS m/z (relative intensity, %): 261 [M+] (2), 201 (3), 199 (40), 142 (22), 126 
(10), 125 (100), 105 (12), 97 (21), 94 (25), 78 (12), 74 (10), 59 (11), 51 (16), 45 
(18).  
 
IR (capillary): ν  3063 (m), 2940 (m), 1906 (w), 1949 (s), 1728 (s), 1726 (s), 1663 
(s), 1495 (m), 1449 (m), 1371 (s), 1348 (s), 1260 (s), 1196 (s), 1071 (s), 1027 (s), 
967 (w), 916 (s), 879 (m), 843 (s), 753 (m) cm−1.  
 
HRMS (EI, 70 eV)  
calcd. For C10H12SClNO3  : 261.022674  
Found                               : 261.022644 
 
 
Optical rotation: [ α]D = -69.4 (c 1, CH2Cl2)  
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5.8      Synthesis of Silylated Homoallylic Alcohols. 
 
5.8.1   (+)-Triethyl-[(Z)-(1R,2R)-1,2-diphenyl-3-methyl-4-[(S)-N-methyl-S- 
phenyl- sulfonimidoyl]-but-3-enyloxy]silane( 50c).  
 
S
Ph
O
NMe
Ph
Me
Ph
Et3SiO
50c  
Following GP3, reaction of sulfoximine 58b (2.85 g, 10 mmol) with benzaldehyde 
(530 mg, 5 mmol) afforded ether 50c (2.37, 94%) as a viscous liquid and 
sulfoximine 58b (1.25 g, 44%).  
 
1H NMR (400 MHz, CDCl3): δ 0.42 (m, 6 H, Si(CH2CH3)3), 0.84 (m, 9 H, 
Si(CH2CH3)3), 2.05 (d, J = 1.1 Hz, 3 H, CH3), 2.79 (s, 3 H, NCH3), 5.16 (d, J 
=9.6,Hz, 1 H, CHPh), 5.57 (d, J = 9.9 Hz, 1 H, SiOCH), 6.08 (d, J = 1.4 Hz, 1 H, S-
CH=C), 7.05 (m, 5 H, Ph), 7.15 (m, 3 H, Ph), 7.25 (m, 2 H, Ph), 7.48 (m, 3 H, Ph), 
7.94 (m, 2 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ  4.85 (Si(CH2CH3)3, u), 6.76 (Si(CH2CH3)3, d), 
21.04 (CH3, d),  29.45 (NCH3, d), 52.62 (CHPh, d), 75.93 (SiOCH, d), 126.34, 
127.31, 127.44, 127.53, 127.62, 127.75, 128.19, 128.73, 128.98 (o-, m-, p-C, d), 
131.89 (CH=C, d), 138.01 (C=CH, u), 141.18, 142.61, 155.72 (i-C, u).  
 
IR (capillary): ν  3063 (s), 3030 (s), 2954 (vs), 2910 (vs), 2877 (vs), 2805 (s), 1613 
(m), 1493 (m), 1457 (m), 1414 (m), 1238 (vs), 1153 (s), 1082 (vs), 1013 (vs), 972 
(s), 841 (vs) cm−1. 
 
CI-MS m/z (relative intensity, %): 506 [M++1] (100), 505 [M+] (3), 504 (2), 477 (2), 
476 (2), 351 (2), 350 (4), 330 (2), 329 (7), 222 (2), 221 (8), 220 (2), 219 (7), 218 
(2), 156 (10).  
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Elemental Analysis:  
Anal. Calcd for C30H39NO2SSi (505.79) : C, 71.24; H, 7.77; N, 2.77  
Found      : C, 71.09; H, 7.68; N, 2.77  
 
Optical rotation    : [α]D = +66.1 (c 0.91, MeOH). 
 
 
 
 
5.8.2 Synthesis of (+)-Triethyl-[(Z)-(1R,2R)-2-phenyl-3-methyl-4-[(S)-N-
methyl-S-phenyl-sulfonimidoyl]-1-(4-methoxyphenyl)-but-3-
enyloxy]silane (50d). 
 
S
Ph
O
NMe
C6H4OMep
Me
Ph
Et3SiO
50d  
 
Following GP3, reaction of sulfoximine 58b (2.85 g, 10 mmol) with 4-
methoxybenzaldehyde (680 mg, 5 mmol) afforded ether 50d (2.60, 97%) as a 
viscous liquid and sulfoximine 58b (1.14 g, 4.0 mmol, 40%):  
 
1H NMR (400 MHz, CDCl3): δ 0.41 (m, 6 H, Si(CH2CH3)3), 0.85 (m, 9 H, 
Si(CH2CH3)3), 2.03 (d, J = 1.4 Hz, 3 H, CH3), 2.80 (s, 3 H, NCH3), 3.71 (s,  3 H, 
OCH3),  5.13 (d, J =9.9, Hz, 1 H, CHPh), 5.55 (d, J = 9.9 Hz, 1 H, SiOCH), 6.07 (d, 
J = 1.1 Hz, 1 H, S-CH=C), 6.70 (m, 2 H, Ph), 7.04 (m, 5 H, Ph), 7.20 (m, 2 H, Ph), 
7.49 (m, 3 H, Ph),  7.94 (m, 2 H, Ph).  
 
 
13C NMR (100 MHz, CDCl3): δ 4.87 (Si(CH2CH3)3, u), 6.80 (Si(CH2CH3)3, d), 20.88 
(CH3, d),  29.46 (NCH3, d), 52.27 (CHPh, d), 54.94 (OCH3, d), 75.32 (SiOCH, d),  
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112.98, 126.28, 127.31, 127.75, 128.18, 128.54, 128.72, 128.97 (o-, m-, p-C, d), 
131.88 (CH=C, d), 138.16 (C=CH, u), 134.82, 141.22, 155.94, 158.60 (i-C, u).  
 
IR (capillary): ν  3060 (s), 3029 (s), 2955 (vs), 2910 (vs), 2876 (s), 2836 (s), 1738 
(m), 1611 (m), 1512 (m), 1445 (m), 1245 (vs), 1175 (s), 1153 (s), 1078 (s), 1048 
(s), 1007 (s), 853 (s), 835 (s) cm−1.  
 
CI-MS m/z (relative intensity, %): 536 [M++1] (100), 535 [M+] (2), 534 (2), 506 (2), 
546 (2), 406 (4), 405 (9), 404 (35), 382 (2), 381 (7), 380 (8), 359 (8), 252 (3), 251 
(12), 249 (7), 156 (10). 
 
 
Elemental Analysis:  
Anal. Calcd for C31H41NO3SSi (535.81) : C, 69.49; H, 7.71; N, 2.61 
Found      : C, 69.27; H, 7.76; N, 2.74 
 
Optical rotation    : [α]D = +57.5 (c 1.01, MeOH).  
 
5.8.3     Synthesis of (-)-(S)-N,N-Dimethylamino-S-[(Z)-(3R,4R)-2-methyl-3-
phenyl-(4-methoxyphenyl)-4-(triethylsilyl)oxy]but-enyl-phenyl-
sulfoxinium tetrafluroborate (49d) 
 
BF4
C6H4OMep
Me
Ph
Et3SiO
S
Ph
O
NMe2
49d  
 
1H NMR (400 MHz, CDCl3): δ 0.42 (m, 6 H, Si(CH2CH3)3), 0.86 (m, 9 H, 
Si(CH2CH3)3), 2.37 (s, 3 H, CH3), 3.15 (s, 6 H, N(CH3)2), 3.74 (s,  3 H, OCH3),  
5.25 (d, J = 9.3 Hz, 1 H, CHPh), 5.37 (d, J = 9.6 Hz, 1 H, SiOCH), 6.78 (m, 2 H, 
Ph), 6.98 (m, 1 H, S-CH=C), 7.04 (m, 5 H, Ph), 7.20 (m, 2 H, Ph), 7.78 (m, 3 H, 
Ph),  8.19 (m, 2 H, Ph).  
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13C NMR (100 MHz, CDCl3): δ 4.80 (Si(CH2CH3)3, u), 6.77 (Si(CH2CH3)3, d), 22.28 
(CH3, d),  37.38 (N(CH3)2, d), 53.48 (CHPh, d), 55.05 (OCH3, d), 75.65 (SiOCH, d), 
113.34, 127.45, 128.04, 128.32, 128.39, 128.62, 128.86, 129.53 (o-, m-, p-C, d), 
115.03 (CH=C, d), 130.72 (C=CH, u), 133.57, 135.94, 159.09, 174.53 (i-C, u). 
 
 
5.8.4 Synthesis of (-)-Triethyl-[(Z)-(1R,2R)-2-Isopropyl-3-methyl-4-[(S)-N-
methyl-S-phenyl-sulfonimidoyl]-1-phenyl-but-3-enyloxy]silane( 50a) 
 
S
Ph
O
NMe
Ph
Me
i-Pr
Et3SiO
50a  
 
Following GP3, reaction of sulfoximine 58a (2.51 g, 10 mmol) with benzaldehyde 
(0.53 g, 5 mmol) afforded ether 50a (2.26, 96%) as a viscous liquid and 
sulfoximine 58a (0.95 g, 3.8 mmol, 38%).  
 
1H NMR (400 MHz, CDCl3): δ 0.50 (m, 9 H, Si(CH2CH3)3, CH3), 0.85 (m, 9 H, 
Si(CH2CH3)3), 0.95 (d, J = 6.4 Hz, 3 H, CH3), 1.94 (m, 1 H, CH(CH3)3), 2.00 (d, J = 
1.1 Hz, 3 H, CH3), 2.30 (s, 3 H, NCH3), 3.87 (dd, J = 9.6,  J = 4.4 Hz, 1 H, CHiPr), 
5.05 (d, J = 4.4 Hz, 1 H, SiOCH), 5.89 (d, J = 1.4 Hz, 1 H, S-CH=C), 7.30 (m, 5 H, 
Ph), 7.50 (m, 3 H, Ph), 7.75 (m, 2 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 4.92 (Si(CH2CH3)3, u), 6.82 (Si(CH2CH3)3, d), 20.76 
(CH3, d), 21.19 (CH3, d), 22.83 (CH3, d), 26.88 (CH(CH3)3, d), 29.00 (NCH3, d), 
51.76 (CHiPr, d), 75.61 (SiOCH, d), 126.80, 126.96, 127.67, 128.16, 128.40, 
128.68 (o-, m-, p-C, d), 131.79 (CH=C, d), 141.39 (C=CH, u), 143.34, 156.89 (i-C, 
u).  
IR (capillary): ν 3061 (s), 3028 (s), 2958 (vs), 2910 (vs), 2876 (vs), 2801 (s), 1609 
(m), 1448 (m), 1415 (m), 1376 (m), 1243 (vs), 1149 (s), 1069 (vs), 1007 (s), 981 
(s), 858 (vs) cm−1.  
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CI-MS m/z (relative intensity, %): 472 [M++1] (100), 470 (6), 444 (2), 443 (4), 442 
(3), 317 (2), 316 (6), 295 (2), 221 (3), 222 (2), 221 (3), 187 (1), 184 (2), 156 (7).  
 
Elemental Analysis:  
Anal. Calcd for C27H41NO2SSi (471.77) : C, 68.74; H, 8.76; N, 2.97  
Found      : C, 68.64; H, 8.43; N, 2.73.  
 
Optical rotation    : [α]D = −130.1 (c 0.88, MeOH).  
 
 
 
 
 
5.8.5 Synthesis of (−)-Triethyl-[(Z)-(1R,2R)-2-Isopropyl-3-methyl-4-[(S)-N-
methyl-S-phenyl-sulfonimidoyl]-1-(4-methoxyphenyl)-but-3-enyloxy] 
silane (50b) 
 
S
Ph
O
NMe
C6H4OMep
Me
i-Pr
Et3SiO
50b  
   
Following GP3, reaction of sulfoximine 58a (2.51 g, 10 mmol) with 4-
methoxybenzaldehyde (680 mg, 5 mmol) afforded ether 50b (2.37, 95%) as a 
viscous liquid and sulfoximine 58a (950 mg, 3.8 mmol, 38%).  
 
1H NMR (400 MHz, CDCl3): δ 0.49 (m, 9 H, Si(CH2CH3)3, CH3), 0.85 (m, 9 H, 
Si(CH2CH3)3), 0.92 (d, J = 6.4 Hz, 3 H, CH3), 1.89 (m, 1 H, CH(CH3)3), 1.96 (d, J = 
1.3 Hz, 3 H, CH3), 2.42 (s, 3 H, NCH3), 3.80 (s, 3 H, OCH3),   3.85 (dd, J = 9.7,  J 
= 5.0 Hz, 1 H, CHiPr), 4.99 (d, J = 4.9 Hz, 1 H, SiOCH), 5.92 (d, J = 1.3 Hz, 1 H, 
S-CH=C), 6.87 (m, 2 H, Ph), 7.26 (m, 2 H, Ph), 7.46 (m, 3 H, Ph), 7.80 (m, 2 H, 
Ph). 
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13C NMR (100 MHz, CDCl3): δ 4.93 (Si(CH2CH3)3, u), 6.85 (Si(CH2CH3)3, d), 20.77 
(CH3, d), 21.21 (CH3, d), 22.69 (CH3, d), 26.99 (CH(CH3)3, d), 29.03 (NCH3, d), 
51.92 (CHiPr, d), 55.08 (OCH3, d), 75.24 (SiOCH, d), 113.05, 127.97, 128.11, 
128.40, 128.64,   (o-, m-, p-C, d), 131.79 (CH=C, d), 141.44 (C=CH, u), 135.69, 
157.17, 158.56 (i-C, u).  
 
IR (capillary): ν 3063 (s), 2956 (vs), 2910 (vs), 2876 (vs), 1611 (m), 1512 (m), 
1462 (m), 1246 (vs), 1174 (s), 1150 (s), 1107 (s), 1079 (s), 1036 (s), 1008 (s), 979 
(s), 855 (s) cm−1.  
 
CI-MS m/z (relative intensity, %): 502 [M++1] (100), 501 [M+] (2), 500 (3), 473 (2), 
472 (4), 427 (2), 426 (4), 372 (4), 371 (13), 370 (51), 347 (8), 346 (12), 342 (7), 
341 (10), 326 (4), 325 (6), 294 (4), 252 (2), 251 (9), 156 (11). 
 
Elemental Analysis:  
Anal. Calcd for C28H43NO3SSi (501.80)  : C, 67.02; H, 8.64; N, 2.79 
Found      : C, 66.98; H, 8.89; N, 2.83.  
 
Optical rotation    : [α]D = −137.3 (c 0.88, MeOH). 
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5.8.6 Synthesis of (−)-Triethyl-[(Z)-(αR,1R)-α-(4-methoxyphenyl)-2-{[(S)-N-
methyl-S-phenyl-sulfonimidoyl]-methene}-cyclohexane-methane-α-
enyloxy]silane (54a).  
 
O
MeN
C6H4MeOp
Et3SiO
SPh
54a  
 
Following GP3, reaction of sulfoximine 9a (2.49 g, 10 mmol) with 4-
methoxybenzaldehyde (680 mg, 5 mmol) afforded ether 54a (2.40, 96%) as a  
viscous liquid and sulfoximine 9a (970 mg, 3.9 mmol, 39%). 
 
1H NMR (400 MHz, CDCl3): δ 0.38 (m, 6 H, Si(CH2CH3)3), 0.83 (m, 9 H, 
Si(CH2CH3)3), 1.15 (m, 1 H, Cy), 1.35 (m, 3 H, Cy), 1.60 (m, 1 H, Cy), 1.95 (m, 1 
H, Cy), 2.15 (m, 1 H, Cy), 2.40 (m, 1 H, Cy),  2.75 (s, 3 H, NCH3), 3.81 (s,  3 H, 
OCH3),  3.88 (m, 1 H, Cy),  4.80 (d, J =9.6 Hz, 1 H, SiOCH),  6.28 (d, J = 1.0 Hz, 1 
H, S-CH=C), 6.85 (m, 2 H, Ph), 7.32 (m, 2 H, Ph), 7.50 (m, 3 H, Ph),  7.96 (m, 2 H, 
Ph).  
 
13C NMR (100 MHz, CDCl3): δ 4.81 (Si(CH2CH3)3, u), 6.75 (Si(CH2CH3)3, d), 
20.69, 27.54, 29.32, 33.64 (Cy, u),  29.12 (NCH3, d),  44.55 (Cy-CH, d), 55.08 
(OCH3, d), 77.37 (SiOCH, d), 113.20, 125.29, 128.20, 128.25, 128.60,  (o-, m-, p-
C, d), 131.58 (CH=C, d), 136.03 (C=CH, u), 141.71, 158.81, 161.45, (i-C, u).  
 
IR (capillary): ν 2952 (vs), 2911 (vs), 2875 (vs), 2838 (vs), 2803 (vs), 1739 (s), 
1700 (m), 1601 (m), 1579 (m), 1512 (s), 1461 (m), 1446 (m), 1242 (vs), 1160 (s), 
1102 (s), 1080 (s), 1045 (s), 1016 (s), 838 (vs) cm−1.  
 
CI-MS m/z (relative intensity, %): 500 [M++1] (29), 470 (2), 387 (2), 386 (6), 369 
(2), 368 (8), 344 (3), 252 (6), 251 (6), 250 (38), 231 (2), 212 (2), 175 (2), 157 (2), 
156 (25), 138 (7), 137 (100), 135 (2), 125 (3).  
                                                             EXPERIMENTAL PART                                                    122  
 
Elemental Analysis:  
Anal. Calcd for C28H41NO3SSi (499.78) : C, 67.29; H, 8.27; N, 2.80 
Found      : C, 67.14; H, 8.13; N, 2.91. 
 
Optical rotation    : [α]D = –238.5 (c 1.02, MeOH).  
 
5.8.7 Synthesis of (-)-Triethyl-[(Z)-(αR,1R)-α-(4-methoxyphenyl)-2-{[(S)-N-
methyl-S-phenyl-sulfonimidoyl]-methene}-cyclooctane-methane-α-
enyloxy]silane (ent-54c)  
 
 
O
MeN
C6H4MeOp
Et3SiO
SPh
ent-54c  
 
 
Following GP3, reaction of sulfoximine ent-9c (2.77 g, 10 mmol) with 4-methoxy-
benzaldehyde (0.68 g, 5 mmol) afforded ether ent-54c (2.53, 96%) as a viscous 
liquid and sulfoximine ent-9c (1.05 g, 38%).    
 
1H NMR (400 MHz, CDCl3): δ 0.20 (m, 1 H, Cy), 0.52 (m, 7 H, Si(CH2CH3)3,Cy), 
0.85 (m, 10 H, Si(CH2CH3)3, Cy), 1.05 (m, 2 H, Cy), 1.20 (m, 2 H, Cy), 1.35 (m, 2 
H, Cy), 1.64 (m, 2 H, Cy), 1.90 (m, 1 H, Cy), 2.73 (s, 3 H, NCH3), 3.37 (m, 1 H, 
CH(Cy)), 3.79 (s,  3 H, OCH3),   5.02 (d, J =5.9 Hz, 1 H, SiOCH),  6.35 (s,  1 H, S-
CH=C), 6.79 (m, 2 H, Ph), 7.20 (m, 2 H, Ph), 7.56 (m, 3 H, Ph),  7.93 (m, 2 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 4.84 (Si(CH2CH3)3, u), 6.91 (Si(CH2CH3)3, d), 
19.42, 24.81, 24.87, 28.12, 33.08, 34.13 (Cy, u),  29.20 (NCH3, d),  48.85 (Cy-CH, 
d), 55.12 (OCH3, d), 76.45 (SiOCH, d), 112.84, 128.45, 128.63, 129.03, 129.26 (o-
, m-, p-C, d), 132.20 (CH=C, d), 134.87 (C=CH, u), 140.31, 158.75, 165.83 (i-C, 
u).  
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IR (capillary): ν 3671 (s), 3602 (s), 3003 (w), 2800 (m), 2732 (s), 2687 (s), 2546 
(s), 2475 (s), 2066 (s), 1894 (s), 1815 (s), 1772 (s), 1726 (s), 1416 (m), 1369 (m), 
1300 (w), 970 (w), 820 (w) cm−1.  
 
CI-MS m/z (relative intensity, %): 528 [M++1] (100), 527 [M+] (2),  498 (4), 397 (6), 
396 (22), 391 (4), 375 (4), 367 (10), 351 (7), 251 (14), 243 (8), 156 (42), 137 (16), 
133 ( 6).  
 
HRMS (EI, 70 ev):  
Calcd for C30H45NO3Si   : 527.288946 
Found      : 527.289127.  
 
Optical rotation    : [α]D = –119.5 (c 1.01, CH2Cl2).  
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5.8.8 Synthese von (Z,SS,2S,3R)-N,N-Dimethylamino-S-(2-(ethoxycarbonyl-
(2-methyl-propan-2-sulfonylamino)-methyl)-cyclooctylidenmethyl)-
phenylsulfoxonium-tetrafluoroborat (ent-53c) 
 
BF4
O
Me2N
R
Et3SiO
SPh
ent-53c  
 
 
1H NMR (400 MHz, CDCl3): δ  0.45 (m, 6 H, Si(CH2CH3)3), 0.65 (m, 1 H, Cy), 0.85-
0.95 (m, 9 H, Si(CH2CH3)3), 1.0−1.11 (m, 3 H, Cy), 1.30-1.75 (m, 4 H, Cy), 1.97−
2.02 (m, 2 H, Cy), 2.26-2.32 (m, 1 H, Cy), 2.60 (m, 1 H, Cy), 3.05 (s, 6 H, 
N(CH3)2), 3.64−3.69 (m, 1 H, CH(Cy)), 3.85 (s,  3 H, OCH3), 4.54 (d, J = 7.1 Hz, 1 
H, SiOCH),  6.95 (m 2 H, Ph), 7.10 (s,  1 H, S-CH=C), 7.25 (m, 2 H, Ph), 7.78 (m, 
3 H, Ph),  8.22 (m, 2 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 4.72 (Si(CH2CH3)3, u), 6.77 (Si(CH2CH3)3, d), 
24.09, 24.21, 24.58, 26.99, 33.48, 33.80 (Cy, u), 37.16 (N(CH3)2, d), 49.40 (Cy-
CH, d), 55.29 (OCH3, d), 77.84 (SiOCH, d), 113.58, 128.44, 128.92, 131.24 (o-, m-
, p-C, d), 116.58 (CH=C, d), 134.61 (C=CH, u), 136.46, 159.44, 184.36 (i-C, u).  
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5.9    Synthesis of Monocyclic/Bicyclic 2,3-Dihydrofurans 
 
5.9.1 Synthesis of (−)-(4R,5R)-Triethyl-(3-methyl-4,5-diphenyl-4,5-dihydro-
furan-2-yl)-silane (45c) 
 
O
Me
SiEt3
45c  
Following GP4, reaction of sulfoximine 50c (2.02 g, 4 mmol) with Me3OBF4 (765 
mg, 5.2 mmol) and LiN(H)tBu (4.4 mmol, 4.4 mL of 1 M in THF)  afforded 
dihydrofuran 45c (1.34 g, 96%) and sulfinamide 29b (600 mg, 89%).  
 
1H NMR (400 MHz, CDCl3): δ 0.85 (m, 6 H, Si(CH2CH3)3), 1.10 (m, 9 H, 
Si(CH2CH3)3), 1.53 (s, 3 H, CH3), 3.78 (dd,  J =6.9, J =1.1 Hz, 1 H, CHPh),   5.25 
(d, J =6.9 Hz, 1 H, COCH),  7.28 (m, 10 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 3.69 (Si(CH2CH3)3, u), 7.90 (Si(CH2CH3)3, d), 11.13 
(CH3, d),  65.37 (CHPh, d), 90.65 (COCH, d), 124.43, 143.63 (C=C, u),  125.31, 
126.96, 127.44, 128.12, 128.60, 128.96 (o-, m-, p-C, d),  144.29, 152.64 (i-C, u). 
 
IR (capillary): ν 3061 (s), 3027 (s), 2954 (vs), 2911 (vs), 2875 (vs), 1634 (m), 1601 
(m), 1493 (m), 1453 (s), 1415 (m), 1261 (m), 1237 (s), 1074 (vs), 1006 (s), 973 (s), 
928 (s) cm−1.  
 
CI-MS m/z (relative intensity, %): 351 [M++1] (100), 350 [M+] (13), 349 (6), 321 (2), 
274 (3), 273 (), 219 (2), 115 (2).  
 
Elemental Analysis:  
Anal. Calcd for C23H30OSi (350.57): C, 78.80; H, 8.63 
 Found                                            : C, 78.82; H, 8.65. 
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Optical rotation: [α]D = −210.0 (c 1.25, CH2Cl2).  
 
5.9.2 Synthesis of (−)-(4R,5R)-Triethyl-(4-isopropyl-3-methyl-5-phenyl-4,5-
dihydro-furan-2-yl)-silane (45a) 
 
O
Me
SiEt3
45a  
 
Following GP4, reaction of sulfoximine 50a (940 mg, 2 mmol) with Me3OBF4 (382 
mg, 2.6 mmol) and LiN(H)tBu (2.2 mmol, 2.2 mL of 1 M in THF)  afforded 
dihydrofuran 45a (600 mg, 95%) and sulfinamide 29c (290 mg, 86%). 
 
1H NMR (400 MHz, CDCl3): δ 0.75 (m, 6 H, Si(CH2CH3)3), 0.85 (d, J = 6.9 Hz, 3 H, 
CH3), 1.00 (m,  12 H, Si(CH2CH3)3, CH3), 1.65 (d, J = 1.0 Hz, 3 H, CH3), 1.94 (m, 1 
H, CH(CH3)3),  2.62 (m,  1 H, CHiPr), 5.09 (d, J = 4.7 Hz, 1 H, SiOCH), 7.32 (m, 5 
H, Ph). 
 
13C NMR (100 MHz, CDCl3): δ 3.28 (Si(CH2CH3)3, u), 7.41 (Si(CH2CH3)3, d), 10.91 
(CH3, d), 16.57 (CH3, d), 20.68 (CH3, d), 28.02 (CH(CH3)3, d), 64.08 (CHiPr, d), 
82.03 (COCH, d), 125.08, 126.81, 128.25 (o-, m-, p-C, d), 122.42, 145.76 (C=C, 
u),  151.33 (i-C, u).  
 
IR (capillary): ν 3062 (s), 3028 (s), 2957 (vs), 2955 (vs), 2876 (vs), 1635 (m), 1458 
(m), 1415 (m), 1384 (m), 1238 (s), 1083 (s), 1007 (s), 962 (s) cm−1.   
 
CI-MS m/z (relative intensity, %): 317 [M++1] (100), 316 [M+](14), 315 (4), 287 (3), 
273 (3), 239 (3), 186 (2), 185 (7), 145 (2), 115 (2).  
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Elemental Analysis:  
Anal. Calcd for C20H32OSi (316.55): C, 75.88; H, 10.19 
Found                                             : C, 75.79; H, 10.28. 
 
Optical rotation: [α]D = −61.9 (c 1.43, MeOH). 
 
5.9.3 Synthesis of (−)-(4R,5R)-Triethyl-(4-isopropyl-3-methyl-5-(4-methoxy-
phenyl)-4,5-dihydro-furan-2-yl)-silane (45b) 
 
O
MeO
SiEt3
45b  
Following GP4, reaction of sulfoximine 50b (1.00 g, 2 mmol) with Me3OBF4 (382 
mg, 2.6 mmol) and LiN(H)tBu (2.2 mmol, 2.2 mL of 1 M in THF)  afforded 
dihydrofuran 45b (620 mg, 90%) and sulfinamide 29c (280 mg , 85%). 
 
1H NMR (400 MHz, CDCl3): δ 0.75 (m, 6 H, Si(CH2CH3)3), 0.90 (d, J =6.9 Hz, 3 H, 
CH3), 1.02 (m, 12 H, Si(CH2CH3)3, CH3),  1.65 (d, J =1.1 Hz, 3 H, CH3), 1.97 (m, 1 
H, CH(CH3)2), 2.62 (m,   1 H,  CHiPr),  3.77 (s, 3 H, OCH3), 5.04 (d, J =4.7 Hz, 1 
H, COCH),  6.87 (m, 2 H, Ph),  7.20 (m, 2 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 3.26 (Si(CH2CH3)3, u), 7.41 (Si(CH2CH3)3, d), 10.91 
(CH3, d),  16.53 (d, CH3), 20.58 (d, CH3), 27.93 (d, CH(CH3)2, 55.11 (OCH3, d), 
63.86 (CHiPr, d), 81.68 (COCH, d), 113.46, 126.15 (o-, m-C, d),   122.28, 137.77 
(C=C, u),  150.98, 158.33 (i-C, u). 
 
 IR (capillary): ν  2954 (vs), 2875 (vs), 2835 (s), 1612 (m), 1512 (m), 1461 (m), 
1416 (s), 1383 (m), 1300 (m), 1247 (vs), 1174 (s), 1083 (s), 1037 (s), 1009 (s), 
961 (s), 819 (s) cm−1.   
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CI-MS m/z (relative intensity, %):  347 [M++1] (100), 346 [M+](26), 345 (6), 317 (3), 
304 (2), 303 (6), 240 (2), 239 (10), 217 (2), 215 (3), 176 (2), 115 (3).  
 
Elemental Analysis: 
Anal. Calcd for C21H34O2Si (346.58): C, 72.78; H, 9.89 
Found                                               :C, 72.75; H, 9.75. 
Optical rotation: [α]D = –84.5 (c 1.01, MeOH).  
 
5.9.4  Synthesis of (−)-(4R,5R)-Triethyl-(3-(4-methoxy-phenyl)-
3,3a,4,5,6,7,8,9-heptahydro-isobenzofuran-1-yl)-silane (ent-51c) 
 
                                      
O
SiEt3
H3CO
ent-51c  
Following GP4, reaction of sulfoximine ent-54c (2.10 g, 4 mmol) with Me3OBF4 
(765 mg, 5.2 mmol) and LiN(H)tBu (4.4 mmol, 4.4 mL of 1 M in THF)  afforded 
dihydrofuran ent-51c (1.34 g, 90%) and sulfinamide 29c (590 mg, 88%).  
 
1H NMR (400 MHz, CDCl3): δ 0.75 (m, 6 H, Si(CH2CH3)3), 1.00 (m, 9 H, 
Si(CH2CH3)3), 1.5−1.79 (m, 9 H, Cy),  1.8-1.85 (m, -1 H, Cy), 2.0−2.06 (m, 1 H, 
Cy), 2.48-2.52 (m, 1 H, Cy), 2.81−2.85 (m, 1 H, Cy), 3.78 (s,  3 H, OCH3),  4.83 (d, 
J =9.3 Hz, 1 H, COCH),  6.87 (m, 2 H, Ph), 7.27 (m, 2 H, Ph). 
 
 13C NMR (100 MHz, CDCl3): δ 3.19 (Si(CH2CH3)3, u), 7.50 (Si(CH2CH3)3, d), 
24.60, 24.66, 25.94, 26.84, 28.97, 29.58 (Cy, u), 55.14 (OCH3, d), 56.41 ((CH)Cy, 
d), 87.88 (COCH, d), 113.52, 126.78  (o-, m-C, d), 129.85, 135.95 (C=C, u), 
152.11, 158.69 (i-C, u). 
 
IR (capillary): ν 2729 (s), 2692 (s), 2545 (s), 2278 (s), 2067 (s), 1878 (s), 1762 (s), 
1680 (s),  1614 (w), 1585 (m), 1416 (m),  1374 (s), 1301 (m), 1174 (w), 1072 (w), 
1017 (w), 959 (m), 828 (w) cm−1. 
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CI-MS m/z (relative intensity, %)  373 [M++1]   (100), 372 [M+] (26), 371 (8), 265 
(7), 241 (22), 253 (2), 251 (5), 245 (2), 230 (2), 229 (8), 133 (2), 221 (2), 75 (3).  
 
 
 
Elemental Analysis:  
Anal. Calcd for C23H36O2Si (372.62): C, 74.14; H, 9.74 
Found                                              : C, 74.22; H, 9.33 
 
HRMS (EI, 70 ev):  
Calcd for C23H36SiO2: 372.248474 
Found                       : 372.248459 
 
Optical rotation: [α]D = −60.5 (c 4.5, CH2Cl2).  
 
5.10    Synthesis of Bicyclic Tetrahydrofurans 
  
5.10.1   Synthesis of (−)-(3R,3aR)-(3-(4-methoxy-phenyl)-1,3,3a,4,5,6-
hexahydro-isobenzofuran(56a) 
 
O
H3CO
56a  
 Following GP5, reaction of sulfoximine 54a (2.00 g, 4 mmol) with Me3OBF4 (765 
mg, 5.2 mmol) and DBU (6 mmol, 912 mg) afforded tetrahydrofuran 16a (640 mg, 
69%) and sulfinamide 29c (560 mg, 84%). 
 
1H NMR (400 MHz, CDCl3): δ 1.10-1.25 (m, 1 H, Cy), 1.40-1.50 (m,  1 H, Cy), 
1.85−1.90 (m, 2 H, Cy), 2.05−2.10 (m, 2 H, Cy), 2.32 (m, 1 H, Cy), 3.85 (s,  3 H, 
OCH3),   4.20 (d, J = 9.9 Hz, 1 H, OCH),  4.33 (m, 1 H, OCH2), 4.66 (m, 1 H, 
OCH2), 5.56 (m, 1 H, CH=C), 6.87 (m, 2 H, Ph), 7.30 (m, 2 H, Ph). 
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13C NMR (100 MHz, CDCl3): δ 21.59, 24.32, 24.65, (Cy, u), 48.00 ((CH)Cy, d), 
55.27 (OCH3, d), 69.99 (OCH2, u), 86.68 (OCH, d), 113.76, 127.44  (o-, m-C, d), 
117.29 (CH=C, d), 133.18 (C=C, u), 140.96, 159.24 (i-C, u) 
 
IR (capillary): ν 2998 (m), 2489 (s), 2287 (s), 2023 (s), 1884 (s), 1764 (s), 1612 
(w), 1586 (m),  1460 (w), 1369 (s), 1303 (m),  1175 (w), 1135 (s), 1096 (m), 954 
(m), 625 (m), 863 (s), 830 (w) cm−1. 
EI-MS m/z (relative intensity, %): 231 [M++1] (4), 230 [M+]  (35), 138 (9), 137 
(100), 135 (17), 94 (40), 91 (8), 79 (68), 77 (18).  
 
HRMS (EI, 70 ev): 
Calcd for C15H18O2: 230.130623 
Found                     : 230.130680 
 
Optical rotation: [α]25D = −21.6 (c 0.20, CH2Cl2). 
 
5.10.2   (−)-(3R,3aR)-3-(4-methoxy-phenyl)-3,3a,4,5,6,7-hexahydro-1H-
cyclohepta[c]furan (56b). 
 
O
H3CO
56b  
 
Following GP5, reaction of sulfoximine 54b (2.05 g, 4 mmol) with Me3OBF4 (765 
mg, 5.2 mmol) and DBU (6 mmol, 912 mg) afforded tetrahydrofuran 16b (702 mg, 
72%) and sulfinamide 29c (676 mg, 87%). 
 
1H NMR (400 MHz, CDCl3): δ 1.20−1.45 (m, 3 H, Cy), 1.65−2.05 (m,  2 H, Cy), 
2.22−2.28 (m, 3 H, Cy), 2.48−2.53 (m, 1 H, Cy), 3.81 (s,  3 H, OCH3),   4.30 (d, J = 
9.2 Hz, 1 H, OCH),  4.33 (m, 1 H, OCH2), 4.58 (m, 1 H, OCH2) 5.67 (m, 1 H, 
CH=C), 6.85 (m, 2 H, Ph), 7.33 (m, 2 H, Ph).  
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13C NMR (100 MHz, CDCl3): δ 27.60, 28.88, 29.04, 29.95 (Cy, u), 52.78 ((CH)Cy, 
d), 55.26 (OCH3, d), 71.93 (OCH2, u), 88.17 (OCH, d), 113.74, 128.03  (o-, m-C, 
d), 119.74 (CH=C, d), 132.94 (C=C, u), 145.83, 159.36 (i-C, u). 
  
IR (capillary): ν 3008 (m), 2838 (w), 2605 (s), 2543 (s), 2373 (s), 2345 (s), 2049 
(s), 1849 (s),  1737 (s), 1615 (w), 1586 (m),  1460 (w), 1383 (w), 1305 (w), 1179 
(w), 1109 (m), 1080 (m), 969 (m), 927 (m), 889 (s), 869 (s), 837 (w) cm−1. 
 
EI-MS m/z (relative intensity, %):  245 [M++1] (7), 244 [M+]  (45), 138 (7), 137 
(100), 136 (9), 135 (18), 109 (8), 108 (29), 93 (47), 91 (12), 80 (11), 79 (28), 77 
(15).  
 
Elemental Analysis:  
Anal. Calcd for C16H20O2 (244.146): C, 78.65; H, 8.25 
Found                                              : C, 78.67; H, 7.74.  
 
HRMS (EI, 70 ev):  
Calcd for C16H20O2: 244.146457 
Found: 244.146330 
 
Optical rotation: [α]D = −34 (c 0.20, CH2Cl2). 
 
Mp: 84−86 °C.  
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5.10.3    Synthesis of (−)-(3R,3aR)-3-(4-methoxy-phenyl)-1,3,3a,4,5,6,7,8- 
octahydro-1H-cycloocta[c]furan (ent-56c). 
 
O
H3CO
ent-56c  
Following GP5, reaction of sulfoximine 54c (2.10 g, 4 mmol) with Me3OBF4 (765 
mg, 5.2 mmol) and DBU (6 mmol, 912 mg) afforded tetrahydrofuran ent-56c (760 
mg, 74%) and sulfinamide 29b (590 mg, 88%). 
 
1H NMR (400 MHz, CDCl3): δ 0.75−1.00 (m, 1 H, Cy), 1.30−1.9 (m,  7 H, Cy), 2.12 
(m, 2 H, Cy), 2.73 (m, 1 H, Cy), 3.80 (s,  3 H, OCH3), 4.44 (m, 2 H, OCH2),   4.54 
(d, J = 4.7 Hz, 1 H, OCH), 5.49 (m, 1 H, CH=C), 6.86 (m, 2 H, Ph), 7.24 (m, 2 H, 
Ph).  
 
13C NMR (100 MHz, CDCl3): δ 25.08, 25.68, 26.22, 28.07, 35.48 (Cy, u), 49.98 
((CH)Cy, d), 55.27 (OCH3, d), 71.61 (OCH2, u), 88.34 (OCH, d), 113.76, 127.34  
(o-, m-C, d), 118.23 (CH=C, d), 134.96 (C=C, u), 143.56, 159.04 (i-C, u).  
 
IR (capillary): ν  3002 (m), 2686 (s), 2547 (s), 2060 (s), 1885 (s), 1722 (s), 1670 
(s), 1611 (w), 1459 (w), 1371 (s), 1301 (m), 1176 (w), 898 (s), 832 (w) cm−1. 
 
EI-MS m/z (relative intensity, %): 259 [M++1] (10), 258 [M+]  (62), 137 (100), 136 
(18), 135 (29), 122 (30), 121 (12), 107 (30), 94 (27), 93 (43), 91 (12), 81 (13), 77 
(16), 68 (10), 67 (12).  
 
 
Elemental Analysis:  
Anal. Calcd for C17H22O2 (258.36): C, 79.03; H, 8.60 
Found                                            : C, 78.68; H, 9.14.  
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Optical rotation: [α]D = –104.8 (c 0.25, CH2Cl2).  
 
Mp: 55-57 °C. 
 
 
5.11    Synthesis of Amino acid derivatives 
 
5.11.1   Synthesis of (+)-(E,Ss,2R,3S)-and (−)-(E,Ss,2S,3R)-(2-(N-methyl-S-  
phenyl-sulfonimidoyl-methylene)-cycloheptyl)-(2-methylpropane-2-  
sulfonylamino)-Acetic Acid Ethyl Ester (E-82c and E-83c) 
 
          
S
O
HN
O
O
NMe
S O
O
E-82c
1
2
4
10
                   
S
O
HN
O
O
NMe
S O
O
E-83c  
 
Following GP6, reaction of sulfoximine 9c (1.50 g, 5.7 mmol) with imino ester 81 
(1.52 g, 6.8 mmol) gave a crude mixture of the alkenyl sulfoximines E-82c and E-
83c in ratio of 23-24:1 in approximately 98% chemical yield (1H NMR). 
Recrystallization from CH2Cl2 afforded E-82c (1.98 g, 72%) as colorless crystals. 
The mother liquor was concentrated in vacuo and the residue was purified by 
preparative HPLC (ethyl acetate/n-hexane, 4:1) to afford an additional 10% of E-
82c (276 mg) and E-83c (110 mg, 4%).  
                      
E-82c: 
 
1H NMR (400 MHz, CDCl3): δ 0.66-0.70 (m, 1 H, Cy), 0.93-1.01 (m, 1 H, Cy), 1.23-
1.25 (m, 1 H, Cy), 1.30 (t, J = 7.1 Hz, 3 H, 12-H), 1.36 (s, 9 H, 18-H), 1.50-1.75 (m, 
3 H, Cy), 1.96-2.00 (m, 3 H, Cy), 2.60-2.61 (m, 1 H, 3-H), 2.65 (s, 3 H, NCH3), 
3.34-3.38 (m, 1 H, Cy), 4.04-4.07 (m, 1 H, 2-H), 4.20-4.28 (m, 2 H, 11-H), 4.99 (d, 
J = 10.7 Hz, 1 H, NH ), 6.32 (s, 1 H, 10-H), 7.53-7.61 (m, 3 H, Ph),  7.90 (m, 2 H, 
Ph).  
                                                             EXPERIMENTAL PART                                                    134  
 
13C NMR (100 MHz, CDCl3): δ 14.01 (C-12,  d), 24.19 (C-18, d), 25.48 (Cy, u),  
27.71 (Cy, u), 28.01 (Cy, u),  28.59 (Cy, u), 29.91 (Cy, u), 29.12 (NMe, d), 52.40 
(C-3, d), 60.28 (C-17, u), 61.93 (C-2, d), 62.02 (C-11, u), 128.83 (C-14, d), 129.07 
(C-15, d), 129.88 (C-10, d), 132.33 (C-16, d), 140.23 (C-13, u), 158.82 (C-9, u), 
170.55 (C-1, u).  
 
 
IR (KBr): ν  3442 (m), 3095 (s), 3061 (m), 2986 (w), 2861 (w), 2806 (s), 2682 (s), 
2074 (s), 1780 (s), 1606 (m), 1396 (s), 1370 (m), 1078 (w), 1019 (m), 980 (s), 857 
(w) cm−1.  
 
EI-MS m/z (relative intensity, %):  485 [M++1] (1), 484 [M+] (2), 284 (28), 214 (30), 
208 (36), 184 (16), 181 (9), 134 (13), 124 (18), 101 (11), 57 (22). 
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1H{1H}-NOE-Experiment (500 MHz, CDCl3) of  E-82c: 
 
[%] H-2 H-5ax H-5eq H-6ax H-7eq H-7eq H-8eq H-8ax H-10 H-14 NH NCH3
H-2  - 5.7 2.4 2.3
H-3 3.8 4.8 2.0 9.4 2.8
H-4ax 2.8 5.0 14.6 2.1
H-4eq 1.9 3.7 3.7 0.7
H-5ax 41.1  - 31.6 3.4 2.4
H-6eq 5.2 37.8  - 4.2
H-7ax 38.3 39.8 3.6 2.4
H-8eq 4.9  - 4.0 4.3 0.5
H-9ax 1.3 4.6  - 30.5 0.8
H-9eq 5.0 45.3  -
H-10 2.5 0.5 12.7  - 0.9 1.6 0.9
H-14 2.2 3.1  - 1.1
H-16
NH 1.1 2.3 2.5 0.8  -
NCH3 0.8  -
H-17
O
bs
er
ve
d 
Fr
eq
ue
nc
y
Emitted Frequency
 
 
 
Elemental Analysis:  
Anal. Calcd for C23H36N2O5S2 (484.67): C, 57.00; H, 7.49; N, 5.78 
Found                                                    : C, 56.63; H, 7.57; N, 5.51. 
 
Optical rotation: [α]D = +58.4 (c 0.50, CH2Cl2).  
 
M.p: 111-113 °C 
The analytical data of E-83c were in agreement with those previously reported.23                     
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5.11.2   Synthesis of (+)-(E,Ss,2R,3S)- and (−)-(E,Ss,2S,3R)-(2-(N-methyl-S-
phenyl-sulfonimidoyl-methylene)-cyclooctyl)-(2-methylpropane-2- 
sulfonylamino)-Acetic Acid Ethyl Ester (E-82d and E-83d) 
     
             
S
O
HN
O
O
NMe
S O
O
E-82d
1
2
4
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S
O
HN
O
O
NMe
S O
O
E-83d  
 
Following GP6, reaction of sulfoximine 9d (1.50 g, 5.4 mmol) with imino ester 81 
(1.44 g, 6.5 mmol) gave a crude mixture of the alkenyl sulfoximines E-82d and E-
83d in ratio of 48-48.5:1 in approximately 98% chemical yield (1H NMR). 
Recrystallization from CH2Cl2 afforded E-82d (2.20 g, 82%) as colorless solid. The 
mother liquor was concentrated in vacuo, and the residue was purified by 
preparative HPLC (ethyl acetate/n-hexane, 4:1) to afford an additional 5% of E-
82d (135 mg) and E-83d (53 mg, 2%).                                
                                                                                                                          
E-82d: 
 
1H NMR (400 MHz, CDCl3): δ 0.90-0.94 (m, 1 H, Cy), 1.07-1.11 (m, 1 H, Cy), 1.24 
(t, J = 7.1 Hz, 3 H, 13-H), 1.36 (s, 9 H, 19-H), 1.45-2.00 (m, 8 H, Cy), 2.46-2.58 (m, 
3 H, Cy), 2.63 (s, 3 H, NCH3), 3.98-4.01 (m, 1 H, 2-H), 4.02-4.14 (m, 2 H, 12-H), 
4.96 (d, J = 10.7 Hz, 1 H, NH ), 6.33 (s, 1 H, 11-H), 7.60 (m, 3 H, Ph),  7.90 (m, 2 
H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 13.96 (C-13,  d), 24.16 (C-19, d), 25.12 (Cy, d),  
25.80 (Cy, u), 26.17 (Cy, u),  26.86 (Cy, u), 28.51 (Cy, u), 29.03 (Cy, u), 29.64  
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(NMe, d), 51.42 (C-3, d), 60.20 (C-18, u), 61.76 (C-2, u), 61.93 (C-12, u), 128.53 
(C-11, d), 128.64 (C-15, d), 128.95 (C-16, d), 132.22 (C-17, d), 140.05 (C-14, u), 
160.41 (C-10, u), 170.68 (C-1, u).  
 
 
 
 
1H{1H}-NOE-Experiment (500 MHz, C5D5NCl3) of  E-82d: 
 
[%] H-2 H-3 H-4ax H-7ax H-7eq H-8eq H-9ax H-9eq H-11 H-15 NH NCH3
H-2  - 6.2 3.3 5.7 2.4 1.8
H-3 2.4  - 9.1 3.7 2.6
H-4ax 3.0  - 7.8 14.6 1.7
H-4eq 2.9 3.7 50.9 0.6
H-7ax 8.6  - 31.6 5.7 2.4
H-7eq 45.9  - 2.9
H-8ax 42.8 3.6 2.4
H-8eq 7.0 2.7  - 4.0 4.3
H-9ax 1.3 14.9 2.5 4.6  - 30.5 0.8
H-9eq 5.0 39  - 4.2
H-11 2.9 0.5 12.7  - 1.6 0.9
H-15 2.2 1.4  - 1.1
H-16 9.4
NH 1.4 2.3 5.0 2.5  -
NCH3 0.6  -
H-17 1.1
O
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, 
 
IR (KBr): ν 3441 (m), 3276 (m), 3058 (m), 2802 (m), 2690 (s), 2345 (s), 1785 (s), 
1610 (m), 1372 (m), 1181 (m), 1022 (m), 955 (m), 917 (m), 805 (s) cm−1.  
 
EI-MS m/z (relative intensity, %): 498 [M+] (1), 425 (9), 362 (20), 299 (21), 298 
(100), 277 (12), 276 (30), 250 (15), 229 (18), 200 (23), 170 (40), 169 (65), 155 
(24), 149 (18), 140 (10), 124 (41), 120 (11), 91 (13).  
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Elemental Analysis:  
Anal. Calcd for C24H38N2O5S2 (498.70): C, 57.80; H, 7.68; N, 5.62  
Found                                                    : C, 57.46; H, 8.08; N, 5.23. 
 
Optical rotation: [α]D = +76.1 (c 1.20, CH2Cl2).  
 
M.p: 78-80 °C 
 
The analytical data of E-82d were in agreement with those previously reported.23                     
                                    
5.11.3   Synthesis of (+)-(E,Ss,2R,3S)-and(−)-(E,Ss,2S,3R)-(2-(N-methyl-S- 
phenyl-sulfonimidoyl-methylene)-cyclohexyl)-(2-methylpropane-2- 
sulfonylamino)-Acetic Acid Ethyl Ester (E-82b and E-83b).  
 
S
O
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O
O
NMe
S O
O
1
2
3
7
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1014
           16
E-82b                   
S
O
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           16
E-83b  
 
Following GP6, reaction of sulfoximine 9b (1.05 g, 4.2 mmol) with imino ester 81 
(1.12 g, 5.1 mmol) gave a crude mixture of the alkenyl sulfoximines E-82b and E-
83b in ratio of 9.7-10:1 in approximately 95% chemical yield (1H NMR). 
Recrystallization from ether afforded E-82b (1.17 g, 59%) as colorless solid. The 
mother liquor was concentrated in vacuo, and the residue was purified by 
preparative HPLC (ethyl acetate/n-hexane, 4:1) to afford an additional 10% of E-
82b (198 mg) and E-83b (158 mg, 8%). 
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E-82b:  
1H NMR (400 MHz, CDCl3): δ 0.67-0.71 (m, 1 H, Cy), 1.30 (t, J = 7.1 Hz, 3 H, 11-
H), 1.35 (s, 9 H, 17-H), 1.40-1.50 (m, 2 H, Cy), 1.55-1.65 (m, 2 H, Cy), 2.12-2.32 
(m, 3 H, Cy), 2.61 (s, 3 H, NCH3), 3.14 (m, 1 H, Cy), 4.08-4.12 (m, 2 H, 10-H), 
4.16-4.28 (m, 1 H),  4.77 (d, J = 7.4 Hz, 1 H, N-H ), 6.28 (s, 1 H, 9-H), 7.50-7.58 
(m, 3 H, Ph),  7.88 (m, 2 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 14.15 (C-11, d), 20.38 (Cy,  u), 24.35 (C-17, d), 
26.32 (Cy, u),  26.45 (Cy, u), 28.74 (Cy, u),  29.31 (NMe, d), 50.04 (C-3, d),57.26 
(C-2, d), 60.28 (C-16, u), 62.14 (C-10, u), 127.57 (C-9, d), 128.85 (C-13, d), 
129.13 (C-14, d), 132.33 (C-15, d), 140.81 (C-12, u), 157.42 (C-8, u), 171.75 (C-1, 
u).  
 
 
1H{1H}-NOE-Experiment (500 MHz, CDCl3) of  E-82b: 
 
[%] H-2 H-3 H-6 H-6' H-9 12
H-2  - 1.7 1.1
H-3 1.5  - 9.6
H-4 4.2
H-5
H-6'
H-7 4.5 0.6  - 1.1
H-12 1.6
NMe 0.9 1.8 0.5 0.7
O
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IR (KBr): ν 3438 (w), 3057 (w), 2993 (m), 2938 (w), 2860 (m), 2797 (m), 2759 (s), 
2727 (s), 1796 (s), 1560 (s), 1525 (s), 1152 (w), 1017 (w), 928 (w), 834 (m), 805 
(s) cm−1.  
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EI-MS m/z (relative intensity, %): 471 [M+ +1] (7), 470 [M+] (27), 271 (11), 270 
(60), 249 (16), 217 (9), 200 (26), 195 (15), 194 (100), 167 (17), 166 (44), 155 (41), 
124 (49), 122 (18), 121 (13), 120 (21), 102 (22), 93 (11), 77 (11), 57 (44) .  
 
 
Elemental Analysis:  
Anal. Calcd for C22H34N2O5S2 (470.65): C, 56.14; H, 7.28; N, 5.95 
Found                                                    : C, 55.65; H, 7.62; N, 5.78. 
 
Optical rotation: [α]D = +28.4 (c 0.25, CH2Cl2). 
 
M.p: 148-150 °C 
 
 
The analytical data of E-83b were in agreement with those previously reported.23                     
  
 
 
5.11.4   Synthesis of (+)-(E,Ss,2R,3S)-and(−)-(E,Ss,2S,3R)- (2-(N-methyl-S-
phenyl-sulfonimidoyl-methylene)-cyclopentyl)-(2-methylpropane-2-
sulfonylamino)-Acetic Acid Ethyl Ester (E-82a and E-83a).  
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Following GP6, reaction of sulfoximine 9a (1.02 g, 4.3 mmol) with imino ester 81 
(1.14 g, 5.2 mmol) gave a crude mixture of the alkenyl sulfoximines E-82a and E-
83a in ratio of 5.7-6:1 in approximately 95% chemical yield (1H NMR). 
Recrystallization from ether afforded E-82a (1.15 g, 58%)  as colorless solid. The 
mother liquor was concentrated in vacuo, and the residue was purified by 
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preparative HPLC (ethyl acetate/n-hexane, 4:1) to afford an additional 12% of E-
82a (237 mg) and E-83a (276 mg, 14%). 
                 
E-82a: 
 
1H NMR (400 MHz, CDCl3): δ 1.28 (t, J = 7.1 Hz, 3 H, 10-H), 1.36 (s, 9 H, 16-H), 
1.60-1.95 (m, 5 H, Cy), 2.62 (m, 1 H, Cy), 2.69 (s, 3 H, NCH3), 2.99 (m, 1 H, 3-H), 
4.12-4.34 (m, 3 H, 9-H, 2-H), 4.88 (d, J = 7.4 Hz, 1 H, N-H ), 6.36 (s, 1 H, 8-H), 
7.50-7.58 (m, 3 H, Ph),  7.92 (m, 2 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 14.0 (C-10, d), 24.10 (Cy,  u), 24.20 (C-16, d), 
27.40 (Cy, u),  30.30 (Cy, u), 29.20 (NMe, d), 50.60 (C-3, d),58.50 (C-2, d), 60.40 
(C-15, u), 62.00 (C-9, u), 127.57 (C-8, d), 128.70 (C-12, d), 129.60 (C-13, d), 
132.40 (C-14, d), 140.00 (C-11, u), 160.50 (C-7, u), 171.30 (C-1, u).  
 
 
 
1H{1H}-NOE-Experiment (500 MHz, CDCl3) of  E-82a: 
 
[%] H-2 H-3 H-6 H-6' H-8 NH
H-2  - 3.5 2.8 1.9
H-3 3.2  - 3.1 4.1
H-4 0.7 2.2 3.1
H-5 1.1 2.5 2.9
H-6' 16.5  -
H-8 2.8 3.8  - 1.7
H-12 2.5 0.7 0.9 1.7 4.0
NH 0.9 2.9 0.8  -
O
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d 
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IR (KBr): ν 3438 (w), 3057 (w), 2993 (m), 2938 (w), 2860 (m), 2797 (m), 2759 (s), 
2727 (s), 1796 (s), 1560 (s), 1525 (s), 1152 (w), 1017 (w), 928 (w), 834 (m), 805 
(s) cm−1.  
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EI-MS m/z (relative intensity, %) 456 [M+] (13), 455 (9), 234 (12), 182 (25), 165 
(17), 156 (16), 155 (41), 124 (49), 122 (18), 121 (13), 120 (21), 102 (22), 93 (11), 
77 (11), 57 (44).  
 
 
 
Elemental Analysis:  
Anal. Calcd for C21H32N2O5S2: C, 55.24; H, 7.06; N, 6.13 
Found                                      : C, 55.07; H, 7.32; N, 5.89. 
 
Optical rotation: [α]D = +14.2 (c 2.9, CH2Cl2).  
M.p: 148-150 °C 
 
 
The analytical data of E-82a were in agreement with those previously reported.23                     
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5.11.5   Synthesis of(−)-(E,Ss,2R,3S)-and(−)-(E,Ss,2S,3R)-5-(N-methyl-S- 
phenyl-sulfonimidoyl)-3-cyclohexyl-2-(2-methylpropane-2-
sulfonylamino)-pent- 4-enoic Acid Ethyl Ester (E-86b and E-87b ).  
 
S
Ph
O NMe
EtO2C
NH
O2S
E-86b                                   
S
Ph
O NMe
EtO2C
NH
O2S
E-87b  
       
Following GP6, reaction of sulfoximine 84b (1.50 g, 5.4 mmol) with imino ester 81 
(1.44 gm, 6.5 mmol) gave a crude mixture of the alkenyl sulfoximines E-86b and 
E-87b in ratio of 5.8-6:1 in approximately 95% chemical yield (1H NMR). 
Purification of this mixture by preparative HPLC (ethyl acetate/n-hexane, 4:1) gave 
E-86b (1.496 g, 56%) as colorless oil, and E-87b (269 mg, 10%) as colorless 
solid. 
                               
 
E-86b: 
 
1H NMR (400 MHz, CDCl3): δ 0.65-1.24 (m, 5 H, Cy), 1.28 (t, J = 7.1 Hz, 3 H, 
OCH2CH3), 1.34 (s, 9 H, C(CH3)3), 1.40-1.70 (m, 6 H, Cy), 2.32 (dt, J = 6.6, J = 
10.9 Hz, 1 H, 3-H), 2.74 (s, 3 H, NCH3), 4.12-4.24 (m, 2 H, OCH2CH3), 4.29 (dd, J 
= 6.8, J = 10.2 Hz, 1 H, 3-H), 4.88 (d, J = 10.1 Hz, 1 H, N-H ), 6.39 (d, J = 14.8 Hz, 
1 H, 5-H), 7.50-7.60 (m, 3 H, Ph),  7.88 (m, 2 H, Ph). 
 
13C NMR (100 MHz, CDCl3): δ 14.1 (OCH2CH3, d), 24.1 (C(CH3)3), d), 25.7 (Cy, u), 
25.9 (Cy, u), 29.3 (NMe, d), 29.4 (Cy, u), 31.2 (Cy, u),  37.6 (Cy, d), 52.8 (C-3, d), 
56.9 (C-2, d), 60.0 (C(CH3)3, u), 61.8 (OCH2CH3, u), 128.4 (o-ph, d), 129.1 (m-ph, 
d), 132.4 (p-ph, d), 133.9 (C-5, d), 139.2 (i-ph, u), 142.6 (C-4, d), 170.5 (C-1, u).  
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IR (KBr): ν 3246 (m), 3055 (m), 2929 (w), 2854 (w), 2800 (s), 2755 (s), 2659 (s), 
1740 (w), 1630 (s), 1581 (s), 1544 (s), 1450 (w), 1395 (s), 1370 (s), 1246 (w), 
1197 (s), 1145 (w), 1083 (w), 983 (s) cm−1.  
 
EI-MS m/z (relative intensity, %) 498 [M+] (7), 278 (8), 277 (30), 276 (100), 231 
(10), 222 (18), 156 (28), 152 (11), 151 (27), 150 (55), 125 (72).  
 
HRMS (EI, 70 ev):  
Calcd for C24H38N2O5S2: 498.222252 
Found                            : 498.222218 
 
Optical rotation: [α]D = −3.4 (c 2.01, CDCl3).  
 
 
The analytical data of E-87b were in agreement with those previously reported.70                     
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5.11.6   Synthesis of (−)-(E,Ss,2R,3S)-and(−)-(E,Ss,2S,3R)-5-(N-methyl-S-
phenyl-sulfonimidoyl)-3-isopropyl-2-(2-methylpropane-2-
sulfonylamino)-pent-4-enoic Acid Ethyl Ester (E-86a and E-87a) 
 
S
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EtO2C
NH
O2S
E-86a                                            
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Following GP6, reaction of sulfoximine 84a (1.02 g, 4.3 mmol ) with imino ester 81 
(1.14 gm, 5.2 mmol) gave a crude mixture of the alkenyl sulfoximines E-86a and 
E-87a in ratio of 1.8-1.9 : 1 in approximately 95% chemical yield (1H NMR). 
Purification of this mixture by preparative HPLC (ethyl acetate/n-hexane, 4:1) gave 
E-86a (1.142 g, 58%) as colorless oil, and E-87a (630 mg, 32%) as colorless solid. 
 
  
 
E-86a: 
 
1H NMR (400 MHz, CDCl3): δ 0.78 (d, J = 6.9 Hz, 3 H, CH(CH3)2), 0.90 (d, J = 6.7 
Hz, 3 H, CH(CH3)2), 1.28 (t, J = 7.2 Hz, 3 H, OCH2CH3), 1.34 (s, 9 H, C(CH3)3), 
1.40-1.70 (m, 6 H, Cy), 2.32 (dt, J = 6.6, J = 10.9 Hz, 1 H, 3-H), 2.74 (s, 3 H, 
NCH3), 4.12-4.24 (m, 2 H, OCH2CH3), 4.29 (dd, J = 6.8, J = 10.2 Hz, 1 H, 3-H), 
4.88 (d, J = 10.1 Hz, 1 H, N-H ), 6.39 (d, J = 14.8 Hz, 1 H, 5-H), 7.50-7.60 (m, 3 H, 
Ph),  7.88 (m, 2 H, Ph).  
 
13C NMR (100 MHz, CDCl3): δ 14.1 (OCH2CH3, d), 19.0 (CH(CH3)2, d), 20.9 
(CH(CH3)2, d), 24.1 (C(CH3)3, u), 28.2 (CH(CH3)2, d), 29.4 (NMe, d), 54.1 (C-3, d), 
57.8 (C-2, d), 60.2 (C(CH3)3, u), 62.0 (OCH2CH3, u), 128.6 (o-ph, d), 129.9 (m-ph, 
d), 133.7 (p-ph, d), 134.5 (C-5, d), 139.3 (i-ph, u), 142.3 (C-4, d), 170.5 (C-1, u).  
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IR (KBr): ν 3127 (m), 3056 (w), 2978 (w), 2955 (w), 2908 (w), 2796 (s), 2719 (s), 
1747 (w), 1629 (s), 1581 (s), 1476 (w), 1450 (w), 1396 (s), 1370 (m), 1222 (w), 
1179 (w), 1145 (w), 1083 (w), 983 (s) cm−1.  
 
EI-MS m/z (relative intensity, %) 460 [M+ +2] (7), 459 [M+ +1] (100), 457 (10), 237 
(8), 236 (29).  
 
Elemental Analysis:  
Anal. Calcd for C21H34N2O5S2 (458.64): C, 54.99; H, 7.47; N, 6.11 
Found                                                   : C, 54.79; H, 7.67; N, 5.94. 
 
Optical rotation: [α]D = −12.7 (c 1.25, CDCl3). 
 
 
The analytical data of E-87a were in agreement with those previously reported.70                     
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5.11.7 Synthesis of (+)- (2-Chloromethyl-cyclohex-1-enyl)-(2-methyl-
propane-2-sulfonylamino)-acetic acid ethyl ester (99) 
 
 
 
 
 
 
 
 
 
 
Sulfoximine E-86c (300 mg, 0.64 mmol) and Me3OBF4 (133 mg, 0.89 mmol) were 
placed under argon in a Schlenk flask. The flask was consecutively evacuated and 
refilled with dry argon (3 times). Then CH2Cl2 (25 mL) was added and the reaction 
mixture was stirred at room temperature for 90 min. Subsequently water (15 mL) 
was added and the reaction mixture was stirred at room temperature for 10 min. 
Then the mixture was extracted with CH2Cl2 and the combined organic phases 
were dried (MgSO4) and concentrated in vacuo and the residue was dried in high 
vacuum for 2 h. The thus obtained salt was dissolved in EtOAc (15 mL) and 
saturated aqueous NH4Cl (20 mL) was added at room temperature, and stirring at 
this temperature was continued for 72 h. The progress of the reaction was 
monitored by using TLC (ethyl acetate). Then the mixture was extracted with ethyl 
acetate and the combined organic phases were dried (MgSO4) and concentrated 
in vacuo. Purification of the residue by flash chromatography (ethyl 
acetate/hexane, 9:1) gave chloride 99 (144 mg, 64%) and sulfinamide (99 mg, 
92%)   as colorless oils.  
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1H NMR (400 MHz, CDCl3): δ 1.29 (t, J = 7.1 Hz, 3 H, H-11), 1.37 (s, 9 H, H-13), 
1.45-2.38 (m, 8 H, Cy), 4.14-4.32 (m, 4 H, H-8, H-10), 4.99 ( d, J = 7.4 Hz,  1 H, 
NH), 5.16 ( d, J = 7.4 Hz,  1 H, H-2).  
 
13C NMR (100 MHz, CDCl3): δ 14.09 (C-11,  d), 22.19 (Cy, u), 22.58 (Cy, u), 24.10 
(C-13, d),  24.64 (Cy, u), 28.22 (Cy,  u),  44.04 (C-8, u), 56.73 (C-1, d), 59.96 (C-
12, u), 62.49 (C-10, u), 131.72 (C-2, u), 133.62 (C-3, u), 170.81 (C-9, u).  
 
IR (KBr): ν 3127 (m), 3056 (w), 2978 (w), 2955 (w), 2796 (s), 2719 (s), 1747 (w), 
1629 (s), 1581 (s), 1476 (w), 1396 (s), 1370 (m), 1222 (w), 1179 (w), 1145 (w), 
1083 (w), 983 (s) cm−1 . 
 
EI-MS m/z (relative intensity, %):   278 [M+ -CO2Et] (37), 195 (25), 179 (16), 160 
(29), 158 (100), 122 (38), 57 (49).  
 
HRMS (EI, 70 ev):  
Calcd for C15H25NO4S-HCl: 315.150425 
Found                                 : 315.150431. 
 
Optical rotation: [α]D = +30.4 (c 1.25, CHCl3). 
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5.11.8   Synthesis of 2-(2-Methyl-propane-2-sulfonyl)-2,3,4,5,6,7-hexahydro-  
1H-isoindole-1-carboxylic acid ethyl ester (100).  
 
N
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O
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10 11
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100  
 
To a solution of chloride 99 (150 mg, 0.43 mmol) in CH2Cl2 (10 ml) was added 
DBU (0.82 mL, 0.55 mmol) dropwise at ambient temperature. After the mixture 
was stirred at ambient temperature for 0.5 h, saturated aqueous NH4Cl (20 ml) 
was added and stirring was continued for 5 min. Then the mixture was extracted 
with CH2Cl2 and the combined organic phases were dried (MgSO4) and 
concentrated in vacuo. Purification of the residue by flash chromatography ( ethyl 
acetate/hexane, 9:1) gave the protected α-amino acid 100 (125 mg, 93%) as a 
colorless  oil.  
 
1H NMR (400 MHz, CDCl3): δ 1.28 (t, J = 7.1 Hz, 3 H, H-12), 1.42 (s, 9 H, H-14), 
1.60-2.10 (m, 8 H, Cy), 4.14-4.26 (m, 3 H, H-3’, H-11), 4.36 (br d, J = 13.1 Hz,  1 
H, H-3), 5.11 (br s, 1 H, H-1).  
 
13C NMR (100 MHz, CDCl3): δ 14.24 (C-12,  d), 22.13 (Cy, u),  22.43 (Cy, u),  22.9 
(Cy, u), 24.22 (C-14,  d),   29.65 (Cy, u), 59.33 (C-3, u), 61.09 (C-11, u), 61.47 (C-
13, u), 70.95 (C-1, d), 128.79 (C-9, u), 133.73 (C-4, u), 170.91 (C-10, u).  
 
IR (CHCl3): ν  2979 (m), 2936 (w), 2874 (m), 1480 (m), 1456 (m), 1393 (s), 1376 
(w), 1321 (s), 1231 (w), 1193 (s), 1130 (s), 1054 (s), 1023 (m), 946 (w), 810 (w), 
756 (s) cm−1. 
 
EI-MS m/z (relative intensity, %) 316 [M++1] (100), 196 (34), 194 (6).  
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HRMS (EI, 70 ev):  
Calcd for C15H25NO4: 315.150425 
Found:                      : 315.150431 
 
Elemental Analysis:  
Anal. Calcd for C15H25NO4S (315,15): C, 57.12; H, 8.22; N, 4.44  
Found                                                 : C, 56.83; H, 8.63; N, 4.10. 
 
Optical rotation: [α]D = +21.4 (c 1.2, CH2Cl2). 
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5.12 Synthesis of Allylic Alcohol derivatives 
 
5.12.1 Synthesis of (−)-(E)-(1S,4S)-4-Cyclohexyl-1-phenyl-oct-2en-1-ol (112) 
 
                                                    
OH
Ph
112  
 
Following GP7, treatment of sulfoximine 14c (384 mg, 1 mmol) with BuCu (3.2 
mmol CuI, 3.2 mmol n-BuLi) afforded the allylic alcohol 112 (215 mg, 75%).  
 
1H NMR (400 MHz, CDCl3): δ 0.89 (t, J = 6.9 HZ, 3 H, C4H9), 1.00-1.50 (m, 10 H, 
Cy, C4H9), 1.95 (br s, 1 H, OH), 1.65-1.89 (m, 8 H, Cy, C4H9), 5.18 (d, J = 5.1 Hz, 
1 H, CHOH), 5.50-5.62 (m, 2 H, =CH), 7.26-7.38 (m, 5 H, Ph). 
 
13C NMR (100 MHz, CDCl3): δ 14.1 (CH3, d), 22.8 (u), 26.70 (u),  29.86 (u), 29.9 
(u), 31.3 (u), 31.6 (u), 42.0 (CyCHCH2, d), 48.3 (Cy, d), 75.1 (CHOH, d), 126.2, 
127.8, 128.0 (o-, m-,p-C, d), 132.9 (=CH, d), 135.8 (=CH, d), 143.5 (i-C, u). 
 
IR (KBr): ν 3786 (s), 3060 (s), 2922 (w), 2852 (w), 2663 (s), 2345 (s), 1951 (s), 
1892 (s), 1602 (s), 1494 (m), 1408 (s), 1316 (s), 1270 (m), 1102 (s), 973 (w), 889 
(s), 851 (s), 743 (w) cm−1. 
 
CI-MS m/z (relative intensity, %):   286 [M+] (3), 271 (3), 270 (20), 269 (100). 
 
Elemental Analysis:  
Anal. Calcd for C20H30O (286.23): C, 83.86; H, 10.56 
Found                                           : C, 83.63; H, 10.46. 
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Optical rotation: [α]D = +15.5 (c 0.51, CH2Cl2).  
 
 
 
5.12.2  Synthesis of (+)-(E)-(3R,6S)-6-Ethyl-2,6-dimethyl-dec-4-en-3-ol (113) 
 
OH
113  
 
Following GP7, treatment of sulfoximine 111c (309 mg, 1 mmol) with BuCu (3.2 
mmol CuI, 3.2 mmol n-BuLi) afforded the allylic alcohol 113 (143 mg, 67%). 
 
1H NMR (400 MHz, CDCl3): δ 0.78 (t, J = 7.4 Hz, 3 H, C4H9), 0.85-0.95 (m, 12 H, 
Me, CH(CH3)2, C4H9), 1.2-1.4 (m, 8 H, C4H9), 1.65 (br s, 1 H, OH), 1.75 (m, 1 H, 
CH(CH3)2), 3.80 (t, J = 5.1 Hz, 1 H, CHOH), 5.35 (dd, J = 7.4, J = 15.9, 1 H, =CH), 
.35 (dd, J = 1.4 Hz, J = 15.9 Hz, 1 H, =CH ). 
 
13C NMR (100 MHz, CDCl3): δ   8.44 (C4H9, d), 14.15 (CH3, d), 18.24, 18.32 
(CH(CH3)2, d) 22.64 (d), 26.30 (d), 33.20, 40.50 (CH2, d), 33.95 (CH(CH3)2, d), 
38.70 (EtMeUCUBuCH, u), 78.80 (CHOH, d), 141.69 (=CH, d), 128.30 (=CH, d). 
 
IR (KBr): ν  3254 (w), 3060 (s), 2965 (w), 2804 (w), 2663 (s), 2345 (s), 1951 (s), 
1892 (s), 1663 (s), 1450 (m), 1237 (s), 1108 (s), 939 (s), 862 (w), 741 (w) cm−1. 
 
CI-MS m/z (relative intensity, %):   212 [M+] (1), 195 (18), 170 (12), 169 (100), 151 
(19), 125 (10), 113 (13), 111 (10), 109 (16), 100 (13), 99 (17), 97 (13), 85 (40), 71 
(72). 
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HRMS (EI, 70 ev): 
Calcd for C23H36SiO2: 212.214057 
Found                       : 212.214015. 
 
Optical rotation: [α]D = +15.5 (c 0.51, CH2Cl2). 
 
 
 
 
5.12.3 Synthesis of (+)-(1R,2S)-2-[2-Butyl-cyclohex-(E)-ylidene]-1-nyl- 
phenyl-ethanol (114) 
 
OH
Ph
114  
Following GP7, treatment of sulfoximine 11c (355 mg, 1 mmol) with BuCu (3.2 
mmol CuI, 3.2 mmol n-BuLi) afforded the allylic alcohol 114 (182 mg, 69%).  
 
1H NMR (400 MHz, CDCl3): δ  0.90 (t, J = 6.9 Hz, 3 H, C4H9), 1.2-1.8 (m, Cy, 
C4H9), 2.2-2.4 (m, 2 H, Cy), 5.36 (d, J = 8.6 Hz, 1 H, CHOH), 5.57 (d, J = 8.6 Hz, 1 
H, =CH), 7.20-7.40 (m, 5 H, Ph). 
 
13C NMR (100 MHz, CDCl3): δ 14.10 (CH3, d), 28.8 (C4H9, u), 23.60 (C4H9, u),  
27.46 (C4H9,u), 28.39 (Cy, u), 29.84 (Cy, u), 31.46 (Cy, u), 33.5 (Cy, u), 44.40 (Cy, 
d), 69.8 (CHOH, d), 123.6 (=CH, d), 127.10, 128.40, 128.75 (o-, m-,p-C, d), 144.50 
(Cy, u), 146.2 (i-C, u). 
 
IR (KBr): ν  3690 (s), 3651 (s), 3083 (s), 2997 (s), 2858 (w), 2669 (s), 2370 (s), 
1957 (s), 1811 (s), 1637 (s), 1601 (s), 1494 (m), 1436 (m), 1234 (s), 1137 (m), 
1316 (s), 920 (w), 864 (s), 770 (w) cm−1. 
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CI-MS m/z (relative intensity, %): 258 [M+] (2), 257 (M+ -1) (2), 242 (21), 241 (100). 
 
 
 
Elemental Analysis:  
Anal. Calcd for C20H30O (286.23): C, 83.67; H, 10.14 
Found                                          : C, 83.90; H, 10.32. 
 
Optical rotation: [α]D = +10.5 (c 0.55, CH2Cl2).  
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6 Crystal Structure Analysis 
 
6.1 Crystal structure of (+)-(E,Ss,2R,3S)-2-(N-methyl-S-phenyl-
sulfonimidoyl-methylene)-cycloheptyl)-(2-methylpropane-2- 
sulfonylamino)-Acetic Acid Ethyl Ester (E-82c) 
 
 
 
 
 
 
 
 
 
 
 
Experimental Details 
 
Crystal data: 
Chemical formula    : C23H36N2O5S2 
formula weight    : 484.68 
Crystal system    : monoclinic 
Space group (No.)    :  P 21  (4) 
Z      : 2 
a (Å)      : 8.986(4) 
b (Å)      : 10.080(2) 
c (Å)      : 14.350(3) 
α  (°)      : 90.0 
β  (°)      : 102.97(3) 
γ (°)      : 90.0 
cell volume    : 1266.6(7)Å3 
Density calc.    : 1.271g/cm3 
Radiation     : CuKα (1.54179Å) 
Range for lattice parameters  : Ε<Θ <Ε 
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Absorption coefficient   : 2.194mm-1 
Temperature          : 150K 
Crystal source    : recrystallized from  
Crystal colour    : colourless 
Crystal shape    : irregular 
Crystal size               : ca. 0.3x0.3x0.3mm 
Data Collection 
Diffractometer type                    : Enraf-Nonius CAD4 
Collection method                          : ω/2Θ - scans 
Absorption correction   : none 
No. of reflections measured  : 2679 
No. of independent reflections    : 2293 
No. of observed reflections  : 2128 
 Θ max  (Ε)               : 72.94 
hmin 6 hmax           :         -11     6  11 
kmin 6 kmax           : -  4    6  4 
lmin 6  lmax           : -17    6  17 
Criterion for observed   : I > 2σ (I ) 
Rint               : 0.050(37) 
Standard reflections    : -1   -1   4; -1   -2   3; 2   -2   -4 
Variation     : 1197(36) 4363(86) 1575(60) 
Refinement:  
On      : F 
Treatment of hydrogens        : Positions calculated. The Us have 
been 
fixed to 1.5ΗU oft the relevant heavy 
Atom prior to final refinement. No H 
parameters refined. 
 
R      : 0.109 
Rw      : 0.135 
Weighting sheme    : w=1/[σ(F)2]  
No. of parameters refined  : 130 
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No. of reflections in refmnt.  : 2126 
Residual electron density  : -1.21/0.94e/Å3  
r*[1]      : not refined 
XABS[2]     :  
Goodness of fit    : 5.77 
Solution     : XTAL3.7[3] 
 
Definitions   :  
Ueq = 1/3ΣiΣjUijai*aj*ai aj 
The anisotropic displacement factor in the structure factor expression is: 
t = exp[-2π2(ΣiΣjUijhihjai*aj* )] 
 
Atomcoordination: 
                           
Atom        x/a                y/b                 z/c             Ueq/Å2                                               
 S2       0.6965(3)      0.4287(6)      0.1531(2)      0.0316(7)                            
 S6       1.1467(2)      0.3774(6)      0.6606(1)      0.0190(5)                            
 O1      1.0349(7)      0.258(1)         0.3798(4)      0.024(2)                             
 O2      1.0432(8)      0.461(1)        0.3187(5)       0.036(2)                             
 O3      0.7939(8)      0.501(1)        0.1070(5)       0.035(2)                             
 O4      0.699(1)        0.285(2)        0.1484(7)       0.062(3)                             
 O5      1.1842(8)      0.243(1)        0.6507(5)       0.028(2)                             
 N1      1.263(1)        0.490(2)        0.6590(6)       0.028(2)                             
 N2      0.7249(9)      0.476(2)        0.2684(5)       0.024(2)                             
 C1      0.802(1)        0.373(2)        0.3408(6)       0.026(2)                             
 C2      0.773(1)        0.430(2)        0.4370(6)       0.023(2)                             
 C3      0.873(1)        0.356(2)        0.5213(6)       0.019(2)                             
 C4      0.836(1)        0.223(2)        0.5490(7)       0.023(2)                             
 C5      0.723(1)        0.225(2)        0.6163(7)       0.026(2)                             
 C6      0.562(1)        0.270(2)        0.5707(8)       0.031(3)                             
 C7      0.553(1)        0.412(2)        0.5268(7)       0.031(2)                             
 C8      0.600(1)        0.411(2)        0.4317(6)       0.024(2)                             
 C9      0.9968(9)      0.435(2)        0.5675(5)       0.015(2)                             
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 C10    1.0786(9)      0.382(2)        0.7689(5)       0.017(2)                             
 C11    1.077(1)        0.511(2)        0.8112(7)       0.030(3)                             
 C12     1.022(1)       0.519(2)    0.8945(9)      0.046(4)                             
 C13     0.971(1)       0.403(2)  0.9323(7)      0.038(3)                             
 C14     0.980(1)       0.275(2)   0.8899(9)      0.043(3)                             
 C15     1.034(1)       0.266(2) 0.8079(8)       0.035(3)                             
 C16     1.400(1)       0.490(2)     0.7373(7)      0.025(2)                             
 C17     0.975(1)       0.383(2)     0.3432(6)      0.025(2)                             
 C18     1.201(1)       0.247(2)     0.3937(7)      0.029(3)                             
 C19     1.242(1)       0.197(2)     0.3069(8)      0.035(3)                             
 C20     0.502(1)       0.487(2)     0.1058(8)      0.035(3)                             
 C21     0.397(2)       0.403(3)     0.144(1)         0.066(4)                             
 C22     0.473(1)       0.465(3)    -0.0031(9)      0.048(4)                             
 C23     0.492(2)       0.637(3)     0.133(1)       0.065(5)                             
 H4a     0.9245(-)      0.1691(-)    0.5798(-)      0.029(-)                             
 H4b     0.7854(-)      0.1681(-)    0.4933(-)      0.029(-)                             
 H5a     0.7645(-)      0.2846(-)    0.6678(-)      0.029(-)                             
 H5b     0.7195(-)      0.1373(-)    0.6464(-)      0.029(-)                             
 H6a     0.4975(-)      0.2615(-)    0.6137(-)      0.037(-)                             
 H6b     0.5223(-)      0.2063(-)    0.5175(-)      0.037(-)                             
 H7a     0.6178(-)      0.4681(-)    0.5699(-)      0.042(-)                             
 H7b     0.4494(-)      0.4439(-)    0.5174(-)      0.042(-)                             
 H8a     0.5425(-)      0.4751(-)    0.3905(-)      0.030(-)                             
 H8b     0.5737(-)      0.3239(-)    0.4025(-)      0.030(-)                             
 H18a   1.2439(-)      0.3389(-)    0.4015(-)      0.027(-)                             
 H18b   1.2457(-)      0.2020(-)    0.4512(-)      0.027(-)                             
 H19a   1.3362(-)      0.2160(-)    0.2961(-)      0.015(-)                             
 H19b   1.1633(-)      0.2003(-)    0.2512(-)      0.015(-)                             
 H19c   1.2503(-)      0.0895(-)    0.3164(-)      0.015(-)                             
 H15     1.0328(-)      0.1835(-)    0.7782(-)      0.027(-)                             
 H14     0.9461(-)      0.1971(-)    0.9174(-)      0.066(-)                             
 H13     0.9330(-)      0.4067(-)    0.9911(-)      0.080(-)                             
 H12     1.0163(-)      0.5999(-)    0.9270(-)      0.071(-)                             
 H11     1.1122(-)      0.5838(-)    0.7828(-)      0.017(-)                             
                                                      CRYSTAL STRUCTURE ANALYSIS                                      159  
 H9       0.9990(-)      0.5243(-)    0.5472(-)      0.016(-)                             
 H1       0.7664(-)      0.2783(-)    0.3297(-)      0.028(-)                             
 H21a   0.4121(-)      0.4163(-)    0.2122(-)      0.106(-)                             
 H21b   0.4213(-)      0.3108(-)    0.1350(-)      0.106(-)                             
 H21c   0.2963(-)      0.4197(-)    0.1142(-)      0.106(-)                             
 H22a   0.5488(-)      0.5187(-)   -0.0292(-)     0.144(-)                             
 H22b   0.3791(-)      0.4815(-)   -0.0364(-)     0.144(-)                             
 H22c   0.5041(-)      0.3725(-)   -0.0156(-)     0.144(-)                             
 H23a   0.5666(-)      0.6894(-)    0.1093(-)      0.088(-)                             
 H23b   0.5242(-)      0.6477(-)    0.2041(-)      0.088(-)                             
 H23c   0.3965(-)      0.6732(-)    0.1134(-)      0.088(-)                             
 H16a   1.4165(-)      0.5758(-)    0.7638(-)      0.088(-)                             
 H16b   1.4896(-)      0.4644(-)    0.7143(-)      0.088(-)                             
 H16c   1.3911(-)      0.4282(-)    0.7867(-)      0.088(-)                             
 H2       0.7964(-)      0.5219(-)    0.4444(-)      0.028(-)                             
 H02     0.7911(-)      0.5783(-)    0.2759(-)      0.024(-)                                  
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6.2 Crystal structure of (−)-(3R,3aR)-3-(4-methoxy-phenyl)-
3,3a,4,5,6,7-hexahydro-1H-   cyclohepta[c]furan (56b). 
  
 
  
 
 
 
Experimental Details 
Crystal data   : 
Chemical formula   : C16H20O2 
formula weight   : 244.33 
Crystal system   : monoclinic 
Space group (No.)   :  P 21 (4) 
Z     : 2 
a (Å)     : 7.441(2) 
b (Å)     : 5.405(2) 
c (Å)     : 16.108(6) 
α  (°)     : 90.0 
β  (°)     : 91.71(2) 
γ (°)     : 90.0 
cell volume   : 647.6(4)Å3 
Density calc.   : 1.253g/cm3 
Radiation    : CuKα (1.54179Å) 
Range for lattice parameters  : 20.61<Θ <37.35° 
Absorption coefficient  : 0.636mm-1 
Temperature   : 150K 
Crystal source   : recrystallized from  
Crystal colour   : colourless 
Crystal shape   : irregular 
Crystal size   : 1.10x0.20x0.14mm 
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Data Collection 
Diffractometer type   : CAD4 
Collection method   : ω / 2Θ  
Absorption correction  : none 
No. of reflections measured : 9336 
No. of independent reflections : 2547 
No. of observed reflections : 2519 
 Θ max  (°)   : 73.16 
hmin → hmax   : -9    → 9a) 
kmin → kmax   : -6    → 6a) 
lmin →  lmax   : -19  → 19a) 
Criterion for observed  : I > 2σ (I ) 
Rint     : 0.07(4) 
Standard reflections   : 3   2   1; 2    1   5; 2   1   6 
Variation    : 10746(210) 6264(91) 905(19) 
Refinement: 
On     : F 
Treatment of hydrogens : Positions except  H16c  located.  
All located positions refinied isotropically 
R     : 0.063 
Rw     : 0.065 
Weighting sheme   : w=1/[18.0σ (F)2] 
No. of parameters refined : 238 
No. of reflections in refmnt. : 2517 
Residual electron density : -0.57/+0.33e/Å3  
r*[1]     : not refined 
XABS[2]    : -0.18(44)b) 
Goodness of fit   : 1.002 
Solution    : XTAL3.7[3] 
Remarks    :  
a)Friedel pairs collected  
b)From separate calculation 
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Definitions: 
Ueq = 1/3ΣiΣjUijai*aj*ai aj 
The anisotropic displacement factor in the structure factor expression is: 
t = exp[-2π2(ΣiΣjUijhihjai*aj* )] 
 
Atomcoordination:                 
                         
Atom         x/a                    y/b                     z/c            Ueq / A2                                               
 O1         0.2266(2)    0.05022(-)        1.09124(9) *  0.0239(8)                            
 O2         0.2369(2)       -0.1942(4)         0.7088(1)   *  0.031(1)                             
 C1         0.3024(3)       -0.2129(6)         0.6261(2)   *  0.033(1)                             
 C2         0.4951(3)       -0.1233(5)         0.6315(1)   *  0.025(1)                             
 C3         0.6162(3)       -0.1607(6)         0.5740(1)   *  0.031(1)                             
 C4         0.8112(3)       -0.0820(6)         0.5785(2)   *  0.034(1)                             
 C5         0.8493(3)        0.1825(6)         0.6052(2)   *  0.033(1)                             
 C6         0.8150(3)        0.2430(6)         0.6955(1)   *  0.032(1)                             
 C7         0.6171(3)        0.2498(6)    0.7179(2)   *  0.030(1)                             
 C8         0.5198(3)        0.0011(5)    0.7150(1)   *  0.023(1)                             
 C9         0.3254(3)        0.0223(5)    0.7439(1)   *  0.025(1)                             
 C10       0.2996(2)        0.0312(5)    0.8356(1)   *  0.022(1)                             
 C11       0.2054(3)        0.2265(5)    0.8703(1)   *  0.024(1)                             
 C12       0.1784(3)        0.2412(5)    0.9551(1)   *  0.022(1)                             
 C13       0.2455(3)        0.0569(5)    1.0073(1)   *  0.020(1)                             
 C14       0.3417(3)       -0.1403(5)    0.9736(1)   *  0.022(1)                             
 C15       0.3680(3)       -0.1521(5)    0.8893(1)   *  0.022(1)                             
 C16       0.1287(3)        0.2494(6)    1.1273(1)   *  0.026(1)                             
 H14       0.404(3)         -0.261(7)     1.011(1)      0.033(7)                             
 H4a       0.878(3)         -0.205(6)     0.616(2)      0.032(7)                             
 H11       0.160(3)           0.353(6)     0.830(2)      0.035(7)                             
 H3a       0.581(3)         -0.269(7)     0.521(2)      0.037(7)                             
 H15       0.444(3)         -0.298(6)     0.867(1)      0.033(7)                             
 H8         0.582(3)         -0.117(5)     0.757(1)      0.008(5)                             
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 H16a     0.003(3)           0.245(6)     1.101(1)      0.025(6)                             
 H6a       0.880(4)           0.136(6)     0.735(2)      0.036(8)                             
 H1a       0.277(4)       -0.373(8)     0.604(2)      0.06(1)                              
 H5b       0.979(3)       0.214(7)     0.591(2)      0.039(7)                             
 H16b     0.132(3)       0.211(5)     1.185(1)      0.021(6)                             
 H7a       0.610(4)      0.326(8)     0.781(2)      0.06(1)                              
 H4b       0.857(4)      -0.088(9)     0.519(2)      0.06(1)                              
 H5a       0.770(3)      0.297(6)     0.569(2)      0.032(7)                             
 H9         0.279(3)       0.166(5)     0.710(1)      0.011(5)                             
 H1b       0.227(4)      -0.113(7)     0.582(2)      0.045(9)                             
 H12       0.104(3)      0.376(7)     0.981(2)      0.034(7)                             
 H7b      0.552(4)           0.359(8)     0.677(2)      0.07(1)                              
 H6b3    0.874(4)       0.397(8)     0.711(2)      0.041(8)                             
 H16c    0.1870(-)          0.4025(-)    1.1172(-)     0.180(-)                             
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6.3 Crystal structure of (−)-(3R,3aR)-3-(4-methoxy-phenyl)- 
1,3,3a,4,5,6,7,8-octahydro-1H-cycloocta[c]furan (ent-56c). 
 
  
 
 
 
 
Experimental Details 
Crystal data   : 
Chemical formula   : C17H22O2 
formula weight   : 258.36 
Crystal system   : orthorhombic 
Space group (No.)   :  P 21 21 21 (19) 
Z     : 4 
a (Å)     : 6.4237(3) 
b (Å)     : 11.7880(6) 
c (Å)     : 18.2871(19) 
α  (°)     : 90.0 
β  (°)     : 90.0 
γ (°)     : 90.0 
cell volume   : 1384.75(17)Å3 
Density calc.   : 1.239g/cm3 
Radiation    : CuKα (1.54179Å) 
Range for lattice parameters : 16.04<Θ <45.60° 
Absorption coefficient  : 0.621mm-1 
Temperature   : 150K 
Crystal source   : recrystallized from  
Crystal colour   : coluorless 
Crystal shape   : irregular 
Crystal size   : 0.80x0.30x0.10mm 
Data Collection  
Diffractometer type   : CAD4 
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Collection method   : ω / 2Θ  
Absorption correction  : none 
No. of reflections measured : 3242 
No. of independent reflections : 2735 
No. of observed reflections : 2637 
 Θ max  (°)   : 72.57 
hmin → hmax   : -7    →  7a) 
kmin → kmax   : -14   → 14a) 
lmin →  lmax   : -22   → 22a) 
Criterion for observed  : I > 2σ (I ) 
Rint     : 0.02(3) 
Standard reflections   : -2   3   2; -2    3   1; 2   -1   -4 
Variation    : 5683(99) 2694(54) 1380(48) 
 
Refinement   : 
On     : F 
Treatment of hydrogens : Positions located and refinied isotropically 
R     : 0.043 
Rw     : 0.051 
Weighting sheme   : w=1/[7.8σ (F)2] 
No. of parameters refined : 260 
No. of reflections in refmnt. : 2630 
Residual electron density : -0.39/+0.23e/Å3  
r*[1]     : not refined 
XABS[2]    : -0.15(37)b) 
Goodness of fit   : 1.005 
Solution    : XTAL3.7[3] 
Remarks    : 
a)Friedel pairs collected 
b)From separate calculation 
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Definitions: 
Ueq = 1/3ΣiΣjUijai*aj*ai aj 
The anisotropic displacement factor in the structure factor expression is: 
t = exp[-2π2(ΣiΣjUijhihjai*aj* )] 
 
Atomcoordination:                 
                            
Atom           x/a                 y/b                     z/c             Ueq/A2  
O1     0.8828(2)       0.2516(1)        0.41435(8) * 0.0305(7) 
O2          0.2432(2)      0.6342(1)    0.32818(8)  * 0.0343(7) 
C1       0.1594(3)     0.7411(2)    0.3499(1)   * 0.0277(9) 
C2        0.3281(3)     0.7965(1)    0.3935(1)   * 0.0236(8) 
C3        0.3059(3)     0.8640(2)    0.4509(1)   * 0.0284(9) 
C4          0.4840(3)        0.9217(2)    0.4884(1)   * 0.0301(9) 
C5          0.5355(3)     1.0376(2)    0.4537(1)   * 0.030(1) 
C6         0.5609(3)     1.0369(2)    0.3710(1)   * 0.0271(9) 
C7         0.7205(3)     0.9516(2)    0.3403(1)   * 0.0279(9) 
C8         0.6298(3)     0.8431(1)    0.3070(1)   * 0.0237(8) 
C9        0.5307(2)      0.7572(1)    0.3595(1)   * 0.0202(8) 
C10       0.4649(3)     0.6483(1)    0.3171(1)   * 0.0243(9) 
C11        0.5742(3)     0.5414(1)    0.3413(1)   * 0.0214(8)                            
C12        0.7692(3)    0.5145(1)    0.3124(1)   * 0.0233(8)                            
C13        0.8777(3)     0.4186(1)    0.3354(1)   * 0.0240(8)                            
C14        0.7898(3)     0.3477(1)    0.3872(1)   * 0.0240(8)                            
C15        0.5948(3)    0.3735(1)    0.4165(1)   * 0.0269(9)                            
C16        0.4899(3)    0.4695(2)    0.3938(1)   * 0.0267(9)                            
C17        1.0593(3)     0.2096(2)    0.3757(1)   * 0.039(1)                             
H10        0.494(3)       0.661(1)     0.261(1)             0.017(5)                             
H8a        0.533(3)          0.861(2)          0.267(1)         0.021(5)                             
H7a        0.817(4)          0.932(2)          0.381(1)         0.038(6)                             
H12        0.824(4)          0.565(2)          0.272(1)         0.037(6)                             
H5a        0.438(4)          1.091(2)          0.467(1)         0.045(7)                             
H9          0.628(4)          0.739(2)          0.397(1)         0.027(6)                             
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H17a      1.033(4)          0.201(2)          0.324(1)         0.034(6)                             
H4a        0.601(4)          0.876(2)          0.484(1)         0.040(7)                             
H7b        0.793(4)          0.989(2)          0.297(1)         0.031(6)                             
H6a        0.589(3)         1.117(2)           0.357(1)         0.025(5)                             
H15        0.540(3)         0.323(2)           0.451(1)         0.028(5)                             
H6b        0.436(3)         1.020(2)           0.346(1)         0.026(5)                             
H3          0.154(5)         0.884(2)           0.472(2)         0.058(8)                             
H1b        0.131(3)         0.788(2)           0.303(1)         0.030(5)                             
H4b        0.449(4)         0.934(2)           0.543(1)         0.035(6)                             
H13        1.015(4)         0.399(2)           0.310(1)         0.047(7)                             
H5b        0.663(4)         1.071(2)           0.476(1)         0.033(6)                             
H1a        0.032(4)         0.727(2)           0.380(1)         0.045(7)                             
H17b      1.086(4)         0.137(2)           0.398(1)         0.044(7)                             
H8b        0.737(4)         0.800(2)           0.276(1)         0.047(7)                             
H16        0.368(4)         0.486(2)           0.417(1)         0.043(7)                             
H17c      1.179(5)         0.264(2)           0.384(2)         0.060(8)  
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